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1. Introduction 
1.1 Asymmetric synthesis 
Chirality reveals itself in mostly all life processes, directly or indirectly. Nowadays, the 
need to obtain enantiopure compounds in organic chemistry whenever applicable is 
the accepted norm. Mainly due to the stringent rules imposed by the food and drug 
administrations this is especially true for the pharmaceutical industry. Great 
advances have been made in conventional and non-conventional ways for retrieving 
molecules in enantiopure form since the well-known findings on crystal separation of 
enantiomers by Louis Pasteur in 1848. To date, several practices are known and 
used by chemists in academia and industry towards this objective. Among these 
there are three general approaches:[1]  
(i)  the use of nature‟s large library of enantiopure substances and their chemical 
modification; 
(ii)  the resolution of racemates by chemical, enzymatic or physical methods; 
(iii) reactions of achiral precursors with chiral reagents and catalysts, including 
chemical and biotechnological methods. 
 
This thesis will give an introduction into the latter approach, more precisely into two 
methods from the area of asymmetric chemical synthesis. While the first, a catalytic 
one, includes the application of small chiral organic molecules in catalysis 
(asymmetric organocatalysis), the second involves the use of stoichiometric amounts 
of chiral auxiliaries for the asymmetric synthesis of -amino acids. Additionally, the 
general concept of mechanochemical synthesis will be introduced. 
The synthesis of chiral, natural amino acid-derived thiourea and their utilization in 
asymmetric organocatalysis will be described, thereafter. Moreover, the asymmetric 
synthesis of -amino acids by derivatization of a specially designed chiral glycine 
equivalent was studied in a second project. The employment of mechanochemical 
methods in both projects will be discussed. 
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1.2 Asymmetric organocatalysis 
At the end of the 20th century, mainly two types of asymmetric catalysis were in the 
center of attention in academia and chemical industry.  
Biocatalysis is typically conducted under aqueous conditions, making it attractive for 
industrial scale processes of deracemization or asymmetric synthesis. Applying 
natural catalysts such as enzymes, highly specific, chemo- and stereoselective 
transformations have been realized. For instance, biocatalysis is widely applied in the 
production of amino acids in their enantiopure form (see section 1.3.2). 
Unfortunately, such catalysts are often too specific and therefore need to be fine-
tuned case-dependently. Furthermore, many biocatalysts are not sufficiently stable if 
reaction conditions are varied and they show low tolerance to organic solvents.[2] 
Metal catalysis with complexes incorporating chiral ligands has also proved highly 
effective in numerous asymmetric catalytic applications. Low catalyst loadings can be 
reached, resulting in excellent chemical yields and selectivities.[3] The 
groundbreaking work of Noyori, Knowles, and Sharpless on chirally catalyzed 
hydrogenation and oxidation reactions should be mentioned, which was awarded 
with the Nobel Prize in 2001.[4] However, metal catalytic systems often lack moisture- 
and air-stability and may cause product contamination by metal traces, which is a 
critical issue in food and pharmaceutical industry. 
In the 21st century, a third powerful tool in catalytic asymmetric synthesis was 
rediscovered. The utilization of small chiral organic molecules, mediating organic 
reactions in a selective and efficient way, offers a possibility to circumvent some 
major drawbacks of the above mentioned, more established pathways. Such 
organocatalysts are often derived from the nature‟s chiral pool and are considered 
easily accessible and transformable. Organocatalyzed reactions generally tolerate 
the use of a wide range of organic solvents, are neither water- nor air-sensitive and 
can be conducted at ambient conditions. Moreover, a high structural diversity of 
substrates is often accepted.[5],[6] Development has also focused on well-designed 
catalytic systems, allowing for the application of low catalyst loadings and making 
organocatalysis a highly efficient tool.[7] An introduction into the field of 
organocatalysis and the development of bifunctional thiourea catalysts in particular 
will be given in this section. 
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1.2.1 Historical background 
The first organocatalytic transformation, the benzoin condensation of two molecules 
of benzaldehyde in the presence of cyanide, was discovered by Wöhler and Liebig in 
1832.[8] However, the first asymmetric organocatalytic reaction was not reported 
before 1908 by Bredig and Fiske. When nicotine was added as a chiral catalyst, the 
decarboxylation rates for (R)- and (S)-camphorcarboxylic acid in acetophenone 
showed notable differences.[9] Shortly after, Bredig also reported on the first 
organocatalyzed asymmetric C-C bond forming reaction, the synthesis of 
mandelonitrile (3), by employing alkaloid catalysts such as quinine (4, Scheme 1).[10]  
 
Scheme 1. Asymmetric synthesis of mandelonitrile catalyzed by quinine (4). 
The discovery of organocatalyzed transformations reaching distinctly higher levels of 
enantioselectivity can be attributed to Pracejus, who reported on the asymmetric 
ester synthesis from phenyl methyl ketene (5), catalyzed by O-acetyl quinine (8). At 
low temperatures (-111 °C) product 7 was obtained with up to 74% ee (Scheme 2).[11] 
 
Scheme 2. Formation of chiral esters catalyzed by O-acetylquinine (8). 
A key event in the history of organocatalysis undoubtedly was the discovery of the 
catalytic activity of (S)-proline (12). Eder, Sauer and Wichert at Schering AG[12] and 
Hajos and Parrish at Hoffman-LaRoche[13] independently described a catalytic 
intermolecular aldol reaction from triketone 9, reaching high enantioselectivities 
(Scheme 3). The underlying work of Knoevenagel,[14] Kuhn,[15] and Langenbeck[16] as 
well as reports of Woodward[17] and Wieland and Miescher[18] on amine-catalyzed 
reactions should be noted.[19]  
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Scheme 3. (S)-Proline-catalyzed intermolecular aldol reactions. 
Further progress in the field of asymmetric amine catalysis in the 20th century was 
slow. While Eschenmoser‟s studies focused on the mechanism of the 
aforementioned aldol reaction,[20] other groups applied the concept in total 
syntheses[21] and transferred it to Michael addition reactions.[22] In 1998, Jacobsen 
reported on proceedings in the asymmetric Strecker reaction. Originally designed as 
resin-bound ligands for (organo)metal catalysis, chiral Schiff base urea and thiourea 
derivatives such as 16 proved effective as organocatalysts in the asymmetric 
hydrocyanation reaction of imines 13 (Scheme 4)[23] and ketoimines.[24] Mechanistic 
studies revealed that the high catalytic activity can be attributed to the capacity of the 
(thio)ureas to activate the electrophile by hydrogen bonding.[25] 
 
Scheme 4. Asymmetric Strecker reaction catalyzed by urea 16. 
The “re-discovery” of asymmetric secondary amine catalysis is attributed to the 
findings of three research groups in the year 2000. Their studies served as a starting 
signal for a fast and intense exploration of organocatalytic reactions in the last 
15 years. Firstly, List, Lerner and Barbas III reported on direct intermolecular aldol 
reactions catalyzed by (S)-proline (12). The cross-aldol products 19 were obtained in 
good yields and with good to high enantiomeric excesses (Scheme 5).[26] 
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Scheme 5. Asymmetric aldol reaction catalyzed by (S)-proline (12). 
Almost at the same time, MacMillan investigated on the enantioselective 
organocatalyzed Diels-Alder reaction between cyclopentadiene (21) and -unsaturated aldehydes 20. The imidazolidinone 24 proved to be an effective 
catalyst and cycloaddition products were generated in high yields and with high to 
excellent stereoselectivity (Scheme 6).[27] 
 
Scheme 6. Asymmetric Diels-Alder reaction catalyzed by (S)-proline (12). 
Other sporadic reports on asymmetric organocatalyzed reactions appeared in the 
20th century, including examples of asymmetric phase-transfer reactions catalyzed by 
cinchona alkaloid derivatives (see section 1.3.3),[28] cinchona alkaloid-catalyzed 
stereoselective anhydride openings[29] as well as chiral N-heterocyclic carbene-
catalyzed benzoin condensation[30] and Stetter reactions.[31]  
1.2.2 Activation modes 
Organocatalysts are typically classified by two factors. Firstly, they act as acids or 
bases (either Brønsted or Lewis acids/bases), resulting in activation of the substrate 
and therefore acceleration of the reaction by lowering of the lowest unoccupied 
molecular orbital (LUMO) or rising of the highest occupied molecular orbital (HOMO), 
respectively. Secondly, the nature of the interaction between the catalyst and the 
activated substrate(s), leading to the transmission of the asymmetric information, 
may be used to differentiate. In this context, organocatalysts interact by ion-pairing, 
covalent bonding or hydrogen-bonding. Selected prominent examples for each type 
of interaction will be illustrated here. 
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A representative example for asymmetric induction through ion-pairing is the 
application of chiral phase-transfer catalysts such as quaternary ammonium or 
phosphonium salts 25 and 26.[32] The use of similar chiral cation catalysts in the 
asymmetric synthesis of -amino acids is described in section 1.3.3. Also chiral 
anions such as phosphates 27 may be applied as ion-pairing catalysts for 
asymmetric induction in reactions that proceed through a cationic intermediate 
(asymmetric counteranion directed catalysis, ACDC).[33] Neutral chiral anion- and 
cation-binding catalysts complete the field of ion-pairing catalysis. An excellent 
overview on the subject was given by Jacobsen.[34] 
 
Figure 1. Examples of organocatalyts acting through ion-pairing interaction. 
Activation by covalent binding of the chiral catalyst to the substrate is a concept 
relying chiefly on strong, directional interactions. Chiral N-heterocyclic carbene 
(NHC) catalysts such as 28, acting as Lewis bases and resulting in Umpolung 
activation, belong to this field.[35] Furthermore, one of the most broadly and 
successfully studied and applied class of organocatalysts is chiral secondary (and 
primary) amines.[19, 36] Diphenylprolinol silyl ethers such as 29 (Jørgensen-Hayashi 
catalyst)[37], acting by HOMO or LUMO activation of substrates by formation of 
enamine or iminium intermediates,[38] and MacMillan imidazolidinon catalyst 30, 
which was also used for singly occupied molecular orbital (SOMO) activation,[39] are 
prominent examples. 
 
Figure 2. Examples of organocatalyts acting through covalent interaction. 
Hydrogen bonding is one of the dominant forces in molecular interaction and 
recognition in biological systems and plays a major role in biocatalysis. Small organic 
molecules that mimic such activation are considered as hydrogen bonding 
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organocatalysts. They are capable of activating substrates according to the principles 
of Brønsted acids or bases.[40] Specific examples are strong acids such as chiral 
BINOL-derived phosphoric acid 31,[41] and weak acids such as squaramide 32[42] or 
diol 33 (TADDOL).[43] Brønsted bases like guanidine derivative 34[44] and cinchona 
alkaloids such as cinchonine 35[29c, 45] can act as hydrogen acceptors. Additionally, 
many of these compounds may be considered as bifunctional organocatalysts, since 
they possess a second complementary acidic or basic binding site allowing their use 
in dual activation strategies.  
 
Figure 3. Examples of organocatalyts acting through hydrogen-bonding activation. 
In this context, another prominent example is chiral bifunctional thiourea catalyst 36, 
introduced by Takemoto.[46] Thioureas were found to be more acidic than their 
O-analogues and therefore superior hydrogen bond donors.[47] This catalyst and the 
underlying concept of promoting asymmetric reactions by bifunctional thiourea 
catalysis have become viable since its first mention in 2003.[48] The evolution and 
important advances in this field will be elucidated in the following section. 
1.2.3 Chiral bifunctional thiourea catalysis 
Intensive efforts towards the application of (thio)ureas as chiral catalysts in 
asymmetric synthesis have been made in the last decades, based on the work of 
Etter who found the excellent complexing abilities of such motifs to form co-crystal 
structures with a variety of hydrogen bond acceptors.[49] Curran and Schreiner 
reported on the catalytic activity of achiral (thio)ureas 37[50] (e.g. in Claisen 
rearrangement) and 38[51] (e.g. in Diels-Alder reaction), respectively. The latter 
Introduction 
 
18 
 
catalyst, bearing a 3,5-bis(trifluoromethyl)phenyl motif, proved superior than other, 
less rigid structures.[52] This effect has also been rationalized by the motifs ability to 
increase the acidity of the organocatalyst.[47] 
 
Figure 4. Achiral (thio)urea structures developed by Curran and Schreiner. 
Based on Jacobsen‟s findings on the use of chiral mono-functional Schiff base 
thioureas on asymmetric Strecker[23-24] and Mannich[53] reactions, Takemoto reported 
on the application of a bifunctional catalyst 36 in 2003. Besides its hydrogen bond 
donor functionality (Brønsted acid) this catalyst bears an additional Brønsted basic 
site for simultaneous activation of two substrates, and to support the formation of a 
more rigid transition state, resulting in a higher stereocontrol. Its ability to promote 
reactions in an enantioselective manner was first exposed in the Michael reaction 
between malonates 39 and nitroolefins 40 (Scheme 7). The catalytic activity in similar 
reactions of nitroolefins with various 1,3-dicarbonyl compounds was also reported.[54]  
 
Scheme 7: Asymmetric Michael addition reaction catalyzed by Takemoto catalyst 36; 
A: Takemoto‟s proposed dual activation mode, thiourea H-bond activation of nitroolefin; 
B: Pápai‟s proposed dual activation mode, thiourea H-bond activation of dicarbonyl. 
While Takemoto proposed an activation mode A based on the nitroolefin-activation 
by ternary complex formation with the thiourea functionality,[54] in silico studies by 
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Pápai revealed an alternative mode B to activate the electrophile by the protonated 
amine site of the catalyst.[55] 
Since then, Takemoto catalyst 36 has displayed to be useful in a variety of highly 
enantio- and diastereoselective asymmetric transformations such as Michael,[56] 
Mannich[57] and aza-Henry[58] reactions. The synthetic utility of the latter was further 
demonstrated by its application in the enantioselective synthesis of NK-1-receptor 
antagonist ()-CP-99,994 45 and trisubstituted piperidines (Scheme 8). 
 
Scheme 8. Use of the Takemoto catalyst 36 in asymmetric aza-Henry reactions. 
Incorporating the chiral cyclohexane diamine scaffold found in the Takemoto catalyst 
36, other effective organocatalysts have been developed. The first acyl-Pictet-
Spengler reaction catalyzed by a chiral thiourea 48 was described by Jacobsen. 
Tetrahydro--carbolines 47 were derived with high enantioselectivity (Scheme 9).[59] 
Other selected similar catalysts are Jacobsen thiourea 49,[60] and glycosyl-thiourea 
50 introduced by Zhou.[61] Their catalytic potential was demonstrated in the 
asymmetric cyanosilylation of ketones and in asymmetric aza-Henry reactions, 
respectively.  
 
Scheme 9. Asymmetric acyl-Pictet-Spengler reaction catalyzed by a chiral thiourea 58. 
 
Figure 5. Structurally diverse thioureas bearing a chiral 1,2-diamino cyclohexane moiety. 
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Following Takemoto‟s general concept of multifunctional activation, various 
bifunctional thioureas with diverse chiral as well as co-functional basic moieties have 
been introduced.  
In 2005, Soós reported on highly enantioselective Michael additions between 
chalcones 51 and nitromethane (43a) promoted by the use of thioureas 53a, bearing 
a readily available and tunable cinchona alkaloid (epiquinine) scaffold (Scheme 
10a).[62] This development was based on the pioneering work of Wynberg and 
Hiemstra in 1981, describing the promotion of enantioselective 1,2- and 1,4-addition 
reactions to cycloalkenones by cinchona alkaloids as chiral bifunctional catalysts.[63] 
Increasing the strength of the hydrogen bond donor by replacing the C9-OH group of 
such alkaloids with a thiourea moiety led to the anticipated increase in the catalysts 
activity. Connon applied this catalyst in the Michael addition of malonate (39a) to 
nitroalkenes 40 (Scheme 10b).[64] Notably, both research groups described the 
relatively low catalytic activity of C9-epimeric quinine-derived thioureas, indicating 
that the proper conformation of the cinchona derivatives is crucial for successful 
catalysis. 
 
Scheme 10. Asymmetric Michael reactions catalyzed by cinchona alkaloid-derived thiourea 53a. 
Hiemstra and co-workers studied the use of thiourea 55, accessible from 
C6‟-functionalized cinchonine derivatives. The stereoselectivity in asymmetric Henry 
reactions of aromatic aldehydes 18 was effectively controlled by this catalyst 
(Scheme 11).[65] 
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Scheme 11. Asymmetric Henry reaction catalyzed by cinchona alkaloid-derived chiral thiourea 55. 
Inspired by the privileged binaphthyl moiety,[66] Wang introduced a bifunctional 
amine-thiourea 58 for the asymmetric Michael addition of 2,4-pentanedione (56) to 
nitroolefins 40. Low catalyst loadings of 1 mol% were sufficient to achieve the 
addition products with high selectivity (Scheme 12).[67] 
 
Scheme 12. Asymmetric Michael addition catalyzed by binaphthyl-based thiourea 58. 
The first enantioselective chiral-thiourea-catalyzed Friedel-Crafts alkylation of indoles 
59 with nitroalkenes 40 was reported by Ricci (Scheme 13).[68] The employed catalyst 
61 bears a 2-indanol scaffold. Testing revealed that both, the free alcoholic function 
of the catalyst and the free indolic proton were crucial for the successful asymmetric 
alkylation. Thus, a bifunctional mechanism was proposed, assuming a weak 
hydrogen bond interaction between these functionalities.  
 
Scheme 13. Asymmetric Friedel-Crafts alkylation catalyzed by chiral thiourea 61. 
A successful approach to integrate a secondary amine as a Lewis base functionality 
into a thiourea catalyst was reported by Tang. Bifunctional pyrrolidine-based thiourea 
64 showed remarkable catalytic properties in Michael additions of cyclohexanone 
(62) to nitroolefins 40. The proposed activation model C involved activation of the 
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carbonyl by formation of an enamine, and hydrogen-bonding activation of the 
electrophile by the thiourea function (Scheme 14).[69]  
 
Scheme 14. Asymmetric Michael addition reaction catalyzed by 64 and proposed activation model C. 
Various reactions are effectively catalyzed by the aforementioned and other 
bifunctional thiourea catalysts.[40a, c, d, 48, 70] Numerous recent examples include (aza-, 
sulfa-)Michael,[71] Mannich,[72] and Strecker[73] reactions applying structurally diverse 
substrates, as well as asymmetric Diels-Alder,[74] aldol,[75] Morita-Baylis-Hillman[76] 
reactions and others[77]. Notably, for some addition reactions an SN1-pathway was 
proposed, induced by anion-abstraction by or anion-binding to the thiourea 
catalyst.[59, 70b, 78] Hence, those reactions proceed based on the underlying concept of 
asymmetric ion-pairing catalysis.[34]  
Further developments in the field also include cascade and domino reactions,[79] 
allowing the enantioselective formation of more complex structures, and the 
development of trifunctional organocatalysts.[78a, 80] 
 
1.3 Asymmetric synthesis of -amino acids 
1.3.1 Occurrence and use of -amino acids 
Amino acids are one of nature‟s most essential building blocks and can therefore be 
found in all living beings.[81] While there are more than 500 naturally occurring amino 
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acids with biological functions known today[82] countless more have been synthesized 
by chemical methods. When classified according to the core-structural functional 
groups' locations, the (biochemically) most important and largest subgroup is the one 
of -amino acids. In those acids the eponymous amino and carboxyl groups are both 
attached to the same -carbon atom, together with one or two organic side chains. 
When referring to amino acids, in (bio-)chemistry the term often applies to the 
23 known proteinogenic or the 20 canonical (“standard”) L--amino acids that may 
build up to protein-structures by forming peptides and polypeptides. In this form they 
are found as the genetic code in all kind of living organisms. Nevertheless, the 
enormous number of nonproteinogenic, natural amino acids, which often result from 
post-translational modification of the standard amino acids,[83] fulfills a vast quantity 
of functions.  
 
Figure 6. Structually diverse nonproteinogenic, natural -amino acids with biological functions. 
Many of those can be found integrated in larger polypeptides, but some serve as 
biologically important molecules in their original form or as derivatives thereof.[84] For 
example S-adenosylmethionine (65, acting as biological methylating agent),[85] 
citrulline (66) and ornithine (67, both to be found in the mammal urea cycle) are 
typical intermediates in metabolic processes, while thyroxine (68) serves as a 
metabolism stimulating hormone for vertebrates.[84, 86] 
Due to their high availability and natural importance, -amino acids have evoked 
huge interest and are studied and practically used in chemistry, biochemistry, biology 
and medicine. Their utilization in the synthesis of various pharmaceuticals and 
agricultural products, in material sciences and in the (animal-)food industry made 
them rather valuable. Therefore, the design and synthesis of both proteinogenic and 
non-proteinogenic amino acids is a multi-billion US-dollar business. Over the last 
decades, the research in this area has resulted in a wealth of methodologies for their 
preparation, especially in enantioenriched form. 
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1.3.2 Asymmetric production methods 
There are four general production methods to obtain optically pure amino acids: 
extraction, fermentation, enzymatic catalysis, and asymmetric chemical synthesis. 
While extraction methods from proteins are still in use for smaller-scale production of 
some L-amino acids such as L-serine (69), L-proline (12), L-hydroxy-proline (70), and 
L-tyrosine (71), these methods are typically not suitable for large-sale synthesis. 
 
Figure 7. Selected examples of L-amino acids. 
Industrial production of -amino acids by biotechnological processes such as 
fermentation and enzymatic catalysis is an established method for almost 
60 years.[87] L-Glutamic acid (72), which is one of the dominant products produced for 
the food sector, is gained in large amounts by fermentation processes. The soil 
bacterium Corynebacterium glutamicum and its specially optimized mutants are 
capable of producing L-glutamic acid with high productivity from a culture medium 
such as sugar cane syrup and a required nitrogen-source like ammonia.[88] Since the 
discovery of this method in the 1950s, advances in the field led to fermentation 
processes for almost all proteinogenic -amino acids using specially developed 
mutants of C. glutamicum or Escherichia coli. Nevertheless, the complicated 
metabolic processes require precise adjustment of reaction conditions 
(pH, temperature, aeration) as well as individually optimized bacterial systems, and 
typically several work-up steps (separation, evaporation, crystallization, drying).[87] 
The utilization of enzyme catalysis for the industrial deracemization of proteinogenic 
and non-proteinogenic amino acids began in the late 1960s with the resolution of 
N-acetyl DL-amino acids by immobilized acylase (Scheme 15).[89] Since then, the 
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continuous enzymatic resolution in enzyme membrane reactors (EMR), developed by 
Degussa AG, has proven to be especially useful[90] and was applied to numerous 
targets such as L-methionine (73) and L-valine (74). 
 
Scheme 15. Enzyme-catalyzed deracemization of acetylated -amino acids. 
Unfortunately, this and other deracemization methods inherent maximum yield per 
cycle of 50%, unless the unwanted enantiomer can be isomerized.[91] In contrast, 
chemo-enzymatic processes that rely on an enzyme-catalyzed asymmetric 
synthesis[92] starting from prochiral substrates have a maximum theoretical yield of 
100%.[93] In this context, the asymmetric amination of fumaric acid by 
aspartate ammonia lyase from E. coli is industrially used to form L-aspartic acid (79), 
which is transferred in large quantities into the sweetener aspartame (82, 
Scheme 16).[87, 94],[95] 
 
Scheme 16. Synthesis of aspartame (82) via L-aspartic acid (79). 
The fourth production method to obtain optically pure amino acids is represented by 
the field of asymmetric chemical synthesis. Less specific in the selectivity towards 
substrates and products, such syntheses are more general and therefore applicable 
for the formation of a broader range of unnatural -amino acids. A multitude of 
methods is available for this application to date, including stoichiometric and catalytic 
approaches.[81],[96],[97] Some strategies, such as the asymmetric Strecker-reaction[73a, 
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98] have been deeply investigated on laboratory scale. Others, such as hydrogenation 
of ,-dehydro--amino acid derivatives utilizing rhodium- or ruthenium-based 
catalytic systems, have already been applied on (multi-)kilogram or industrial 
scales.[99],[100] 
By far the most prominent example is the use of Knowles catalyst in the preparation 
of L-dopa (L-3,4-dihydroxyphenylalanine, 85) by Monsanto (Scheme 17).[101] The 
asymmetric hydrogenation of the (Z)-enamide 83 relies on a rhodium-catalytic 
system based on the chiral biphosphine ligand (R,R)-DIPAMP (86). The amino acid 
85 can be produced at scale and used as a psychoactive drug for the clinical 
treatment of Parkinson‟s disease.[4b, 102]  
 
Scheme 17. Monsanto L-Dopa 85 synthesis. 
1.3.3 Use of achiral nucleophilic glycine equivalents 
To compete against the most commonly used biocatalytic methods in industrial 
synthesis of -amino acids, a synthetic method needs to be as practical and 
economical as possible. Those aspects have often been neglected, rendering many 
known purely chemical procedures prohibitively expensive.[92a, b, 96e] In this context, 
the derivatization of nucleophilic equivalents of the structurally simplest -amino acid 
glycine 75 is probably the most economically sound and direct way for the synthesis 
of structurally diverse -amino acids.[103] 
Simple achiral nucleophilic glycine equivalents 87a and 87b were introduced by 
Stork[104] and O‟Donnel, respectively.[105] These Schiff bases derived from glycine 
esters can be alkylated under homogeneous conditions and subsequent hydrolysis of 
the addition product 88 gives access to the corresponding alkylated -amino acid 
ester 89 (Scheme 18). 
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Scheme 18. Alkylation of achiral glycine equivalents for the preparation of substituted -amino acids. 
This concept was further refined by O‟Donnell, demonstrating that similar imines can 
be alkylated under catalytic conditions.[105-106] When applying a cinchona alkaloid-
based chiral phase-transfer catalyst 92 these reactions proceeded stereoselectively. 
With Schiff base 90, derived from benzophenone and tert-butyl ester of glycine, the 
best results regarding selectivity were achieved (Scheme 19).[28b] 
 
Scheme 19. Asymmetric alkylation of glycine equivalents catalyzed by chiral phase-transfer 
catalyst 92. 
The nature of the ideal chiral phase-transfer catalyst for such transformations was 
subject of many investigations over the last decades.[107] 
N-(Anthracenyl)methylcinchonidium bromides, introduced by Lygo,[108] and O-allyl 
substituted derivatives 93 thereof, studied by Corey,[28c] proved superior than the 
original catalyst 92, reaching high level of asymmetric induction (Scheme 20a, up to 
98% ee).[102, 109] In 1999 and 2005, respectively, N-spiro C2-symmetrical chiral 
quaternary ammonium bromides 25[110] and 94[111] were introduced as chiral phase-
transfer catalysts by Maruoka (Scheme 20b and 20c). They provided excellent 
stereochemical control, leading to alkylated Schiff bases 91 with an enantiomeric 
excess of up to 99%, and were also applicable in the preparation of ,-disubstituted 
amino acids.[112],[32, 109g, 113] 
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Scheme 20. Asymmetric alkylation of glycine equivalents 90 catalyzed by chiral phase-transfer 
catalysts. 
1.3.4 Use of chiral nucleophilic glycine equivalents 
The application of chiral nucleophilic glycine equivalents for the asymmetric synthesis 
of -amino acids is another widespread method. In this context, the use of bis-lactim 
ethers 95 derived from glycine (75) and L-valine (74) or L-tert-leucin was first reported 
by Schöllkopf.[114] Enolation with n-BuLi, subsequent alkylation, and hydrolysis gave 
the -amino acid methyl esters 97 with high enantioselectivity (up to >95% ee, 
Scheme 21). 
 
Scheme 21. Asymmetric alkylation of chiral glycine equivalents 95. 
Other similar reagents derived from glycine (75) and a chiral auxiliary have been 
developed since then (Figure 8). 5,6-Diphenylmorpholin-2-one (98) introduced by 
Williams[115], trycyclic iminolactones 99 by Lu[116], and imidazo- and oxazolidinones 
100 designed by Seebach[117] have shown remarkable synthetic utility. In these cyclic 
templates, one of the in situ formed enolate faces is effectively shielded from the 
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incoming electrophile. Also acyclic templates, such as Myers glycinamide 101[118] and 
Evans oxazolidinone 102,[119] have been used in asymmetric alkylation reactions. 
 
Figure 8. Selected chiral glycine equivalents. 
Unfortunately, the preparation of these equivalents typically requires multi-step 
sequences, and the low C-H activity of the glycine methylene moiety in all of these 
examples demands the use of rather inconvenient reaction conditions. Strong bases 
(n-BuLi), low temperatures (usually 78 °C) and the use of anhydrous techniques are 
mandatory to form the corresponding enolates 
1.3.5 Use of Ni(II)-complexes as nucleophilic glycine equivalents 
Another nucleophilic equivalent of glycine (75) was introduced by the Belokon group 
in 1985,[120] describing the formation of asymmetric Ni(II)-complexes 106 with 
(S)-2-[N-(N‟-benzylprolyl)amino)-benzophenone (BPB, (S)-105) as a chiral ligand 
(Scheme 22). Complex 106 could be functionalized by aldol condensation with 
aldehydes and ketones, yielding -hydroxy--amino acids with high stereoselectivity 
(up to 88% ee).[120] The selectivity originates from the effective shielding of one side 
of the square planar complex 106 by the N-benzyl group, which is assumed to 
stabilize the conformation of the complex by weak interactions with the central nickel 
atom.[121] 
The thermodynamically controlled, diastereoselective derivatization of 106 was later 
achieved through a multitude of different types of reactions[103, 122] such as aldol[120, 
123] or Michael addition,[124] Mannich reaction,[125] alkyl halide alkylation,[126] and 
oxidative coupling reactions.[127] Functionalization was typically conducted at room 
temperature and did not require dry solvents, rendering this method useful for a 
large-scale preparation of target amino acids. Furthermore, the chiral ligand (S)-105 
was easily recovered after acidic hydrolysis of the functionalized complex 107, a 
transformation that was undertaken to achieve the target -amino acid (S)-77. 
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Pioneering works in this field were carried out mainly by the groups of Belokon and 
Soloshonok. 
 
Scheme 22. Synthesis and application of chiral glycine equivalent 106. 
1.3.5.1 Functionalization by alkyl halide alkylation 
The alkylation of Ni(II)-complexes of glycine by using alkyl halides was reported by 
Belokon in 1988.[126a] Due to its high C-H acidity (pKA= 18.8), deprotonation of 106 
does not require the use of organolithium reagents. Applying sodium hydroxide in 
DMF or MeCN at ambient temperature, treatment with alkyl halides, and subsequent 
hydrolysis gave the corresponding -amino (S)-77 acids in good yields with good to 
high selectivity (Scheme 23a and 23b). Likewise, phase-transfer catalysis (PTC) 
conditions were suitable for this reaction. By using 10% aq. NaOH together with TBAI 
in DCM, products were obtained in good yields but with somewhat compromised 
selectivity (Scheme 23c).  
 
Scheme 23. Alkylation of 106 under homogeneous and PTC conditions. 
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Under homogeneous conditions, subsequent second alkylation of the glycine moiety 
is a competing side reaction, which could be prevented by fine-tuning of reaction 
conditions, or utilized for the synthesis of cyclic amino acids.[128]  
 
Figure 9. Structurally diverse -amino acids prepared by alkylation of chiral Ni(II)-complexes of 
glycine. 
Further investigations were made, and the substrate scope was enlarged to produce 
sterically constrained,[126d, 129] fluorinated,[126b] unsaturated,[126c, 130] and photo-
reactive[131] -amino acids with typically high to virtually complete stereochemical 
control (>90% ee). Pyrenylalanine ((S)-77a),[129d] bis-4-fluorophenyl-substituted 
(S)-2-aminopropanoic acid (S)-77b,[129e, 132] -CF3-norvaline (S)-77c,[126f] and 
photoreactive phenylalanine   (S)-77d[131, 133] are selected examples. Moreover, the 
synthesis of borono-amino acid (S)-77e[134] and phosphorylated amino acid 
(S)-77f[135] was reported. 
 
Scheme 24. Synthesis of 109 via asymmetrically alkylated Ni(II)-complex 107g. 
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In this context, an elegant route to fully protected methyl N-Boc-(2S,4R)-4-
methylpipecolate (109) was described by Brimble.[136] The structural motif of 
(2R,4R)-4-methylpipecolic acid is one of the key components in the potent and 
selective thrombin inhibitor argatroban 110.  
Different functionalities in chiral glycine equivalent 106 were substituted to study their 
influence on alkylation reactions. In this context, introduction of ortho-halogen 
substituents at the N-benzyl function led to increased selectivities and shorter 
reaction times. This effect was assumed to be caused by a stronger aryl-nickel 
interaction, resulting in a more rigid complex 111.[137]  
The exchange of the (S)-proline moiety for achiral structures was studied extensively 
by Soloshonok. In this context, complex 112, derived from 2-[N-(-picolyl)-
amino]benzophenone, and complex 113, incorporating a dibutylamine moiety, was 
found to be an efficient substrate in bisalkylation reactions to form 
sym-,-bisalkylated amino acids under homogeneous conditions.[138] 
 
Figure 10. Examples of chiral Ni(II)-complexes of glycine with varied functionalities. 
1.3.5.2 Alkyl halide alkylation under PTC conditions 
The alkylation of complex 106 under homogeneous, thermodynamically controlled 
conditions allowed the formation of the corresponding alkylated complexes in 
diastereomeric ratios of typically >95:5 (see 1.3.5.1). In contrast, kinetically controlled 
alkylation under PTC conditions typically occurred with noticeably lower 
stereochemical control.[126a, g] Nevertheless, due to the use of milder reaction 
conditions a main advantage of the latter approach is the prevention of side products 
and the acceptance of a broader range of alkylation reagents. 
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Scheme 25. Asymmetric alkylation of 106 under PTC conditions in 1,2-dichloroethane. 
In 2012, Soloshonok and co-workers reported on an improved protocol for this type 
of transformation.[126g] Their studies revealed 1,2-dichlorethane as a suitable solvent, 
and by applying chiral glycine complex 106 as well as TBAI as the phase-transfer 
catalyst, the addition of various activated alkyl halides proceeded with 
diastereoselectivities of up to 94:6 (Scheme 25). Subsequent treatment of the 
diastereomeric mixture of products with NaOMe in MeOH led to epimerization of the 
minor diastereomer. In this manner, products 107 were obtained as a single isomer 
in excellent yields. 
1.3.5.3 Functionalization by Michael addition reaction 
There are two conceptionally different cases known for the functionalization of chiral 
nickel glycine complexes by Michael addition reaction. Firstly, the use of glycine 
Schiff base as a nucleophilic partner with various Michael acceptors, and secondly, 
the use of Ni(II)-complexes of dehydroalanine as electrophilic acceptor.[122b]  
 
Scheme 26. Asymmetric Michael addition reactions of Ni(II)-complex 106. 
The first use of 106 as a Michael donor was reported by Belokon.[139] Its reaction with 
methyl acrylate 114a or acrylonitrile 114b gave the addition products in high yields 
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with a dr of 95:5 (Scheme 26a). The use of substituted acrylates 116 resulted in a 
mixture of diastereomeric products due to low control over the newly formed 
stereocenter in the amino acid side chain (Scheme 26b). Notably higher selectivity 
was observed, when a CF3-moiety was installed at the -position of the Michael 
acceptor.[124a, b, 140] 
Further investigations included the addition of -halogen acrylates,[124f, 141] 
di-tert-butyl methylenemalonate,[142] and -unsaturated carbonyl compounds[143] 
with typically high diastereoselectivity. Contrary, utilization of vinylphosphonates[135b] 
and vinylsulfonates[144] resulted in product mixtures of rather low 
diastereoselectivities (dr of 65:35 and 73:27, respectively).  
 
Scheme 27. Asymmetric Michael addition to Ni(II)-complex 118. 
The derivatization of Ni(II)-complex 106 by aldol reaction with formaldehyde and 
subsequent dehydration of the intermediate serine-complex resulted in the formation 
of dehydroalanine complex 118. This derivative proved its utility as a Michael 
acceptor in reactions with nucleophiles such as MeOH (Scheme 27).[145] 
1.3.5.4 Functionalization by aldol addition reaction 
The first aldol addition of nickel complex 106 to formaldehyde was described by 
Belokon in 1985.[120] Addition products were received with diastereomeric ratios of up 
to 98:2. S-configuration of the newly formed stereocenter was favored when 
triethylamine or low amounts of sodium methanolate were applied as base. Contrary, 
reactions with an excess of sodium methanolate led to the formation of R-configured 
amino acids. Hence, the stereochemical outcome was found strongly pH-dependent 
(Scheme 28). 
 
Introduction 
 
35 
 
 
Scheme 28. Asymmetric aldol addition reactions of Ni(II)-complex 106 to formaldehyde. 
Further studies at high pH-vales with various aliphatic aldehydes revealed, that the 
stereochemical outcome was also time dependent. While almost pure 
(S)(2S,3R)-configurated Ni(II)-complexes 121 were formed initially, after long 
reaction times those were transformed into complexes (R)(2R,3S)-121 with 
diastereomeric ratios of up to 95:5 (Scheme 29). Whereas the steric bulk of 
aldehydes had little influence on the stereochemical outcome of the kinetic product, it 
was crucial for the diastereoselectivity in the formation of the thermodynamic 
one.[123a]  
 
Scheme 29. Asymmetric aldol addition reactions of Ni(II)-complex 106 to aldehydes. 
A proposed plausible mechanism included the deprotonation of the side chain 
hydroxy group and subsequent rearrangement of the intermediate aldol condensation 
products. The ionized hydroxyl group is assumed to substitute the carboxyl group in 
the main coordination sphere of the central Ni-atom to form intermediate 
(S)(2R,3S)-122. In this intermediate unfavorable steric interaction of the carboxylate 
with the N-benzyl group controls the configuration at the -carbon, while the 
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thermodynamically preferred trans-relationship of the carboxylate and the alkyl-group 
determines the configuration at the -position . 
Further aldol addition reactions have been described applying 106 and other chiral 
Ni(II)-complexes of glycine. An recent overview was given by Soloshonok and 
Sorochinsky.[122a] 
 
1.4 Reactions under solvent-free mechanochemical conditions 
The concept of applying mechanical force as a tool in pharmacy and chemistry is 
going back to ancient times. Mortar and pestle were used for the crushing and fine 
grinding of substances for subsequent use as ingredients in food or drugs 
(hand/manual grinding).[146] For this purposes it is still utilized in nowadays chemistry 
laboratories and in pharmacies. On an industrial scale the crushing of ores and 
minerals is conducted in ball mills, where mechanical milling is performed with the aid 
of milling balls. While in most processes milling is mainly used for a particle size 
reduction and efficient mixing, the energy distributed to the system can additionally 
cause various processes, of which one is the activation of chemical reactions.[147] 
Taking into account IUPAC‟s definition of a mechanochemical reaction as a 
“chemical reaction that is induced by the direct 
absorption of mechanical energy”,[148] 
(organic) synthesis under grinding/milling conditions can be considered as 
mechanochemistry. The earliest surviving document describing a mechanochemical 
reaction is a book written by Theophrastus of Eresus in or around 315 B.C. 
It provided information about the reduction of cinnabar to mercury in a copper mortar 
(eq. 1).  
 
Although the manual grinding technique still finds application in organic synthesis it 
bears several disadvantages, mainly due to low reproducibility.[147] Hence, laboratory 
ball mills are applied for bench scale applications, offering the possibility to exactly 
control process parameters like reaction time and milling speed and therefore the 
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energy entry.[149] Such utilization of the laboratory scale ball milling technique, also 
referred to as high speed ball milling (HSBM), has more recently attracted the 
attention of organic chemists.[149-150] 
The use of HSBM in organic synthesis with focus on C-C bond formations as well as 
asymmetric organocatalyzed reactions will be described in the following sections. 
1.4.1 Mechanochemistry in laboratory ball mills 
On laboratory scale, mainly three versions of ball mills are used. Mixer mills (MM) 
generate energy by oscillation of the milling beaker at variable frequencies in a 
horizontal plane, causing collisions of the milling balls with the top and bottom ends 
of the beaker (Figure 11a). In Vibrational ball mills (VBM) the degree of freedom 
regarding the oscillation is increased (two-dimensional oscillation) and the trajectory 
of the milling containment is therefore more complicated as compared to mixer 
mills.[151]  
Planetary mills (PM) consist of a central disk on which disks of smaller diameter are 
mounted, carrying the milling beaker (Figure 11b). Rotation of the disks in opposite 
directions leads to typical centrifugal trajectories of the milling balls in the beaker 
together with collision with the beaker walls or between milling balls.  
 
(a) (b) 
Figure 11. Schematic description of movement in a mixer mill (a) and a planetary mill (b). 
Beakers and balls can be of different size, shape and materials such as stainless 
steel, yttrium or magnesium stabilized zirconia, tungsten carbide, or copper. 
Chemical inert materials are preferred, but in some cases the material itself may act 
as a reaction partner or catalyst (e.g. eq. 1). Together with the filling degree and the 
type of mill applied, those variants are referred to as technological parameters. 
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These, as well as process parameters (milling time and speed, temperature) and 
chemical parameters (reaction type, reaction ratio, catalyst, presence of liquids, etc.) 
characterize a process or reaction performed in a ball mill and independently may 
affect its outcome.[147] 
With respect to ecologic and economic challenges[152] one of the most obvious 
advantages of performing organic synthesis mechanochemically is the reduction of 
the amount of waste by omission of solvents in the reaction.[153] Hence, such 
processes are considered to be solvent-free (solventless).[154] Nevertheless, in some 
cases small amounts of solvent are added. Even though they are not sufficient 
enough for the complete dissolution of substrates, they effectively support the 
process by liquid assisted grinding (LAG). 
1.4.2 Mechanochemical organic synthesis by C-C bond forming reactions 
The field of organic synthesis under mechanochemical conditions in ball mills is 
broad and covers a multitude of different reaction types. It includes the forming of 
covalent C-C and carbon-heteroatom bonds as well as processes that (additionally) 
may involve metal-ligand coordination bonds and non-covalent interactions. The 
efficient creation of C-C bonds is of great interest for organic chemists, and there are 
numerous ways known to achieve this objective. Consequently, the development of 
solventless, mechanochemical pathways is truly attractive and various methods have 
been described.[150g, i] Amongst others, the technique is used in condensation, 
nucleophilic alkylation, and metal-promoted or metal-catalyzed reactions. Moreover it 
can be utilized in asymmetric organic synthesis.  
1.4.2.1 Condensation reactions 
Condensation reactions to form C-C single or double bonds are manifold and well-
studied in traditional organic synthesis. Some of these have been shown to be 
feasible using ball milling techniques and selected examples will be described here. 
The Knoevenagel condensation of aryl aldehyde 123 with malononitrile (124a) and 
methyl cyanoacetate (124b) was achieved by milling with CaCO3 or CaF2, giving the -unsaturated products 125 in good yields of typically more than 80% 
(Scheme 30).[155] Hantzsch-1,2-dihydropyridine was reported to serve as a catalyst 
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for this reaction and as a reductant in the subsequent hydrogenation of the double 
bond.[156] Catalyst free protocols for the mechanochemical supported Knoevenagel 
condensation were developed by Kaupp and Ondruschka.[155b, 157] 
 
Scheme 30. Mechanochemical Knoevenagel condensation. 
Aldol reactions can be conducted mechanochemically under basic or acidic catalysis. 
In 2000, Raston and Scott described the first crossed aldol condensation in a mixer 
mill.[158] Additional examples have been reported since, including aldol addition 
reactions without further condensation,[159] aluminium-catalyzed reactions,[160] and 
self-condensation of cyclohexanone.[161] 
Mack found that the Morita-Baylis-Hillman reaction of methyl acrylate (114a) with 
various aryl aldehydes 123 could be performed under basic catalysis in the ball mill. 
The addition products 126 were obtained in good yields after short reaction times 
(Scheme 31).[162] 
 
Scheme 31. Mechanochemical Morita-Baylis-Hillman reaction. 
Michael addition reactions of 1,3-dicarbonyl compounds to chalcones 127a and 
azachalcones 127b in ball mills were first reported by Wang.[163] While in solution 
usually strong bases are applied to this kind of transformation, the mechanochemical 
reaction was enhanced by the weak base K2CO3 (Scheme 32). It was shown that the 
corresponding products 128 could be obtained with similar yields when malonic acid 
ester 39b was replaced by ethyl acetoacetate.[164] azo-Michael addition reactions of 
aliphatic and aromatic amines to chalcones were reported by Li, achieving the 
corresponding addition products without the need for an additional catalyst.[165]  
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Scheme 32. Mechanochemical Michael addtion reaction. 
Cascade reactions, typically including condensation reactions and nucleophilic 
addition steps, are a powerful tool for the construction of heterocycles and complex 
molecules. Hence, such pathways are of great interest for organic chemists and have 
found their way into the field of mechanochemistry.[150g, 166] A selected example is the 
formation of tetrahydroxanthenone 131 from salicylaldehyde (129) and 
2-cyclohexen-1-one (130) reported by Bräse (Scheme 33). The reaction proceeds by 
an oxo-Michael-aldol reaction pathway.[167] 
 
Scheme 33 Mechanochemically initiated oxo-Michael-aldol reaction. 
1.4.2.2 Alkylation reactions 
The direct base mediated alkylation of cylohexanones with 4-bromobenzyl bromide 
(133) was reported by Mack in 2010. Depending on the strength and size of the base 
applied, either the thermodynamic product 134 or the kinetic product 135 was mainly 
obtained in the alkylation of 2-methyl cyclohexanone (132).  
 
Scheme 34. Mechanochemical alkylation of 2-methyl cyclohexanone 132. 
Thus, it was demonstrated that reactions can be selective and driven by kinetics, 
although ball milling is theoretically an extremely high energy process.[168] Utilizing 
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NaNH2 as a base, 55% conversion towards the thermodynamic product 134 were 
observed after only 10 minutes in this reaction.[161] 
1.4.2.3 Metal-mediated reactions 
Metal-promoted and metal-catalyzed reactions have been widely employed in 
mechanochemical organic synthesis and selected examples will be summarized 
here.  
The first FeCl3-mediated oxidative homocoupling of phenols by manual grinding and 
heating of the resulting solid mixture was described by Toda in 1989.[169] 
Mechanochemical protocols for this reaction under HSBM conditions were developed 
by Tanner and Shayesteh to obtain racemic 2,2‟-dihydroxy-1,1‟-binaphthyl (137) and 
other dehydrogenative homocoupling products in short reaction times 
(Scheme 35).[170] 
 
Scheme 35. Mechanochemical, FeCl3-mediated homocoupling of 2-naphthol (137).
 
Manganese(III) acetate is a well-known single-electron transfer reagent to generate 
radicals from carbonyl compounds, and was used under mechanochemical 
conditions for this purpose.[171] In this context it was applied in radical reactions of 
fullerene C60 (138) with cyclic 1,3-diketones 139 (Scheme 36).
[172]  
 
Scheme 36. Radical functionalization of fullerene C60 (138) under HSBM conditions.
 
Metal-catalyzed cross coupling reactions have been widely investigated in the field of 
mechanochemistry. Prominent examples include Pd-catalyzed Suzuki reactions 
studied by Peters,[173] Leadbeater[174] or Ondruschka[175] (e.g. Scheme 37a[173]), and 
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Sonogashira coupling reactions either executed with the use of a copper co-catalyst 
(as reported by Mack)[176] or under copper-free conditions (as reported by Stolle, 
Scheme 37b).[177] Also mechanochemical, Pd-catalyzed Heck reactions have been 
investigated.[178] Recently, the Rh-catalyzed C-H-bond functionalization by oxidative 
Heck reaction was reported by Bolm (Scheme 37c).[179] 
First observed as a side reaction in the Sonogashira coupling, Stolle additionally 
explored the copper-catalyzed Glaser coupling of terminal alkynes 149. 
Homocoupling products 150 were obtained in high yields after short milling times 
(Scheme 37d).[177b, 180] 
 
Scheme 37. Metal-catalyzed coupling reactions under mechanochemical conditions.  
Most interestingly, Stolle also reported on a copper-catalyzed mechanochemical 
click[181] reaction, a 1,3-dipolar cycloaddition of terminal alkynes 149 and azides 151. 
Copper acetate was applied as a catalyst and silica served as a milling auxiliary 
(Scheme 38a). The addition products 152 were received in excellent yields after only 
10 minutes of milling.[182] Mack and Ranu further investigated on mechanochemical 
click reactions, utilizing a copper milling beaker and copper balls or a supported 
copper catalyst (Cu/Al2O3), respectively. In both cases, the required azides were 
formed in situ from NaN3 (153) and aliphatic halides 154 (Scheme 38b).
[183] 
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Scheme 38. 1,3-Dipolar cycloaddition reactions performed in ball mills. 
1.4.2.4 Asymmetric mechanochemical reactions 
Asymmetric synthesis under solventless HSBM conditions has been in the focus of 
several investigations. Especially in asymmetric organocatalysis (see chapter 1.2) 
reactions may benefit from this technique by the increased mixing efficiency at high 
concentration of reactants. Moreover, by shortening reaction times, reducing catalyst 
loadings, and omitting solvents, a higher level of sustainability can be reached. An 
overview on asymmetric organocatalysis under mechanochemical conditions 
constitutes the main topic of this section. 
Pioneering studies on asymmetric transformations under mechanochemical 
conditions were carried out by Bolm and coworkers. By adding quinidine (159), the 
enantioselective opening of cyclic anhydrides with alcohols was possible and 
ee-values of 13-64% were obtained (Scheme 39).[184] 
 
Scheme 39. Asymmetric opening of cyclic-anhydrides under HSBM conditions. 
The mechanochemical enantioselective aldol addition of ketones 160 and substituted 
benzaldehydes 161 in an organocatalytic manner was also reported by Bolm.[184a, 185] 
When (S)-proline (12) was employed as a catalyst, high yields and 
diastereoselectivities were achieved together with moderate to excellent 
enantiomeric excesses (45-99% ee) in the transformations to anti-aldol product 162. 
Reactions proceeded remarkably faster than solvent-free reactions using 
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conventional magnetic stirring, and only a low excess of ketone was required in the 
milling protocol.  
 
Scheme 40. Mechanochemical initiated asymmetric aldol adition catalyzed by (S)-proline (12). 
Other catalysts have been applied in similar reactions. For instance, (S)-binam-
L-prolinamide (163) utilized by Nájera,[186] and ,-dipeptides 164a, 164c and 164e 
as well as thioamide derivatives 164b and 164d thereof, employed by Juaristi, 
proved to be efficient organocatalysts for aldol reactions under ball milling conditions 
(Scheme 41).[187] In further studies, ,-dipeptides were also used as catalysts 
promoting the formation of aldol products with slightly lower stereoselectivity.[188] 
 
Scheme 41. Asymmetric aldol reaction under ball milling conditions. 
An example for the mechanochemically conducted asymmetric Morita-Baylis-Hillman 
reaction was described by Friščić. Bis-thiourea catalyst 166 was applied in the 
addition of benzaldehyde (1) to 2-cyclohexen-1-one (130), giving the addition product 
with low enantioselectivity (Scheme 42).[189] 
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Scheme 42. Chiral thiourea-catalyzed Morita-Baylis-Hillman reaction under HSBM conditions. 
Pioneering work in the field of asymmetric Michael reactions under HSBM conditions 
was carried out by Šebesta, examining the addition of aldehydes 167 to -nitrostyrenes 40, catalyzed by (S)-proline (12) and derivatives thereof. ,-Diphenylprolinol trimethylsilyl ether (29) proved to be most effective, and addition 
products 168 were obtained in good to high yield and with moderate to high 
stereoselectivity (Scheme 43).[190] 
 
Scheme 43. Asymmetric, mechanochemical Michael addition reaction. 
In 2012, Xu reported on the mechanochemical, asymmetric addition of 1,3-dicarbonyl 
compounds 169 to nitroolefins 40 catalyzed by squaramide catalyst 170. Only 
0.5 mol% of the catalyst was sufficient to facilitate the reaction, giving the addition 
products 170 in high yield and with excellent enantioselectivity of 91-99% ee 
(Scheme 44).[191] 
 
Scheme 44. Sqaramide-catalyzed asymmetric Michael addition reaction in the ball mill. 
An intensive study examining the use of different chiral hydrogen-bonding catalysts 
under solvent-free conditions has been carried out by Šebesta. Structurally diverse 
thioureas and squaramides were applied in the Michael addition of indole (59a) or 
Introduction 
 
46 
 
dimethyl malonate (39a) to -nitrostyrene (40a) under HSBM conditions. The results 
were compared to corresponding experiments in solution. In many cases 
mechanochemically performed reactions were accelerated and the enantioselectivity 
was improved (for examples see Scheme 45a and 45b).[192] 
 
Scheme 45. Investigations on the effect of meachochemical activation on organocatalyzed 
asymmetric Michael addition reactions. 
Lamaty showed that cinchonidine-derived catalyst 93 served as an effective phase-
transfer catalyst in the asymmetric alkylation of Schiff base of glycine tert-butyl ester 
90 in the ball mill. When KOH was utilized as a base, alkylated products were 
obtained in excellent yields and with enantioselectivities up to 75% ee. Since 
catalyst-free transformations could be performed reaching similar yields, the 
existence of different phases, probably by melting of some of the reactants, was 
assumed to explain the achieved stereoselectivities.[193] 
 
Scheme 46. Asymmetric alkylation of glycine equivalent 90 under HSBM conditions. 
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1.4.2.5 Miscellaneous reactions 
Other types of organic transformations were examined under HSBM conditions. 
Diels-Alder and Grignard reactions as well as oxidation and reduction with solid 
reagents were conducted in this context, and examples of amino acid derivatization, 
peptide synthesis, metal organics, and fullerene chemistry have been explored 
mechanochemically. An excellent overview on the topic of ball milling including these 
examples was given by Stolle and Ranu.[150i] 
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2. Results and discussion 
2.1 Synthesis and application of natural amino acid-derived thioureas 
Various chiral scaffolds have been applied as building blocks for the design and 
synthesis of structurally diverse thiourea derivatives operating as bifunctional 
hydrogen-bonding organocatalysts in stereoselective transformations (see section 
1.2.3). One of the most prominent classes used for this purpose are chiral primary 
diamines, especially trans-1,2-diaminocyclohexane. This C2-symmetric chiral 
representative is commercially available, since it is a component in a byproduct 
amine stream in the industrial Nylon 66 production.[194] Its racemic mixture can be 
resolved by enantiomerically pure D- or L-tartaric acid.[195] Besides its cost-efficient 
availability, its easy derivatization established it as an ideal choice in chiral (thio)urea 
synthesis (e.g. Jacobsen‟s catalyst 16 and Takemoto catalyst 36). Additionally, 
starting from N,N-difunctionalized diamines 172 it is possible to access bifunctional 
(thio)ureas 173 with a tertiary amine basic site (Scheme 47). 
 
Scheme 47. Synthesis of chiral (thio)ureas 172 from N,N-difunctionalized 1,2-cyclohexadiamines 171. 
Besides trans-1,2-diaminocyclohexane, other diamines have successfully been 
applied as chiral linkers between the acidic and basic functional groups of 
bifunctional (thio)urea organocatalysts. Selected examples are 
(R,R)-1,2-diphenylethylenediamine-derived thiourea 174 and pseudoephedrine-
derived thiourea 175, which were used as catalysts for asymmetric Michael addition 
reactions by Chen[54, 196] and Bolm,[197] respectively (Figure 12). 
 
Figure 12. Chiral thioureas applied by Chen and Bolm. 
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In 1998, the preparation of enantiomerically pure 3-amino-substituted cyclic amines 
178 from -amino acids 176 was reported by Moon and Lee.[198],[199] Their five-step 
pathway included the esterification and N-protection of the applied chiral amino acid 
followed by reduction to the diol 177 and its subsequent mesylation. Treatment of the 
resulting dimethanesulfonates with ammonium hydroxide or benzyl amine led to the 
formation of 178 (R= H or Bn) in good overall yields (Scheme 48). 
 
Scheme 48. Synthesis of cyclic amines 178 as described by Moon and Lee.
[198] 
Such cyclic amines are biologically active, and they constitute essential parts of the 
molecular structures of drugs such as Bruton‟s tyrosine kinase inhibitor Ibrutinib 
(179, trade name Imbruvica),[200] Janus kinase inhibitor Tofacitinib (180, trade names 
Xeljanz, Jakvinus),[201] or Pim kinase inhibitor AZD1208 (181).[202] 
  
Figure 13. Drugs bearing a chiral cyclic diamine moiety. 
2.1.1 Research objective 
The elegant synthetic pathway towards 3-amino cyclic amines provided by Moon and 
Lee could open an easy access to various similar scaffolds 178 with diverse 
substitution patterns at the heterocyclic nitrogen atom. Deprotection of the 3-amino 
function and subsequent treatment with isothiocyanates was envisioned to lead to 
the formation of new bifunctional thioureas 182 (Scheme 49).  
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Scheme 49. Envisioned synthetic route towards chiral thioureas 182. 
The aim of this project was the synthesis of such thioureas containing the 3-amino 
cyclic amine scaffold as a chiral spacer,[199a] and to test for their capability as 
bifunctional organocatalysts in asymmetric Michael addition reactions. Moreover, the 
possibility to perform such reactions under solventless mechanochemical conditions 
was investigated. 
2.1.2 Synthesis of natural amino acid-derived bifunctional thioureas 
The preparation of enantiomerically pure 3-aminosubstituted cyclic amines from 
(S)--amino acids 79 and 72 was realized by applying the aforementioned protocol 
(see section 2.1) with slight modifications (Scheme 50). The esterification of 
commercially available amino acids was achieved by treatment with thionyl chloride 
in methanol. For improved and reproducible yields of the dimethylester hydrochloric 
salts 183, the chlorinating agent was slowly added to the mixture of acid and alcohol 
at 0 °C with the aid of a syringe pump (an addition speed of ~30 mL/h was chosen). 
The resulting mixture was allowed to reach room temperature and stirred for 16 h 
before concentration in vacuo. Treatment of crude 183 with di-tert-butyl dicarbonate 
under basic conditions in dry DCM then gave the N-Boc-dimethylesters 184 in 
quantitative yield. Again, the slow addition of reagents by the aid of a syringe pump 
proved useful. Consecutively, the reduction of diesters 184 was conducted with 
in situ formed calcium borohydride.[203]  
 
Scheme 50. Synthesis of chiral diols 177. 
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The success of this reduction was highly depending on the use of finely grinded 
calcium chloride and sodium borohydride, which were mixed in dry ethanol prior to 
the addition of an ethanolic solution of the diester. This reduction procedure proved 
superior to others applying lithium borohydride (no conversion), lithium aluminum 
hydride (44% yield of 177b after 72 h) or a sodium borohydride-iodine system[204] (up 
to 35% yield of 177b after 16 h) as reducing agents. Starting from L-aspartic acid (79) 
and L-glutamic acid (72), the amino diols were received in good yields of 84% and 
78%, respectively. 
Next, dimesylation of the amino diols 177 was executed in dry DCM using 
methanesulfonyl chloride. The reactions proceeded smoothly and gave the target 
products 185 in quantitative yield. Subsequently, an array of N-Boc-protected 
3-amino cyclic amines was accessed when the doubly activated substrates 185 were 
stirred in an excess of a primary amine. Five sterically diverse endocyclic-
N-substituted 3-amino piperidines 178b-f and one endocyclic-N-methylated 
pyrrolidine 178a were received from -amino acids 79 and 72 in yields of 49-71% 
over 5 steps. The likewise tested cyclization reaction of 185 with less nucleophilic 
aniline did not proceed (Scheme 51). 
 
Scheme 51. Synthesis of chiral diamines 178. 
Two more steps led to the target thioureas. N-Boc group cleavage was achieved with 
hydrochloric acid in methanol, affording the corresponding HCl-salts 186a-f. 
Subsequently, liberation of the diamines under basic conditions and addition of the 
respective isothiocyanates led to thioureas 182a-s in good to excellent yields of 
66-99% (Table 1). While most thioureas were achieved as yellow or (off-)white solids, 
some were isolated as orange or colorless glues (see section 5.4.3). Thiourea 182q, 
obtained from iso-butyl isothiocyanate, revealed a highly hygroscopic character. 
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Table 1. Synthesis of thioureas from N-Boc-protected cyclic diamines. 
 
 
Entry Diamine R R2 Product Yield [%]a 
1 178a (n= 1) Me 3,5-(CF3)2-C6H3 182a 86
 
2 178b (n= 2) Me 3,5-(CF3)2-C6H3 182b 81
 
3 178c (n= 2) i-Pr 3,5-(CF3)2-C6H3 182c 66 
4 178d (n= 2) t-Bu 3,5-(CF3)2-C6H3 182d 82 
5 178e (n= 2) Cy 3,5-(CF3)2-C6H3 182e 92 
6 178f (n= 2) Bn 3,5-(CF3)2-C6H3 182f 94 
7 178b (n= 2) Me C6H5 182g 89
 
8 178b (n= 2) Me 4-CH3-C6H4 182h 67 
9 178b (n= 2) Me 4-CF3-C6H4 182i 98 
10 178b (n= 2) Me 4-NO2-C6H4 182j 99 
11 178b (n= 2) Me 4-Cl-C6H4 182k 95 
12 178b (n= 2) Me 3,5-Cl2-C6H3 182l 70 
13 178b (n= 2) Me 4-F-C6H4 182m 96 
14 178b (n= 2) Me 2-naphthyl 182n 97 
15 178b (n= 2) Me 2,6-(CH3)2-C6H3 182o 79 
16 178b (n= 2) Me Bn 182p 96 
17 178b (n= 2) Me i-Bu 182q 94 
18 178b (n= 2) Me CH2Cy 182r 99 
19 178d (n= 2) t-Bu Bn 182s 97 
a) After column chromatography. 
The reduction of 1-benzylpiperidine substituted thiourea 182f to achieve the 
piperidine substituted analogue 182t was not successful, resulting in partial 
decomposition into a mixture of unidentified compounds. No target thiourea product 
was obtained by any means (Scheme 52). 
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Scheme 52. Attempts towards the reduction of N-benzyl substituted thiourea 182f. 
In similar way to the previously described synthesis, thiourea ent-182d was prepared 
from D-glutamic acid (ent-176b). Similar yields as compared to the preparation of 
182d were achieved (Scheme 53). 
 
Scheme 53. Synthesis of ent-182d. 
2.1.3 Application of natural amino acid-derived bifunctional thioureas 
Michael addition reactions belong to the most efficient and well-studied methods for 
C-C and C-heteroatom bond formations. Nitroalkenes constitute a popular class of 
electrophiles for such transformations,[205] since the corresponding addition products 
bear a flexible nitro functional group suitable for further derivatization.[206] When -substituted cyclic ketones are applied as nucleophiles in Michael addition 
reactions,[207] products with a quaternary stereogenic center are formed.[208] With 
3-amino cyclic amine-derived thioureas 182 in hand, the Michael addition of -nitrocyclohexanone (187) to nitroalkenes 40 therefore was chosen as a model 
reaction to reveal catalytic activities and to be a good indicator for the intrinsic 
stereoselectivity during the C-C bond formation affording dinitrocyclohexanone 
188.[209],[210] An initial experiment was conducted at room temperature in Et2O using 
10 mol% of thiourea 182b as a catalyst. In this manner, the Michael addition of -nitrocyclohexanone (187) to 2-fluoro--nitrostyrene (40b) gave 188b in a 
satisfactory yield of 81%, with a diastereomeric ratio of 94:6 and an enantiomeric 
ratio of 93:7 (Table 2, entry 1). No reaction occurred in the absence of the catalyst.  
Solvent screening experiments were conducted at room temperature to particularly 
monitor the effect on the stereochemical outcome of this reaction (Table 2). 
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Reactions performed in other ethers such as THF and MTBE gave the addition 
product in lower yield but with similar stereoselectivity (entries 2 and 3). In 
1,4-dioxane the yield and enantioselectivity dropped notably (entry 4). Nonpolar 
n-heptane was a suitable solvent for the transformation, giving the product 188b in a 
high yield of 87% and with good selectivity (dr of 91:9, er of 91:9, entry 5). Both high 
yield and selectivity were achieved when DCM became part of the screening 
process. The -nitro ketone 188b was isolated in 90% yield with a dr of 94:6 and an 
er of 94:6 in this case (entry 6). The use of toluene and benzene did not lead to 
improvements, affording good selectivities (er of 91:9 and 93:7, respectively) but 
rather low yields of 68% and 50% (entries 7 and 8). Remarkably, in protic polar 
solvents, such as methanol or iso-propanol, only poor yields and stereoselectivities 
were obtained (entries 9 and 10). The polar aprotic solvent acetonitrile served as an 
appropriate reaction medium, and product 188b was received in good yield of 82% 
and with an enantiomeric ratio of 90:10. With DCM selected as the most suitable 
solvent for this transformation, the amount of catalyst was varied next under 
otherwise unchanged reaction conditions. Reducing the amount of catalyst loading to 
5 mol% showed no effect regarding the enantioselectivity (Table 2, entry 12). 
Nevertheless, while the diastereomeric ratio of the product 188a was slightly 
enhanced, the catalyst was remarkably less active in this reaction than in the one 
using 10 mol% of catalyst (cf. entries 12 and 6). Running the transformation with an 
increased amount of catalyst 182b (20 mol%) gave the addition product in high yield 
but with somewhat compromised diastereo- and enantioselectivity (entry 13).  
Table 2. Solvent screening experiments and variation of the catalyst loading. 
 
Entrya Solvent Yield [%]b dr (anti:syn)c erc 
1 Et2O 81 94:6 93:7 
2 THF 51 95:5 92:8 
3 MTBE 68 92:8 94:6 
4 1,4-dioxane 55 95:5 87:13 
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Table 2. continued 
5 n-heptane 87 91:9 91:9 
6 DCM 90 94:6 94:6 
7 toluene 68 95:5 91:9 
8 benzene 50 93:7 93:7 
9 MeOH 6 64:36 69:31 
10 iso-PrOH <5 90:10 71:29 
11 CH3CN 82 87:13 90:10 
12 DCMd 28 96:4 94:6 
13 DCMe 94 90:10 93:7 
a) Use of 187 (0.3 mmol), and 40b (0.2 mmol) in 1 mL of solvent. b) After column chromatography. 
c) Determined by HPLC of the crude product using a chiral stationary phase. d) Use of 5 mol% of 
catalyst 182b. e) Use of 20 mol% of catalyst 182b. 
In order to evaluate their organocatalytic capability, also the other prepared thioureas 
182 were tested in the same Michael addition reaction under the optimized conditions 
(Table 3). First, thiourea 182a bearing an N-methylpyrrolidine scaffold was applied. 
Product 188b was isolated in 78% yield with a diastereomeric ratio of 94:6 and an 
enantiomeric ratio of 85:15 (Table 3, entry 2). Compared to catalysis with its 
piperidine-based analogue 182b, yield and stereoselectivity were degraded (entry 1 
versus entry 2). Increasing the steric bulk of the substituent at the endocyclic nitrogen 
of the piperidine-based catalyst led to improvements in the enantioselectivity 
(entries 3-7). The best result with respect to yield and enantioselectivity was 
achieved applying thiourea 182d, bearing an N-tert-butyl substituent. Thereby, 
product 188b was obtained in 91% yield with a dr of 90:10 and an er of 97:3 
(entry 4). Using ent-182d the reaction resulted in the formation of 188b in 81% yield 
with dr and er values of 95:5 and 3:97, respectively. The reasons why the dr and 
yield differed from the result achieved with 182d remained unexplored.  
Next, thioureas 182g-o, sharing the N-methyl-substituted piperidine-based scaffold 
but differing in the substitution pattern of the thiourea aryl fragment, became part of 
the screening process. Although with all these thioureas the diastereoselectivity was 
high, the yields decreased and the enantiomeric ratios dropped to the range of 90:10 
(Table 3, entries 8-16). These results showed a minor effectiveness of these 
catalysts than the 3,5-bis(trifluoromethyl)phenyl substituted analogue 182b. This is in 
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agreement with previous findings on the superior properties of this scaffold in 
thiourea-catalysts[47, 52, 211]  
Table 3. Catalyst screening experiments. 
 
Entrya Catalyst Yield [%]b dr (anti:syn)c erc 
1 182b 90 94:6 94:6 
2 182a 78 94:6 85:15 
3 182c 76 90:10 96:4 
4 182d 91 90:10 97:3 
5 ent-182d 91 95:5 3:97 
6 182e 72 90:10 96:4 
7 182f 79 94:6 94:6 
8 182g 56 88:12 88:12 
9 182h 33 92:8 88:12 
10 182i 65 93:7 91:9 
11 182j 25 95:5 89:11 
12 182k 84 93:7 91:9 
13 182l 79 91:9 92:8 
14 182m 82 93:7 92:8 
15 182n 82 89:11 89:11 
16 182o 84 95:5 87:13 
17 182p 91 94:6 96:4 
18 182q 58 93:7 92:8 
19 182r 74 92:8 92:8 
20 182s 90 82:18 97:3 
21 189 17 87:13 40:60 
22 190 23 66:34 50:50 
23 36 89 94:6 22:78 
24 29 31 92:8 56:44 
a) Use of 187 (0.3 mmol) and 40b (0.2 mmol) in 1 mL of DCM. b) After column chromatography. 
c) Determined by HPLC of the crude product using a chiral stationary phase.  
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Figure 14. Catalysts used in the catalyst screening experiments. 
When the thiourea aryl group was exchanged for alkyl groups such as iso-butyl or 
cyclohexyl-CH2 enantioselectivity did not improve (Table 3, entries 18 and 19). 
Interestingly, the desired enhancement in selectivity was achieved by replacing the 
aryl group by an unsubstituted benzyl group. Michael addition product 188b was 
obtained in 91% yield having a dr of 94:6 and an er of 96:4 utilizing thiourea 182p as 
a catalyst (entry 17). Regarding the yield (90%) and er (97:3), almost the same 
values were observed in the catalysis with thiourea 182s, bearing both beneficial 
structural units, benzyl substituent and N-tert-butyl-substituted piperidine scaffold, 
implemented in one structure. Surprisingly, the diastereomeric ratio (82:18) was 
remarkably low in this example (entry 20). 
Two more related compounds incorporating the N-methyl-substituted piperidine 
scaffold were tested as potential catalysts in the described Michael addition reaction. 
Low enantioselectivity was obtained with sulfonamide 190[212] and the use of 
thiophosphinamide 189 resulted in a racemic mixture of products (Table 3, entries 21 
and 22).[213] In a final attempt to compare the catalytic properties of thioureas 182 
with those of established catalyst structures, Takemoto thiourea 36[46] and the 
Jørgensen-Hayashi catalyst 29[37] were tested. While both compounds did activate 
the addition reaction, products were observed with only low to moderate 
enantiomeric ratios (entries 23 and 24). 
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Table 4. Condition screening experiments for the Michael addition reaction. 
 
 
Entrya 
Ratio 
187 : 40b 
T [°C] Yield [%]b dr (anti:syn)c erc 
1 1.5 : 1 rt 91 90:10 97:3 
2 1 : 1 rt 80 89:11 96:4 
3 1 : 1.5 rt 88 89:11 97:3 
4d 1 : 1.5 rt 81 89:11 96:4 
5 1 : 1.5 50 68 77:23 93:7 
6 1 : 1.5 0 90 91:9 98:2 
7e 1 : 1.5 -10 81 90:10 98:2 
a) Reactions were carried out on a 0.2 mmol scale in 1 mL of DCM. b) After column chromatography. 
c) Determined by HPLC of the crude product using a chiral stationary phase. d) Use of 0.5 mL of DCM 
as solvent. e) Reaction time extended to 72 h.  
Based on the catalyst screening results, thiourea 182d was chosen for subsequent 
studies. An additional condition screening revealed that changing the substrate ratio 
to an 1.5-fold excess of nitroalkene 40b (Table 4, entries 1-3) and lowering the 
temperature to 0 °C was beneficial for the stereochemical outcome of the reaction 
(entries 5-7). Reducing the amount of solvent used in the reaction led to 
compromised yields (entry 4).  
Studies regarding the substrate scope in the Michael addition reaction of -nitrocyclohexanone to nitroalkenes were carried out under the optimized conditions 
with catalyst 182d. All tested -nitrostyrenes 40a-h and 2-furyl-substituted nitroalkene 
40i reacted well, and the corresponding addition products 188a-i were obtained in 
yields ranging between 58% and 90% (Table 5). Although the optimized addition to 
2-fluoro--nitrostyrene resulted in high yields of the dinitrocyclohexanone 188b 
(Table 4, entry 1), the low yield of 58% in the conversion of the o-chloro-substituted 
nitroalkene 188c (Table 4, entry 3) indicates that steric reasons may play an 
important role in the catalyzed addition process. Electronic effects of the substituents 
on the aryl of the nitrostyrenes seemed not to matter to a large extend, since similar 
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yields were obtained with either electron-withdrawing or electron-donating functional 
groups.  
Table 5. Substrate scope of the Michael addition reaction. 
 
 
Entrya Nitroalkene R Product Yield [%]b dr (anti: syn)c erc 
1 40b 2-F-C6H4 188b 90 91:9 98:2 
2 40a C6H5 188a 77 99:1 97:3 
3 40c 2-Cl-C6H4 188c 58 89:11 97:3 
4 40d 4-F-C6H4 188d 75 93:7 97:3 
5 40e 4-Cl-C6H4 188e 73 91:9 97:3 
6 40f 4-Br-C6H4 188f 82 88:12 97:3 
7 40g 4-MeO-C6H4 188g 88 97:3 98:2 
8 40h 4-Me-C6H4 188h 78 93:7 98:2 
9 40i 2-furyl 188i 73 97:3 96:4 
a) Use of 187 (0.4 mmol), 40 (0.6 mmol) and thiourea 182d (0.04 mmol) in 2 mL of DCM. b) After 
column chromatography. c) Determined by HPLC of the crude product using a chiral stationary phase. 
Diastereoselectivities were generally high (around 90:10) and all products were 
received in enantiomeric ratios above 96:4. In that respect, highest results were 
achieved in the addition to nitrostyrenes 40b, 40g and 40h (er of 98:2, entries 1, 7 
and 8). The er of the products 188b and 188c could be improved to >99.5:0.5 by 
recrystallization from Et2O. 
Finally, it was confirmed that up-scaling of the reaction was unproblematic. Starting 
from 3.6 mmol of 2-fluoro--nitrostyrene (40b), 0.927 g (83%) of product 188b with 
an er of 98:2 was obtained after 23 h, applying 10 mol% of thiourea 182d at 0 °C. 
The catalyst could be recovered in 88% yield by column chromatography. 
The relative and absolute configuration of Michael adduct 188c was determined to be 
S,S by X-ray crystallographic analysis (Figure 15).[214] 
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Figure 15. Crystal structure of 188c. 
These results were in agreement with the most probable activation modes based on 
those proposed by Takemoto[54] (Figure 16, mode D) and Pápai[55] (Figure 16, 
mode E, see also section 1.2.3). Following their suggestions, either the nitroalkene or 
the deprotonated -nitrocyclohexanone is activated by hydrogen bonding to the 
thiourea moiety of the catalyst, while the residual substrate is activated by the 
(protonated) amine of the piperidine-scaffold. Both models account for the observed 
stereoselectivity. 
 
Figure 16. Plausible activation modes for the thiourea-catalyzed Michael addition reaction of 
2-nitrocyclohexanone (187) to nitroalkenes 40. 
2.1.4 Synthesis and application of natural amino acid-derived selenourea 
Isoselenocyanates are similar in reactivity but less utilized than their 
sulfur-analogues. A one-pot procedure for their preparation starting from 
corresponding formamides was described by Barton and optimized by Lopez.[215] 
The use of isoselenocyanates in the synthesis of selenoureas and their subsequent 
application (e.g. as antioxidants or in the synthesis of seleno-heterocyclic 
compounds) has also been described.[215b, c, 216] It was envisioned that the addition of 
such isoselenocyanates to 3-amino cyclic amines 178 could lead to the formation of 
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corresponding selenoureas to be applied as organocatalysts in Michael addition 
reactions. 
The synthesis of phenyl isoselenocyanate (192) was accomplished following the 
literature procedure.[215c] By treating formanilide (191) with triphosgene 
[bis-(trichloromethyl) carbonate, BTC] under basic conditions in DCM the 
corresponding phenyl isocyanide was formed in situ. Addition of elemental selenium 
gave the target compound 192 in 52% yield. Selenourea 193 was then obtained in 
91% yield by addition of N-methyl-substituted 3-amino piperidine-HCl salt 186b in 
THF (Scheme 54a). 
 
Scheme 54. Synthesis and application of selenourea 193. 
Application of selenourea 192 as a catalyst in the Michael addition of -nitrocyclohexanone (187) to 2-fluoro--nitrostyrene (40b) resulted in the formation 
of the addition product 188b in good yield and with good stereoselectivity (Scheme 
54). Compared to the reaction with its thiourea-analogue 182g it proved to be 
similarly reactive (cf. Table 3, entry 8). Unfortunately, the selenourea seemed to 
decompose under the applied reaction conditions. Even when proceeded in the 
darkness[215c] an insoluble black residue was found after 17 h reaction time. 
Nevertheless, this is the first reported use of a selenourea in asymmetric 
organocatalysis.[217] 
2.1.5 Bifunctional thioureas in mechanochemical Michael addition reactions 
After the successful application of bifunctional thioureas 182 as organocatalysts in 
solvent-based Michael addition reactions a further investigation on this 
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transformation was taken into consideration. In particular, the use of 
mechanochemical techniques was an appealing possibility. The idea for these 
studies was based on earlier reports by Bolm[184-185, 218] and others (see 
section 1.4.2.4) showing that indeed organocatalytic reactions can benefit from 
solvent-free mechanochemical conditions, resulting in higher reaction efficiency. 
Three factors, the high local reagent concentration, the lack of solvent interference to 
hydrogen bonding,[219] and the effective reagent mixing in the solvent-free media, are 
expected to be advantageous. 
The solvent-free coupling of -nitrocyclohexanone (187) and 2-furyl-substituted 
nitroalkene 40i was chosen as a test reaction, since in the solvent-based 
methodology the lowest er value was obtained with this substrates (er of 96:4, 
Table 5, entry 9). A FRITSCH planetary micro mill Pulverisette 7 classic line was 
applied for this project utilizing together with grinding vessels and balls made of ZrO2. 
A first experiment, employing thiourea 182b as a catalyst, showed that the addition 
proceeded smoothly leading to product 188i in 83% yield with a dr of 95:5 and an er 
of 92:8 after only 30 minutes (Table 1, entry 1). A screening of different reaction and 
milling conditions was carried out next. Neither variation of the substrate ratio 
(entries 1-3) nor of the reaction time (entries 4-6) or the milling speed (entries 7 and 
8), lead to better enantioselectivities or yields. Typically, reactions were carried out in 
milling cycles consisting of 15 minutes of milling followed by a 15 minutes pause. 
This procedure was proven to be necessary by performing a non-stopped 30 min 
reaction, providing the addition product 188i in only 66% yield (entry 9). Overheating 
was assumed to lead to decomposition of one or more of the involved reaction 
partners.  
The use of various milling auxiliaries such as neutral quartz sand, acidic silica or 
basic aluminum oxide (entries 10-12), and the addition of small amounts of DCM for 
liquid-assisted grinding (entries 13 and 14) were also tested, but none of these 
changes led to observable improvements neither in yield nor in enantioselectivity. 
Hence, the initially tested conditions (entry 1) were chosen for further studies 
regarding the ideal catalyst. 
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Table 6. Screening of reaction and milling condiions. 
 
 
Entrya 
Ratio 
187 : 40i 
Time 
[min] 
Milling 
speed 
[rpm] 
Additive 
Yield 
[%]b 
dr 
(anti:syn)c 
erc 
1 1.5 : 1 30 300 - 83 95:5 92:8 
2 1 : 1 30 300 - 60 93:7 89:11 
3 1 : 1.5 30 300 - 40 95:5 89:11 
4 1.5 : 1 15 300 - 56 91:9 88:12 
5 1.5 : 1 45 300 - 76 93:7 89:11 
6 1.5 : 1 60 300 - 74 95:5 89:11 
7 1.5 : 1 30 150 - 63 92:8 89:11 
8 1.5 : 1 30 500 - 83 95:5 91:9 
9d 1.5 : 1 30 300 - 66 92:8 90:10 
10e 1.5 : 1 30 300 quartz sand 63 91:9 87:13 
11e 1.5 : 1 30 300 acidic silica 69 91:9 83:17 
12e 1.5 : 1 30 300 basic Al2O3 63 92:8 91:9 
13 1.5 : 1 30 300 DCM (1 equiv.) 75 93:7 91:9 
14 1.5 : 1 30 300 DCM (3 equiv.) 69 95:5 92:8 
a) Reactions were carried out on a 0.2 mmol scale; ball milling conditions: cycles of 15 min at 300 rpm 
and 15 min pause, 20 balls with a diameter of 0.4 cm. b) After aqueous workup and column 
chromatography. Because a small amount (1-5%) of 187 remained in the product, the “yield” reported 
here was corrected after analysis by 1H-NMR spectroscopy. c) Determined by HPLC of the crude 
product using a chiral stationary phase. d) Milling without pause. e) 15.4 mg (20 wt%) of the additive.  
Eight structurally diverse thioureas 182 were tested in catalyst screening 
experiments. In comparison to initially used thiourea 182b the application of 
pyrrolidine-based urea 182a resulted in lower yield of 188i and a reduced 
stereoselectivity (Table 7, entries 1 and 2). Replacing the thiourea 
3,5-bis(trifluoromethyl)phenyl moiety for a 2-naphthyl or benzyl substituent also did 
not improve the addition reaction outcome (entries 3 and 4). Better results could be 
achieved by replacing the methyl substituent on the endocyclic nitrogen atom for 
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bulkier tert-butyl or cyclohexyl groups (entries 5 and 6). Best results regarding the 
diastereoselectivity (dr of 96:4) and enantioselectivity (er of 95:5) were obtained by 
the use of thiourea 182s bearing an endocyclic tert-butyl substituent as well as a 
benzyl moiety connected to the thiourea scaffold (entry 7). Due to its glue-like nature, 
this catalyst was frozen with liquid nitrogen under argon atmosphere for easier 
transfer before weighting in.  
Table 7. Catalyst screening experiments. 
 
 
Entrya Catalyst Yield [%]b 
dr 
(anti:syn)c 
erc 
1 182b 83 95:5 92:8 
2 182a 69 90:10 76:24 
3 182n 57 85:15 91:19 
4 182p 64 89:11 90:10 
5 182d 77 93:7 93:7 
6 182e 92 92:8 92:8 
7 182s 85 96:4 95:5 
8 182g 71 92:8 85:15 
9 193 66 55:45 82:18 
10 194 78 80:20 78:22 
11 36 67 95:5 20:80 
a) Use of 187 (0.3 mmol), 40i (0.2 mmol) and catalyst (0.02 mmol); ball milling conditions: 2 x15 min at 
300 rpm and 15 min pause, 20 balls with a diameter of 0.4 cm. b) and c) as in Table 6. 
 
Figure 17. Catalysts used in the catalyst screening experiments. 
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In the series of thiourea 182g, selenourea 193 and urea 194 (the latter prepared by 
addition of N-methyl-substituted 3-amino piperidine-HCl salt 186b to phenyl 
isocyanate in THF), the first gave the best stereoselectivities (Table7, entries 8-10). 
None of these catalysts, however, reached the superior values obtained with thiourea 
182s (entry 1).  
Finally, Takemoto thiourea 36 was included in the screening process as an 
established bifunctional thiourea catalyst. When it was applied under the solvent-free 
conditions the diastereoselectivity in the test reaction remained high but yield and 
enantioselectivity were compromised as compared to results achieved with most 
thioureas 182 (entry 11).  
Based on all results, thiourea 182s became the catalyst of choice for subsequent 
studies (Table 8). Investigation on the required catalyst loading revealed that a 
reduced amount of catalyst led to increased enantioselectivities (Table 8, entries 
1-4). Thus, use of only 2.5 mol% (instead of the previously used 10 mol%) of thiourea 
182s was sufficient to provide the formation of 188i with an er of 96:4 while the yield 
remained nearly unchanged (83% versus 85%, entries 3 and 1). Remarkably, high 
stereoselectivity (dr of 97:3, er of 96:4) was also observed with a catalyst loading as 
low as 1 mol%, but the yield dropped significantly to 57% in this attempt (entry 4). 
With the intent to study possible milling effects, grindings balls of smaller diameter 
were examined (entries 5-7). While the stereochemical outcome of the reaction 
remained high (dr of >96:4, er of >94:6), yields were notably lower (≤66%). This was 
traced back to peculiar amounts of unreacted substrates to be found at the cover and 
in blind spots of the reaction vessel after these reactions. Applying liquid assisted 
grinding technique by addition of small amounts of DCM did not improve the reaction 
outcome (entry 8) 
In order to overcome the problem of traces of -nitrocyclohexanone (187) to be found 
in the product after workup, the substrate ratio again became part of the screening 
process (entries 9 and 10). Unfortunately, with a stoichiometric amount of reagents or 
an excess of nitroalkene 40i used, the yield of the reaction dropped to values ≤65%, 
even after enhanced reaction times (entries 9-12). The solution for this problem was 
found in the reaction workup. When the crude reaction mixture was subjected to 
column chromatography without preliminary aqueous workup, addition product 188i 
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was obtained in high yield of 86% in pure form with a high dr of 94:6 and a high er of 
96:4, applying 1.5 equivalents of nitroalkene 40i.  
Table 8. Screening of milling conditions in the Michal addition reaction catalyzed by thiourea 144s. 
 
 
Entrya 
Ratio 
145 : 146i 
Catalyst 
loading 
[mol%] 
Milling balls 
diameter 
[cm] 
Milling 
time 
[min] 
Yield 
[%]b 
dr 
(anti:syn)c 
erc 
1d 1.5 : 1 10 0.4 30 85 96:4 95:5 
2d 1.5 : 1 5 0.4 30 70 93:7 96:4 
3d 1.5 : 1 2.5 0.4 30 83 96:4 96:4 
4d 1.5 : 1 1 0.4 30 57 97:3 96:4 
5d,e 1.5 : 1 2.5 0.1 30 47 97:3 94:6 
6d 1.5 : 1 2.5 0.2 30 66 97:3 96:4 
7d 1.5 : 1 2.5 0.3 30 35 96:4 96:4 
8d,f 1.5 : 1 2.5 0.4 30 77 95:5 96:4 
9d 1 : 1 2.5 0.4 30 63 96:4 96:4 
10d 1 : 1.5 2.5 0.4 30 65 95:5 96:4 
11d 1 : 1.5 2.5 0.4 60 61 94:6 93:7 
12d,g 1 : 1.5 2.5 0.4 80f 52 97:3 96:4 
13h 1 : 1.5 2.5 0.4 30 86 94:6 96:4 
a) Reactions were carried out on a 0.4 mmol scale; ball milling conditions: cycles of 15 min at 300 rpm 
and 15 min pause. b) After aqueous workup and column chromatography. c) Determined by HPLC of 
the crude product using a chiral stationary phase. d) Because a small amount (1-5%) of 187 remained 
in the product, the “yield” reported here was corrected after analysis by 1H-NMR spectroscopy. e) Use 
of a grinding vessel and grinding balls made of WC. f) Addition of DCM (2 equiv.). g) Ball milling 
conditions: 8 cycles of 10 min at 300 rpm and 5 min pause. h) Crude product directly transferred to 
column chromatography. 
With the optimized milling condition in hand, the substrate scope of the 
organocatalyzed mechanochemical Michael addition reaction of -nitrocyclohexanone (187) to various nitroalkenes 40 was finally determined (Table 
9). As in the similar reactions performed in solvent, all transformations proceeded 
smoothly regardless the applied electrophile. Most remarkably, the corresponding 
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addition products 188 were isolated in 80-95% yield after only 30 minutes reaction 
time, rendering these reactions 34-fold faster than the ones performed in DCM. In 
addition, the observed diastereomeric ratios were 95:5 or higher and all enantiomeric 
ratios were above 96:4. In many examples slightly higher values were obtained than 
in corresponding reactions in solution (Table 9 versus Table 5). Neither the yield nor 
the diastereo- or the enantioselectivity were influenced by the electronic nature of the 
electrophile. Electron-withdrawing as well as electron-donating groups were tolerated 
as substituents on the aryl unit of the applied -nitrostyrenes. 
Table 9. Substrate scope of the solvent-free Michael addition reaction. 
 
 
Entrya Nitroalkene R Product Yield [%]b dr (anti:syn)c erc 
1 40i 2-furyl 188i 86 94:6 96:4 
2 40b 2-F-C6H4 188b 91 96:4 97:3 
3 40a C6H5 188a 95 96:4 98:2 
4 40c 2-Cl-C6H4 188c 91 96:4 99:1 
5 40d 4-F-C6H4 188d 88 94:6 97:3 
6 40e 4-Cl-C6H4 188e 93 98:2 98:2 
7 40f 4-Br-C6H4 188f 86 96:4 97:3 
8 40g 4-MeO-C6H4 188g 80 95:5 97:3 
9 40h 4-Me-C6H4 188h 91 95:5 97:3 
a) Use of 187 (0.4 mmol), 40 (0.6 mmol) and thiourea 182d (0.01 mmol); ball milling conditions: 2 x 
15 min at 300 rpm and 15 min pause, 20 balls with a diameter of 0.4 cm. b) After column 
chromatography. c) Determined by HPLC of the crude product using a chiral stationary phase. 
It was possible to scale-up the reaction without problems. In this context, product 
188b was obtained in 97% yield (1.024 g) with an enantiomeric ratio of 98:2 from 
3.6 mmol of -nitrocyclohexanone (187) and 1.5 equivalents of -nitrostyrene (40a). 
In this reaction 1.78 mmol (0.49 equiv.) of the latter could be recovered by column 
chromatography. 
The absolute configuration of the product 188a was assumed to be very likely S,S by 
comparison of calculated and measured ECD- and VCD-spectra of this compound. 
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The theoretical calculations and plotting of the theoretical and experimental data 
were performed by Mersmann.[220] The result is in agreement with the one obtained 
previously by X-ray crystal structure analysis (see section 2.1.3). 
2.1.6 Attempts towards the derivatization of dinitrocyclohexanones 
The further functionalization of addition products 188 was thought to be 
accomplished by reduction of the (terminal) nitro moiety. Various methods have been 
described for the reduction of alkyl and aryl nitro compounds to the corresponding 
amines,[206a] and some were applied on the addition product 188b. Unfortunately, 
neither the palladium-catalyzed reduction with hydrogen (at different pressures and 
temperatures) nor the use of reduction systems such as LiAlH4,
[221] NaBH4/Pd/C
[222] 
or ammonium formate/Pd/C[223] yielded the desired amine 195. Also aryl nitro 
reduction with stannous chloride under ultrasonic irradiation[224] and reductive 
cyclization of -nitrocarbonyl compounds utilizing Fe/AcOH[225] have been previously 
described, but both methods could not be successfully employed in this case 
(Scheme 55). 
 
Scheme 55. Attempts towards functionalization of Michael addition product 147a. 
A single attempt towards a Nef-type transformation of the dinitrocyclohexanone 188i 
was undertaken to convert the terminal nitro moiety into aldehyde 196,[206b] but 
treatment with sulfuric acid caused decomposition of the substrate. 
 
2.2 Asymmetric synthesis of -amino acids 
Chiral glycine equivalents have been studied for more than 30 years for the 
asymmetric preparation of -amino acids. Various chiral auxiliaries have been 
employed so far, of which the Ni(II)-complex-based approach introduced by 
Belokon[120] shows the most advantages. The applied chiral glycine complexes such 
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as 106 can easily be prepared and their derivatization is possible at operationally 
convenient reaction conditions (see section 1.3.5). 
Despite its many reported applications, giving access to numerous unnatural -amino 
acids, the use of pronucleophile 106 still offers room for improvement. When 
alkylated by treatment with alkyl halides under homogeneous conditions in DMF, high 
stereoselectivities can be obtained (dr of >95:5) but yields are often compromised 
(Scheme 56a). This is assumed to be due to somewhat harsher reaction conditions 
and the formation of double-alkylated side products. In contrast, high yields of 
mono-alkylated products were achieved under PTC conditions, but complex 106 
cannot rival other chiral glycine equivalents in terms of diastereoselectivity (dr of up 
to 94:6, Scheme 56b).  
 
Scheme 56. Alkylation of chiral glycine equivalent 106 under homogeneous and PTC conditions. 
One of the three building blocks for complex 106 is readily available 
2-amino-benzophenone (103). Straightforward ways for the preparation of substituted 
analogues of this diarylketone have been described.[226] Those could be successfully 
applied in the synthesis of complex heterocyclic compounds such as 
2-phenylquinazolines,[227] 1,4-benzodiazepines,[228] 2,3-diaryl-substituted indoles,[229] 
and benzofuoroquinolines,[230] of which some were positively tested as 
pharmacologically important compounds.  
A two-stage method for the synthesis of substituted 2-amino benzophenones 200 
was reported by Lothrop and Goodwin in 1943.[231] Grignard addition of the 
corresponding aryl-magnesium boride 198 to 2-methyl-3H-1,4-benzoxazin-4-one 
(197) provides access to N-acetyl substituted amino benzophenone 199 which can 
be hydrolyzed with dilute hydrochloric acid (Scheme 57). 
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Scheme 57. Synthesis of substituted 2-amino benzophenones 200. 
2.2.1 Research objective 
Tuning of the incorporated structural features of 106 was envisioned to give similar 
chiral Ni(II)-complexes of glycine with improved stereocontrolling properties (for 
previous attempts see section 1.3.5). By incorporating an ortho-substituted 
benzophenone moiety, the introduction of an axial chirality element into the nickel 
complex structure was intended. Preliminary results in the Soloshonok group showed 
that the benzylation of compound 201, bearing an ortho-chloro substituent, under 
PTC conditions led to a 70:30 mixture of diastereomers 202 and 203, arising from 
different orientations of the chlorinated phenyl ring (Scheme 58).  
 
Scheme 58. Benzylation of Ni(II)-complex 201 under PTC conditions. 
Combining the privileged structural features of 106 and 201 a specially designed 
glycine equivalent should be accessible, possessing two elements of chirality: 
stereogenic centers and a chiral axis (Figure 18).  
 
Figure 18. Chiral glycine equivalents containing elements of central and axial chirality. 
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The aim of the present project was the preparation of such an improved chiral glycine 
equivalent, and to study its stereocontrolling properties in alkylation, aldol addition, 
and Michael addition reactions. A project proposal was established in collaboration 
with Prof. Soloshonok, and part of the experimental work was carried out in his 
laboratories at UPV/EHU San Sebastián, Spain, in the context of an exchange 
program supported by the DAAD. In addition to conventional solution-based 
methods, the applicability of solvent-free mechanochemical techniques for these 
transformations were also studied in an individual second part. 
2.2.2 Synthesis of a chiral glycine equivalent bearing an element of axial chirality 
The synthesis of a structurally new chiral glycine equivalent was started from 
(S)-proline (12). Following the literature procedure, benzylation of the amino acid with 
benzyl chloride gave the N-benzylated (S)-proline 103 in 75% on a multi-gram scale 
(Scheme 59).[232]  
 
Scheme 59. Synthesis of N-benzyl (S)-proline 103. 
Next, by thionyl chloride-initiated condensation with commercially available 2-amino-
2‟,5-dichloro benzophenone (204) the corresponding amide (S)-205 was obtained in 
89% yield (Scheme 60). Interestingly, utilizing a different reported procedure with 
1-methyl imidazole and methanesulfonyl chloride led to low conversion (only 7% yield 
after 16 h).[232] The target Ni(II)-complexes were subsequently achieved by formation 
of the Schiff base with glycine (75) and subsequent in situ complexation of the 
resulting imine with an nickel salt (Scheme 60). Two new elements of chirality, a 
stereogenic center at the prolinyl nitrogen, and a chiral axis between the imine 
carbon and the ortho-chlorophenyl group (resulting from hindered rotation around the 
respective C-C bond) are formed during this process. While the former was highly 
stereoselectively induced resulting in R-configuration solely, the generation of the 
latter was less determined, probably also due to the elevated temperature required 
for the formation of the complex in methanol. Hence, two diastereomeric complexes 
Results and discussion 
 
73 
 
206 and 207 were received, which were formed in a 1:2 ratio (206:207) in high yield 
of 78%.  
 
Scheme 60. Synthesis of Ni(II)-complexes 206 and 207. 
Both complexes could be separated by column chromatography and therefore 
obtained in diastereomerically pure form as crystalline red compounds, and their 
relative configurations were unambiguously determined by X-ray crystal structure 
analyses (Figure 19).[233] Complexes 206 and 207 have S- and R- configurations at 
the chiral axes, respectively. Whereas in complex 206 the ortho-chlorine substituent 
as well as the N-benzyl moiety are located at one face of the square planar 
Ni(II)-complex, in complex 207 they are located at opposite sites. 
   
(a) (b) 
Figure 19. Crystal structures of (a) 206[233a] and (b) 207.[233b] 
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2.2.3 Derivatization by alkylation under phase-transfer catalytic conditions 
In order to determine the inductive potential of 206 and 207 in diastereoselective 
alkylations, benzylation by treatment with benzyl chloride under PTC conditions was 
chosen as a model reaction. Standard reaction conditions involved the addition of 
tetrabutylammonium iodide (TBAI) as a phase transfer catalyst and 30% aqueous 
sodium hydroxide as base. Benzylation was performed at room temperature in 
1,2-dichloroethane (Scheme 61).[126g, 234] As expected, the diastereoselectivities in 
the model reactions of 206 and 207 differed significantly, although both gave the 
alkylated products in good to high yields. Whereas a mixture of diastereomers of the 
benzylated complexes 209 in a 43:57 ratio was obtained from the latter 
transformation, the former afforded a single diastereomer 208a (Scheme 61). Hence, 
as anticipated from its structural features, in complex 206 the stereocontrolling 
elements cooperated by shielding the same face of the complex for the incoming 
electrophile (matched case), while in complex 207 such beneficial effect was missing 
(mismatched case). Therefore, complex 206 was chosen for subsequent studies 
regarding its derivatization. 
 
Scheme 61. Benzylations of Ni(II)-complexes 206 and 207 under PTC conditions. 
It has been reported that monoalkylation of glycine equivalents can be performed 
under solid-liquid phase-transfer conditions.[235] Hence, reactions of 206 were next 
carried out without water as additional reaction medium, but using crushed sodium 
hydroxide as the solid base. Transformations proceeded smoothly and the substrate 
scope was investigated applying these conditions. 
A variety of differently substituted benzyl bromides were first examined as 
electrophiles (Table 10). All alkylation reactions with symmetrically substituted benzyl 
bromides 210a-g gave the corresponding alkylated complexes 208a-g with good 
yields (73-89%) and with virtually complete stereocontrol (dr of >98:2, entries 1-7). 
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Electron-withdrawing substituents were tolerated as well as electron-donating ones, 
and most notably also poly-fluorinated benzyl bromide 210h gave good results in the 
formation of pentafluoro-phenylalanine equivalent 208h (entry 8).[236] Similar 
outcomes in both yield and stereoselectivity were obtained when ortho- and meta-
substituted benzyl bromides 210i-n were utilized (entries 9-14). Particularly 
noteworthy is the alkylation of 206 with [2-(bromomethyl)phenyl]diphenylphosphine 
oxide (210k, entry 11). The transformation proceeded well and with excellent 
stereocontrol, despite the steric demand of this alkylating agent. The corresponding 
phosphine oxide containing amino acid equivalent 208k was obtained in 
77% yield.[135a, 237]  
Next, unsaturated alkyl bromides such as allyl and propargyl bromides became part 
of the screening process (entries 15-18). The products 208o-r were obtained as a 
single diastereomer with good to high yields (76-89%). Aspartic acid derivative 208s 
could be prepared with a diastereomeric ratio of >98:2 in almost quantitative yield, 
when 206 was alkylated with methyl bromoacetate (210s, entry 19). It was noted that 
this reaction can hardly be conducted under homogeneous conditions.[126g] Reaction 
of 206 with 2-(bromomethyl)naphthalene (210t) worked also well, resulting in the 
alkylation product 208t in 87% yield as a single diastereomer (entry 20). 
PTC alkylations of Ni(II)-complexes of glycine with non-activated alkyl halides have 
been described as more challenging.[126g] Nevertheless, alanine-derived complex 
208u could be obtained in 90% yield with a dr of 94:6, when methyl iodide was 
applied as electrophile (entry 21). The slightly lower stereoselectivity in this reaction 
was assumed to be due to the small size of the methyl substituent. The reaction did 
not proceed well with sterically demanding alkyl iodides (entry 22) or secondary alkyl 
bromides (entry 23), low conversion and the formation of a mixture of unidentified 
compounds was observed. 
Finally, 3,4-dibenzyloxybenzyl bromide (210x, derived by a three-step procedure 
from 3,4-dihydroxybenzaldehyde)[112c, 238] was employed in an attempt to prepare 
(S)-3,4-dihydroxyphenylalanine (L-dopa) derivative 208x. The reaction proceeded 
well and gave access to the alkylated product in 88% yield with a dr of 93:7 
(entry 24). 
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Table 10. Substrate screening experiments in the alkylation of 206. 
 
Entrya alkyl halide R Product Yield [%]b drc 
1 210a C6H5CH2 208a 78 >98:2 
2 210b 4-CF3-C6H4-CH2 208b 80 >98:2 
3 210c 4-Br-C6H4-CH2 208c 77 >98:2 
4 210d 4-NO2-C6H4-CH2 208d 81 >98:2 
5 210e 4-BrCH2-C6H4-CH2 208e 73 >98:2 
6 210f 3,5-F2-C6H3-CH2 208f 89 >98:2 
7 210g 3,5-(MeO)2-C6H3-CH2 208g 88 >98:2 
8 210h C6F5-CH2 208h 84 >98:2 
9 210i 2-Br-C6H4-CH2 208i 83 >98:2 
10 210j 2-I-C6H4-CH2 208j 91 97:3 
11 210k 2-Ph2(O)P-C6H4-CH2 208k 77 >98:2 
12 210l 3-F-C6H4-CH2 208l 90 >98:2 
13 210m 3-MeO-C6H4-CH2 208m 83 >98:2 
14 210n 3-NO2-C6H4-CH2 208n 89 >97:3 
15 210o CH2=CH-CH2 208o 76 >98:2 
16 210p PhCH=CH-CH2 208p 88 >97:3 
17 210q HC≡C-CH2 208q 89 >98:2 
18 210r CH3CH2C≡C-CH2 208r 81 >98:2 
19 210s MeO2CCH2 208s 96 >98:2 
20 210t 2-naphthyl-CH2 208t 87 >98:2 
21d 210u Me 208u 90 96:4 
22d 210v CH(CH3)2 208v n.d. n.d. 
23 210w CH(CH3)C6H5 208w n.d. n.d. 
24 210x 3,4-(OBn)2-C6H3-CH2 208x 88 93:7 
a) Use of 206 (0.07 mmol), alkyl bromide 210 (0.17 mmol), NaOH (2.7 mmol) and TBAI (0.007 mmol) 
in 0.7 mL of (CH2Cl)2. b) After column chromatography. c) Determined by 
1H NMR spectroscopy. 
d) Use of the alkyl iodide as alkylating agent.  
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The S-configuration of the newly created stereogenic center was established by 
X-ray crystal structure analysis of propargylinated complex 208p.[239] As expected, 
the newly introduced substituent at C2 is pointing to the sterically less shielded side 
of the nickel complex (Figure 20). 
 
Figure 20. Crystal structure of 208p.[239] 
Scaling up of the reaction was found quite feasible. In fact, 1 g of 206 was alkylated 
with benzyl bromide (210a), affording 208a in a significantly improved yield of 96% 
and with the same excellent diastereoselectivity as at the smaller scale (>98:2, 
cf. Table 9, entry 1). Disassembly of the resulting complex with 6N HCl in methanol 
under standard conditions,[240] gave (S)-phenylalanine [(S)-82] in 72% yield with an er 
of 98:2 after purification by cation exchange resin (Dowex). The chiral amide (S)-205 
could be recovered in 95% yield (Scheme 62). Scaling up and disassembly 
experiments were performed in collaboration with Xia Chen and Prof. Hong Liu. 
 
Scheme 62. Disassembly of 208a to give (S)-phenylalanine [(S)-82]. 
Bis-'-amino acids represent an interesting class of compounds and can be 
frequently found in nature as subunits of peptidic molecules. As such, they play an 
important role in the structure of peptidoglycane cell walls, and can act as efficient 
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controlling elements for the secondary peptide structures by cross-linking. Their 
synthesis by phase-transfer catalyzed alkylation of Belokon Ni(II)-complex 106 with -dibromide reagents has been described by Soloshonok.[241] While high 
stereoselectivities (>97:3) were observed, yields were only moderate. Therefore, 
alkylation of 206 with '-dibromo-para-xylene (211) was studied (Scheme 63). Both 
electrophilic sites of 211 reacted well and aryl-bridged dinickel complex 212 was 
obtained as a single product in 89% yield with a dr of >98:2. 
 
Scheme 63. Alkylation of 206 with ‟-dibromo-para-xylene (211). 
2.2.4 Derivatization by Michael addition reaction 
Homologation of glycine equivalents by Michael addition gives rise to a variety of 
structurally complex and otherwise barely accessible amino acids,[122b] such as -substituted, -constrained derivatives with relevance for the design of de novo 
peptides (see section 1.3.5.3).[242] The addition of crotonic acid methyl ester (213) to 
Ni(II)-complex 206 was chosen as a test reaction. Due to the formation of two 
consecutive stereogenic centers and the minimal steric impact of the methyl group, 
this is considered to be a difficult transformation.[124c, 243] The addition reaction was 
carried out under homogeneous conditions in acetonitrile, applying DBU as a base. 
In this manner, the reaction proceeded well and gave the Michael addition product as 
a single diastereomer (dr of > 95:5) in high yield of 91% (Scheme 64). The absolute 
configuration of the product was determined to be S,S of the newly formed 
stereogenic centers, by comparison of chiroptical properties and spectral data to 
those reported in the literature.[124a, b] 
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Scheme 64. Michael addition reactions of crotonic acid methyl ester to complex 206. 
2.2.5 Derivatization by aldol addition reaction 
Aldol addition reactions are another relevant possibility for the derivatization of chiral 
glycine equivalents, since they give a straightforward access to biologically important -amino--hydroxy acids.[122a] Initially, the addition of chiral glycine equivalent 206 to 
benzaldehyde was chosen as a test reaction. Whereas TLC indicated conversion, the 
corresponding aldol product could not be isolated by column chromatography, but 
was always obtained as a mixture with the starting complex. 1H NMR spectroscopy 
led to the assumption, that a fast retro-aldol reaction (during chromatographic work-
up on silica gel and in CDCl3) may be the reason for this observation. Hence, the 
additions of 206 to n-butyraldehyde and 2-methylpropanal were chosen to study the 
directing power of the new nickel complex in aldol transformations. When NaOMe 
was applied as a base in methanol, on the initial stages of the process (under kinetic 
control) the formation of at least two compounds could be observed by TLC. Stirring 
of the reaction mixture over night led to a complete conversion of this intermediates 
to the final product which could be obtained in 74% (216a) and 71% yield (216b), 
respectively (Scheme 65). 
 
Scheme 65. Aldol additions of complex 206 in methanol. 
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In these thermodynamically controlled reactions the stereoselectivity was complete. 
Only one out of four theoretically possible diastereomers was obtained in both cases. 
The relative stereochemistry of product 216a was determined to be R,S of the newly 
formed stereogenic centers by X-ray crystal structure analysis (Figure 21).[244] This 
result can be explained by involvement of a reaction intermediate 215, in which the 
alkoxy moiety is bound to the central nickel ion and the sodium carboxylate group is 
directed to point away from the stereochemistry-controlling substituents (see 
section 1.3.5.4). Upon protonation, complex 215 rearranges to the final product 216. 
Although the absolute configuration of the newly formed stereogenic center at the -carbon is opposite to the one obtained in alkylation and Michael addition reactions, 
the stereochemical preference in the aldol process therefore is the same. 
Interestingly, X-ray structure analysis revealed that in complex 216a the aryl ring of 
the N-benzyl moiety is not pointing towards the benzophenone moiety. Therefore the 
typical complex rigidity improvement by interaction of this scaffold with the central 
nickel atom cannot be assumed.[137] It should also be noted, that reaction of 206 with 
sterically demanding trimethylacetaldehyde did not lead to the desired addition 
product 216c, even after long reaction time of 3 days. 
 
Figure 21. Crystal structure of 216a.[244] 
2.2.6 Derivatization under solvent free conditions in a ball mill 
A variety of C-C bond forming reactions can be conducted under solventless 
conditions in ball mills. In this context, in 2010 Mack intensively studied the alkylation 
of in situ formed enolates with alkyl halides,[161, 168] and in 2012 Lamaty reported on 
the asymmetric alkylations of glycine-ester Schiff bases, catalyzed by chiral 
cinchonidine-derived phase-transfer catalysts (see section 1.4.2.4).[193] Based on 
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these findings, investigations on the (asymmetric) alkylation of Ni(II)-complexes of 
glycine under mechanochemical conditions were carried out. 
First tests for the initiation of such bond forming processes in planetary ball mills 
(Pulverisette 7 classic line and Pulverisette 7 premium line) led to promising results. 
The alkylation of an achiral Ni(II)-complex 113 with 2-iodobenzyl bromide (210j) was 
chosen for initial studies and these transformations proceeded well with Cs2CO3 and 
TBAI as base and phase-transfer-catalyst, respectively (36-79% yield). Unfortunately, 
the alkylation product was not provided in reproducible yields. This observation was 
traced back to the existence of blind spots in the grinding vessel, leading to lower 
mixing efficiency. Considerable amounts of substrates could be found in these spots 
after milling. Attempts to overcome this problem by addition of milling auxiliaries, 
variation of the size of grinding balls, and change of the substrates stoichiometry 
failed. The solution came from the selection of a differently shaped grinding vessel to 
be used in a RETSCH Mixer Mill MM 400. Employing this equipment, the reaction 
could be conducted in a reproducible manner, and milling of the reaction partners at 
30 Hz for 45 min gave the addition product 217 in 32% yield. By mischance, 
significant amounts (17%) of a second product were obtained, identified to be the 
doubly alkylated complex 218 (Table 11, entry 1).  
An optimization of the reaction and milling conditions was performed to increase both 
yield and selectivity towards the mono-alkylated product (Table 11). Most 
interestingly, alkylation was found to proceed without the need for a catalyst, and 217 
was gained in 45% yield while the amount of 218 was diminished to 6% (entry 2). 
The addition of solid milling auxiliaries such as Na2CO3, NaCl, and sand was tested 
next. Under those conditions, the formation of 218 was further reduced and 217 
could be isolated in up to 61% (entries 3-5). Nevertheless, conversion was not 
complete even after prolonged reaction time and 4-44% of starting material 113 could 
be recovered in these approaches.  
The high energy input by milling was assumed to be beneficial for the subsequent 
second alkylation towards 218 but may provoke the decomposition of the 
Ni(II)-complexes involved. In this context it should be noted that increased 
temperatures of the grinding vessels were observed after milling. Taking this findings 
and assumptions into account, advantageous effects were expected by variation of 
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operational factors. In fact, an increased yield of 217 was observed with shortened 
milling cycles (entry 4) or with a reduced milling speed (entries 7 and 8). Carrying out 
the reaction at 20 Hz for 135 minutes led to an excellent yield of 89%. The formation 
of 218 was not observed under these conditions (entry 8).  
Table 11. Screening of reaction and milling conditions. 
 
Entrya 
Additive  
(equiv.) 
Milling 
speed 
[Hz] 
Milling 
time 
[min]b 
Yield of 
re-isolated 113 
[%]c 
Yield of 
217 (218) 
[%]c 
1 TBAI (10) 30 1 x 45 0 32 (17) 
2 - 30 1 x 45 0 45 (6) 
3 Na2CO3 (35) 30 3 x 45 44 43(0) 
4 NaCl (25 wt%) 30 3 x 45 7 50 (0) 
5 sand (50 wt%) 30 1 x 45 4 61 (4) 
6 - 30 6 x 5 10 61 (4) 
7 - 25 2 x 45 4 56 (3) 
8 - 20 3 x 45 5 89 (0) 
9d - 20 3 x 45 3 50 (0) 
10e - 20 3 x 45 6 72 (0) 
11f - 20 5 x 45 4 81 (0) 
12e (CH2Cl)2 20 3 x 45 1 78 (1) 
13g sand (100 wt%) - 6 x 5 35 56 (0) 
a) Use of 113 (0.1 mmol), 210j (0.24 mmol), and Cs2CO3 (1.1 mmol). b) In repetitive millings the break 
time between consecutive milling cycles was approximately 10 min. After each cycle the milling vessel 
was opened and a sample was analyzed by TLC. c) After column chromatography. d) Use of 
1.3 equiv. of 210j. e) Use of 5 equiv. of Cs2CO3. f) Use of 2 equiv. of Cs2CO3. g) Performed by manual 
grinding in a mortar. 
This result could not be further improved. Attempts to reduce the amount of base or 
alkylating agent decreased the yields (Table 11, entries 9-11), as did the addition of a 
small amount of 1,2-dichloroethane to establish liquid-assisted grinding conditions 
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(entry 12). Remarkably, the alkylation could even be initiated by manual grinding in a 
mortar. Using sand as milling auxiliary, 56% of mono-alkylated product 217 could be 
obtained after 30 min of grinding (6 cycles of 5 minutes grinding time followed by a 
10 minutes pause), together with 35% of unreacted starting complex 113 (entry 13). 
Wang[245] and Mack[246] individually reported that bases can be more reactive in 
reactions under solventless ball milling conditions than in solution. Moreover it was 
described that the cation of the base may have a major influence on the 
effectiveness of such transformations. Hence, the effect of the base on the 
solventless alkylation of 113 with 2-iodobenzyl bromide (210j) in the ball mill became 
the main subject of investigations (Table 12).  
In the absence of base, the reaction did not proceed and the formation of 217 was 
therefore not observed (Table 12, entry 2). The application of representative (liquid) 
organic bases such as 1,4-diazabicyclo[2.2.2]octane (DABCO) and triethylamine 
proved to be less effective than Cs2CO3 (entries 3 and 4 versus entry 1), as did the 
use of the inorganic bases Na2CO3 and KOH (entries 5 and 6). In all these examples, 
yields were below 36%. Although higher reactivity was reached by employing lithium 
tert-butoxide and its sodium equivalent, in both cases increased amounts of the 
bis-alkylated product 218 were produced (17% and 49%, respectively, entries 7 and 
8). Use of the latter also resulted in the formation of significant quantities of 
unidentified degradation products.  
Finally, superior results regarding the yield of 217 could be obtained with NaOMe 
(entries 9-15). After optimization of reaction parameters, the addition of 1 equivalent 
of MgSO4 (as an additional grinding support and potential desiccant) proved 
beneficial, and 217 was isolated in 95% yield (entry 14). 
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Table 12. Screening of bases. 
 
Entrya 
Base  
(equiv.) 
Additive 
(equiv.) 
Milling 
time 
[min]b 
Yield of 
re-isolated 113 
[%]c 
Yield of 
217 (218) 
[%]c 
1 Cs2CO3 (11) - 3 x 45 5 89 (0) 
2d - - 1 x 45 70 1 (0) 
3d DABCO (20) - 1 x 45 90 0 (0) 
4 Et3N (10) - 1 x 45 78 5 (0) 
5d Na2CO3 (35) - 13 x 45 64 32 (0) 
6 KOH (20) - 2 x 45 4 36 (13) 
7 tert-BuOLi (20) - 3 x 45 1 51 (17) 
8e tert-BuONa (20) - 1 x 45 0 2 (49) 
9 NaOMe (10) - 4 x 45 18 74 (1) 
10 NaOMe (20) - 1 x 45 4 88 (2) 
11f NaOMe (20) - 1 x 45 1 65 (2) 
12g NaOMe (20) - 1 x 45 4 76 (9) 
13 NaOMe (20) MgSO4 (5) 1 x 45 83 17 (0) 
14 NaOMe (20) MgSO4 (1) 1 x 45 2 95 (1) 
15 NaOMe (20) Na2SO4 (1) 1 x 45 3 86 (10) 
a) Use of 113 (0.1mmol) and 210j (0.24 mmol). b) In repetitive millings the break time between 
consecutive milling cycles was approximately 10 min. After each cycle the milling vessel was opened 
and a sample was analyzed by TLC. c) After column chromatography. d) Milling speed was 30 Hz. 
e) Decomposition leading to unidentified byproducts as indicated by 1H NMR spectroscopy. f) Use of 
1.2 equiv. of 210j. g) Use of 1.7 equiv. of 210j.  
The substrate scope for the asymmetric alkylation of chiral nickel complex 206 was 
then studied under these optimized conditions, with one small adjustment. It was 
found that reducing the amount of the alkylating agent 210j to a 1.5-fold excess did 
not influence the yield of the reaction to a great extent (cf. Table 13, entries 1 and 2). 
Besides reactivity, stereochemical issues were set in focus in these studies, and in 
this context excellent results were achieved. Product 208j was obtained with virtually 
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complete diastereoselectivity, together with a trace amount of doubly alkylated 
product 219 (Table 13, entry 2).  
Similar results were observed, when other symmetrically (entries 3-9) or 
unsymmetrically substituted benzyl bromides (entries 10-14) became part of the 
screening process. All products 208a-n were formed with excellent 
diastereoselectivities (>98:2) in good to high yields after short reaction times of less 
than 60 minutes. The electronic nature of the aryl substituents was not found to have 
any significant influence on the reaction outcome. Compared to reactions performed 
in solution (see section 2.2.3) most products were obtained in slightly higher yields.  
Table 13. Substrate screening experiments using NaOMe/MgSO4.
 
 
Entrya 
Alkyl 
halide 
R 
Milling 
time 
[min] 
Yields of 
219 (206) 
[%]b 
Yield of 
208 [%]b 
dr of 
208c 
1d 210j 2-I-C6H4-CH2 60 2 (3) 90 (208j) >98:2 
2 210j 2-I-C6H4-CH2 60 2 (3) 89 (208j) >98:2 
3 210a C6H5-CH2 45 10 (2) 76 (208a) >98:2 
4 210b 4-CF3-C6H4-CH2 30 7 (0) 87 (208b) >98:2 
5 210c 4-Br-C6H4-CH2 45 2 (1) 89 (208c) >98:2 
6 210d 4-NO2-C6H4-CH2 60 3 (2) 75 (208d) >98:2 
7 210f 3,5-F2-C6H3-CH2 30 11 (0) 77 (208f) >98:2 
8 210g 3,5-(MeO)2-C6H3-CH2 60 0 (0) 90 (208g) >98:2 
9 210h C6F5-CH2 30 1 (0) 93 (208h) >98:2 
10 210i 2-Br-C6H4-CH2 45 7 (3) 89 (208i) >98:2 
11 210k 2-Ph2(O)P-C6H4-CH2 45 0 (0) 37 (208k) >98:2 
12 210l 3-F-C6H4-CH2 45 1 (1) 86 (208l) >98:2 
13 210m 3-MeO-C6H4-CH2 30 0 (4) 92 (208m) >98:2 
14 210n 3-NO2-C6H4-CH2 60 6 (3) 81 (208n) >98:2 
15e 210o CH2=CH-CH2 30 0 (0) 90 (208o) >98:2 
16 210p PhCH=CH-CH2 45 6 (4) 83 (208p) >98:2 
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Table 13. continued 
17 210q HC≡CCH2 30 0 (0) 86 (208q) >98:2 
18 210r CH3CH2C≡CCH2 20 0 (0) 99 (208r) 96:4 
19 210s MeO2CCH2 60 0 (65) 0 (208s) n.d. 
20 210t 2-naphthyl-CH2 45 1 (1) 98 (208t) >98:2 
21f,g 210u Me 60 0 (0) 60 (208u) 98:2 
22e,f 210u Me 30 0 (6) 63 (208u) 98:2 
23 210y C6H13-CH2 45 0 (68) 0 (208y) n.d. 
a) Use of 206 (0.1 mmol), alkylating agent 210 (0.15 mmol), NaOMe (2.0 mmol) and MgSO4 
(0.1 mmol); Ball milling conditions: 3 milling balls with a diameter of 1.0 cm, 30 min at 20 Hz and 
10 min pause, After each milling cycle the milling vessel was opened and a sample was analyzed by 
TLC, the duration of the next milling cycle (15 or 30 min) depended on the reaction progress 
determined by TLC. b) After column chromatography. c) Determined by 1H NMR spectroscopy. d) Use 
of 0.25 mmol of alkylating agent 210. e) Use of methyl iodide as alkylating agent. g) After 30 min 
another 0.15 mmol of MeI were added.  
High yields ranging from 83% to 99% were obtained in the reactions of 206 with allyl 
and propargyl bromides. The alkylation to products 208o-r proceeded with excellent 
to virtually complete stereoselectivity (entries 15–18). While the milling of 206 with 
methyl bromoacetate (210s) did not lead to the corresponding alkylated product, but 
partly decomposition of the starting complex (entry 19), the alkylation with 
2-(bromomethyl)naphthalene (210t) proceeded particularly well, giving the mono-
alkylated product in 98% yield as one single diastereomer.  
Somewhat lower yields (60%-63%) were obtained in alkylation reactions utilizing 
methyl iodide (entries 20 and 21), presumably due to the volatile character of the 
alkylating agent 210u. No reaction occurred with less active 1-iodoheptane 
(208y, entry 23). Noteworthy, no difference in reactivity and selectivity was observed 
between coupling reactions with solid or liquid alkylating agents. 
Commonly, the isolated amount of undesired bis-alkylation product 219 was lower 
than 5%. In those cases where it exceeded this value, reactions were repeated, 
changing the base from NaOMe/MgSO4 to Cs2CO3 (Table 14, entries 1-8). Thus, the 
amount of 219 formed could be further reduced without influencing the 
stereoselectivity in the formation of mono-alkylated products 208. The attempted 
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trifluoromethylthiolation of 206 with N-(trifluoromethylthio)phthalimide (210z) did not 
proceed under these conditions (entry 9).[247] 
Table 14. Substrate screening experiments using Cs2CO3.
 
 
Entrya 
Alkyl 
halide 
R 
Milling 
time 
[min]b 
Yields of 
219 (206) 
[%]b 
Yield of 
208 [%]b 
dr of 
208c 
1 210a C6H5-CH2 45 1 (0) 92 (208a) >98:2 
2 210b 4-CF3-C6H4-CH2 60 1 (0) 91 (208b) >98:2 
3 210f 3,5-F2-C6H3-CH2 60 1 (1) 84 (208f) >98:2 
4 210i 2-Br-C6H4-CH2 6 0 (1) 80 (208i) >98:2 
5 210k 2-Ph2(O)P-C6H4-CH2 75 0 (0) 40 (208k) >98:2 
6 210n 3-NO2-C6H4-CH2 45 1 (2) 84 (208n) >98:2 
7 210p PhCH=CH-CH2 45 0 (1) 81 (208p) >98:2 
8d,e 210u Me 30 0 (0) 54 (208u) 98:2 
9f 210z SCF3 60 0 (41) 0 (208z) n.d. 
a) as in Table 13, but using Cs2CO3 (0.5 mmol) instead of NaOMe+MgSO4. b)-e) as in Table 13. f) Use 
of N-(Trifluoromethylthio)phthalimide (210z) as alkylating agent. 
Up-scaling of the reaction proved to be more complicated under mechanochemical 
conditions than in similar alkylations in solution. Full conversion was hampered by 
the formation of a hard solid in the grinding vessel, which needed to be scratched of 
the wall of the vessel with a spatula after each milling cycle. Thus, with 3 equivalents 
of Cs2CO3 the reaction between 206 and 2-iodobenzyl bromide (210j) on a 1.5 mmol 
scale afforded 208j in 84% (980.0 mg, dr of >98:2) together with 14% of the 
recovered starting complex. This technical problem may be solved by an engineering 
adjustment (e.g. use of harder or heavier grinding balls). 
Other derivatization reactions of complex 206 under mechanochemical conditions 
were carried out to examine changes in reactivity and selectivity in comparison with 
similar reactions in solution (see sections 2.2.3-2.2.5.) Firstly, alkylation with 
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'-dibromo-para-xylene (211) did not lead to the formation of aryl-bridged dinickel 
complex 212 (cf. Scheme 63). Under solventless conditions a mixture of unidentified 
products was received instead. Secondly, Michael addition reactions of crotonic acid 
methyl ester (213) to 206 applying NaOMe as base resulted in the formation of the 
addition product 214 in low yield of 13% and with compromised selectivity 
(dr of 86:14) after 60 minutes of milling at 20 Hz (cf. Scheme 64). Optimization of 
reaction and milling conditions has not been conducted and may lead to 
improvements in both transformations. 
Thirdly, the aldol addition reactions of 206 with n-butyraldehyde or 2-methylpropanal 
could be initiated by milling together with NaOMe at 20 Hz. While in the former case 
the thermodynamic product 216a was obtained in good yield of (76%) with excellent 
stereoselectivity (dr of >98:2), addition product 216b was formed in 82% yield but 
with slightly lower selectivity (dr of 95:5, Scheme 66). Remarkably, the reaction time 
was extensively shortened as compared to reactions in solution (90 minutes versus 
24 hours). 
 
Scheme 66. Aldol additions of complex 206 under solventless conditions in a ball mill. 
2.2.7 Further functionalization reactions 
Since some of the alkylated complexes synthesized in this project bear functional 
sites approachable for further modifications, such transformations became part of the 
studies.  
Firstly, 2-iodobenzyl substituted nickel complex 208j was chosen as a potential target 
for copper-catalyzed phosphination in an attempt to achieve phosphine containing, 
chiral -amino acid equivalent 220. P-Functionalized amino acids were envisioned to 
serve as precursors to chiral P,N-ligands for the subsequent use in metal 
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catalysis.[248] Following a procedure described by Buchwald,[249] 208j was treated with 
diphenylphosphane under basic conditions, applying 5 mol% of copper iodide as 
catalyst and DMEDA as a ligand. Unfortunately, after 16 h at 85 °C in toluene only 
little conversion of the starting complex was observed, and the target complex 220 
could not be isolated. Interestingly, a single attempt of similar transformation with 
achiral nickel complex 217 led to full conversion, but the target phosphine complex 
221 was only received in low yield (21%) together with protonated product 222 (61%, 
Scheme 67). Further experiments will be necessary to investigate on the 
functionalization towards product 220 and to obtain 221 in sufficient quantity as to 
allow for complete characterization and possible application. 
 
Scheme 67. Copper-catalyzed phosphination of 217. 
Secondly, terminal alkyne complex 208p was expected to be accessible for 
1,3-dipolar cycloaddition reactions (click-reactions).[181] When terminal alkynes are 
reacted with azides in this manner, 1,2,3-triazoles are formed, which are an important 
motif in biological and medicinal chemistry. Consequently, the utilization of alkynyl-
functionalized - and -amino acids as building blocks in the formation of constrained 
peptidomimetics has been reported.[250] Copper-catalyzed additions with azides have 
also been previously shown to be feasible under mechanochemical conditions in ball 
mills (see section 1.4.2.3).[182-183]  
In a first attempt, the reaction of 208p with benzyl azide (151a) was carried out in a 
mixer mill using copper acetate as a catalyst. Low conversion and yield indicated that 
the transformation was possible but needed further adjustments. In this context, a 
one-pot two-step asymmetric alkylation/click reaction sequence was developed.[251] In 
a first step, the alkylation of Ni(II)-complex 206 with propargyl bromide was 
conducted by milling for 30 minutes in the presence of NaOMe/MgSO4 (cf. Table 13, 
entry 16). After opening the grinding vessel, benzyl azide (151a), copper acetate 
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(as a catalyst), sodium ascorbate (as an additive), and silica gel (as a milling 
auxiliary) were added. Milling the resulting mixture of solids for 75 minutes gave 
1,2,3-triazole 223 in 88% yield as a single diastereomer (Scheme 68). It should be 
noted, that the addition of both sodium ascorbate as additive and silica gel as milling 
auxiliary, was essential for a fast reaction towards 223. 
 
Scheme 68. Sequential asymmetric one-pot alkylation/click reaction under HSBM conditions. 
2.2.8 Epimerization of the mismatched chiral Ni(II)-complex 
Having proven that nickel complex 206 was highly effective in controlling the 
stereochemistry in derivatization reactions, the possible use of its diastereomer 207, 
which was formed in significant quantities during the complex formation (Scheme 
60), became part of these studies. On the one hand, treatment of 207 with 6N HCl 
led to hydrolysis of the complex. Amide (S)-205 could be received in quantitative 
yield after basic work-up and was utilizable for the formation of another portion of 
complexes 206 and 207. On the other hand, epimerization by rotation around the 
chiral axis should allow for the conversion of diastereomer 207 into 206.  
Different techniques were trialed to achieve such transformation (Table 15). While 
the milling of 207 in a planetary ball mill did not lead to any epimerization (entry 1), 
treatment of the complex by ultrasound irradiation resulted in a 4:6 (206:207) mixture 
of diastereomers (entry 2).[252] Unfortunately, degradation of the complex was 
observed and the yield was compromised (44%) in the latter reaction. A similar effect 
was observed when a solution of 207 was conventionally heated to 100 °C. Analysis 
by TLC and 1H NMR indicated a slow epimerization rate and decomposition. Thus, 
after long reaction time a 2:1 (206:207) mixture of diastereomers was formed, but 
products could only be isolated in 31% yield (entry 3). Good epimerization rates and 
high yields were finally obtained by microwave heating/activation.[252b, c, 253] In this 
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manner, pure diastereomer 207 was rapidly converted into a 55:45 mixture of 206 
and 207, which could be isolated in high yields (entries 4 and 5). 
Table 15. Epimerization of 207. 
 
Entry technique T [°C] 
reaction 
time 
dr 
(206:207)a 
Yield 207+206 
[%]b 
1c Ball milling rt 6 h 0:100 95 
2d ultrasound rt 20 h 40:60 44 
3e conventional heating 100 90 h 65:35 31 
4f microwave 110 5 min 55:45 quant. 
5g microwave 140 45 min 55:45 82 
a) Determined by 1H NMR spectroscopy. b) After column chromatography. c) Milling of 207 
(0.35 mmol) at 600 rpm in a planetary mill. d) Treatment of 207 (0.35 mmol) in 20 mL of CHCl3 at 
37 kHz. e) Heating of a stirred solution of 207 (0.3 mmol) in 1.7 mL of DMSO-d6. f) Microwave heating 
of a stirred solution of 207  (0.17 mmol) in 0.5 mL of DMSO-d6 at 150 W. g) Microwave heating of a 
stirred solution of 207 (2.47 mmol) in 5.0 mL of (CH2Cl)2 at 150 W. 
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3. Summary 
3.1 Syntheses and application of bifunctional thioureas 
Besides metal- and bio-catalysis, organocatalysis has become a well-established 
methodology in asymmetric organic synthesis. The search for easy accessible and 
effective catalysts as well as for new applications is therefore a part of the ongoing 
research. In this context, the use of a multitude of different bifunctional thiourea-
catalysts has been reported, controlling the stereoselectivity of reactions by 
hydrogen-bonding (Brønsted acid) and simultaneous basic activation. Chiral 
diamines can be found included in many such thioureas, providing both 
stereochemical information and a basic site. Organocatalysts incorporating a chiral 
3-amino piperidine scaffold were unprecedented prior to this work. Following a 
synthetic pathway originally reported by Moon and Lee,[198] it was possible to obtain 
five N-substituted 3-amino piperidines analogues 178b-f and a pyrrolidine analogue 
178a after 5 synthetic steps, starting from natural L-glutamic and L-aspartic acid, 
respectively. Acidic deprotection and subsequent addition to isothiocyanates led to 
the formation of 19 structurally different thioureas 182a-s in high yields of up to 99% 
(Scheme 69). The formation of an unsubstituted piperidine-thiourea 182t bearing a 
secondary amine (Lewis base) functionality was a limitation of this protocol and could 
not be achieved by other procedures, either. 
 
Scheme 69. Synthesis of chiral bifuntional thioureas 182 incoporating a 2-amino cyclic amine scaffold. 
The prepared thioureas 182 were then tested as organocatalysts in the Michael 
addition reaction of -nitrocyclohexanone (187) to 2-fluoro--nitrostyrene (40b) in 
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DCM. With regard to stereocontrol and yield, catalyst 182d was better than its 
analogues 182, and also than well-established Takemoto thiourea 36. Under 
optimized conditions, addition of 187 to aryl nitroalkenes 40a-i resulted in the 
formation of products 188a-i in yields of 58-90% with enantiomeric ratios of 96:4 to 
98:2 (Scheme 70).[217]  
 
Scheme 70. Application of 182d as an organocatalyst in an asymmetric Michael addition reaction. 
In conclusion, the elegant procedure of Moon and Lee towards 3-amino cyclic 
amines was successfully employed in the synthesis of thioureas 182. These 
Brønsted acid / Brønsted base bifunctional compounds proved capable of catalyzing 
Michael addition reactions in an asymmetric manner. The stereochemical outcome of 
the addition products was in agreement with the proposed bifunctional activation 
modes.[54-55] Moreover, a selenourea 193 was prepared and employed as a catalyst 
in the asymmetric transformation. 
In a related project, the effect of HSBM conditions on the described asymmetric 
Michael additions was studied. It was reported before, that organocatalytic reactions 
can benefit from solvent-free, mechanochemical conditions. Especially in hydrogen 
bond mediated catalysis the lack of solvent interference and the effective reagent 
mixing was assumed to be advantageous.[254] 
 
Scheme 71. Solvent-free, asymmetric Michael addition reaction catalyzed by 182s in a ball mill. 
Extensive screening of milling and reactions conditions revealed catalyst 182s to be 
most effective in mechanochemically executed, asymmetric Michael addition 
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reactions of -nitrocyclohexanone (187) to aryl nitroalkenes 40a-i. Addition products 
were provided in high yields and with excellent stereoselectivities (Scheme 71). In 
comparison to the results achieved in solvent-phase reactions, transformations were 
faster, more stereoselective and proceeded with a lower catalyst loading.[220b] 
 
3.2 Asymmetric synthesis of -amino acids 
The asymmetric synthesis of natural and unnatural -amino acids is of great interest 
in academia and industry, and there is a variety of methods known for this purpose to 
date. One of the most direct and economically sound chemical approaches is the 
derivatization of chiral glycine equivalents. Chiral Ni(II)-complexes of glycine can 
serve this function and with this type of compounds a variety of alkylations, aldol 
additions, Michael additions and other reactions have been reported.[103, 122]  
A mixture of structurally optimized nickel complexes 206 and 207, containing 
elements of central and axial chirality, was synthesized from ligand (S)-205, derived 
from 2-amino-2‟,5-dichloro benzophenone (204) in good yield (Scheme 72). In 
benzylation of the separated complexes under PTC conditions chiral glycine 
equivalent 206 proved to be highly stereocontrolling in this transformation, resulting 
in a single diastereomer of the alkylated complex 208a. This was assumed to be 
achieved by a cooperating effect (matched case) of the stereogenic elements. Both 
the N-benzyl substituent and the ortho-chloro-phenyl substituent effectively shielded 
the same side of the corresponding enolate derived from the complex. Epimerization 
of the “mismatched” complex 207 into a mixture of 206 and 207 (dr of 55:45, 
206:207) was achieved by microwave heating. 
Scheme 72. Synthesis of Ni(II)-complexes 206 and 207 from 2-amino-2‟,5-dichloro benzophenone. 
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Further investigations on the alkylation of 206 under PTC conditions displayed that 
the reaction was tolerant towards various activated substrates 210 such as allyl, 
propargyl, and substituted benzyl bromides. Yields were typically high, and in most 
cases the stereoselectivity was virtually complete (Scheme 73). Use of non-activated 
methyl iodide was suitable for the formation of an alanine derivative 208u with slightly 
lower selectivity. Complex 206 therefore proved superior to its most widely used 
analogue 106 (introduced by Belokon[120]) in alkylation reactions under 
PTC conditions,[126g] although sterically more demanding alkyl iodides could not be 
applied in the process. Scaling up of the benzylation reaction of 206 and isolation of 
the target L-phenyl-alanine (S)-81 by acidic disassembly of the corresponding nickel 
complex was also demonstrated (Scheme 73). 
 
Scheme 73. Alkylation of Ni(II)-complex 206 under PTC conditions. 
Moreover, 206 was successfully applied in highly stereoselective Michael and aldol 
addition reactions, giving access to -substituted, -constrained or -amino--hydroxy acid complexes 214 and 216, respectively (Figure 22). 
 
Figure 22. Michael addition product 214 and aldol addition products 216 received from 206. 
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Alkylation reactions of enolates,[168] and asymmetric alkylation of glycine Schiff bases 
with the help of a chiral phase-transfer catalyst[193] have been described under HSBM 
conditions. Hence, the employment of this technique in the derivatization of 
Ni(II)-complexes of glycine was explored in an ensuing project. 
An achiral Ni(II)-complex 113 was chosen as a suitable substrate for the intensive 
studies of milling and reaction conditions for mechanochemically initiated alkylation. 
A crucial aspect was the prevention of double alkylation in the high energy process, 
and the use of NaOMe as a base and MgSO4 as an additive turned out to be 
advantageous in this context. With the optimized conditions in hand, alkylation 
reactions of chiral complex 206 were carried out with a variety of alkyl halides 
(Scheme 74). Most reactions proceeded in an excellent manner, providing the mono-
alkylated product 208 in high yield and with virtually complete stereocontrol. The 
amount of bisalkylation product 219 was typically low (<5%), and it could be further 
reduced by changing the applied base from NaOMe/MgSO4 to Cs2CO3. 
 
Scheme 74. Alkylation of 206 under solvent-free mechanochemical conditions. 
Whereas the use of solid or liquid alkylation reagents did typically not affect the 
reaction outcome, the use of volatile methyl iodide resulted in a lower yield of the 
alkylation product 208u.  
Further experiments revealed that also aldol reactions could be carried out in a 
similar mechanochemical manner (cf. Figure 22b) and gave the thermodynamic 
addition products 215 in remarkably short reaction time with high stereoselectivity. 
Contrary, Michael addition reactions of crotonic acid methyl ester (213) to 206 did not 
proceed well, product 213 was yielded in 13% and with a dr of 86:14.  
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Finally, exceedingly demonstrating the synthetic value of the solventless 
HSBM technique, a “one-pot/two step” asymmetric alkylation/click reaction was 
developed.[182-183, 251] Alkylation with propargyl bromide (210q) and subsequent 
copper-catalyzed 1,3-dipolar cycloaddition with benzyl azide (151a) led to the 
1,2,3-triazole-substituted amino acid derivative 224 in high yield and with excellent 
stereoselectivity (Scheme 75). 
 
Scheme 75. Sequential asymmetric one-pot alkylation/click reaction under HSBM conditions. 
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4. Outlook 
4.1 Organocatalysis 
The integration of a chiral 2-amino cyclic amine scaffold into thioureas proved to 
result in a variety of compounds 182 that were successfully applied as 
organocatalysts in asymmetric Michael addition reactions. In future work, the 
prepared catalysts could be tested in other asymmetric transformations to investigate 
on their catalytic capability. Moreover, the chiral scaffold may be included in 
structurally different bifunctional catalysts such as squaramides amines 224, which 
have evolved as a powerful class of hydrogen-bonding catalysts in the last 
decade.[42, 255] The synthesis of these compounds might be started from chiral amine 
178, methyl squarate 225 and primary amine 226 (Figure 23a). 
 
Figure 23. Integration of the 2-amino cyclic amine scaffold into thioureas with potentially interesting 
properties. 
Inspired by bifunctional catalyst 64,[69] the formation of a similar secondary amine 
substituted thiourea 227 was envisioned. It could be accessible by the reduction of 
the corresponding N-benzyl substituted analogue, although initial attempts towards 
this transformation remained unsuccessful.  
The excellent results received in organocatalytic reactions under ball milling 
conditions led to the assumption that this technique should also prove useful in more 
complex transformations. Organocatalyzed domino/cascade reactions have opened 
opportunities for the efficient asymmetric synthesis of complex molecular structures 
by decreasing the number of laboratory operations as well as the quantities of 
reagents and solvents used.[79a, 255b, 256] Such one-pot reactions might benefit from 
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the capability of HSBM to initiate highly stereocontrolled reactions under solvent-free 
conditions. Increased reaction rates and higher efficiencies might be reached. 
Asymmetric mechanochemical domino/cascade reactions are unprecedented to date. 
4.2 Asymmetric synthesis of -amino acids 
The studies in this project revealed a generally high to excellent level of stereocontrol 
to be reached in derivatization reactions of novel complex 206. Thus, this complex 
may be tested in those kinds of transformations that represented a limitation in the 
use of its unsubstituted benzophenone-derived analogue 106. Recently, Pd-
catalyzed arylation reactions of 106 have been reported by Xu and Sun, giving 
access to L-arylglycine complexes in diastereomeric ratios of up to 86:14 
(Scheme 76).[257] Transformations of that kind may benefit from the advantageous 
effects of complex 206. Moreover, the corresponding chiral ligand (S)-205 or other 
axial prochiral ligands may be employed in attempts towards chemical kinetic 
resolution of amino acids. A similar approach on this topic was reported by 
Soloshonok and Liu,[258] and preliminary experiments were performed by 
Bremerich.[259] 
 
Scheme 76. Pd-catalyzed arylation of 106 as reported by Xu and Sun . 
Besides the commercially available 2-amino-2‟,5-dichloro benzophenone moiety 
applied in this project, other substituted amino benzophenones are accessible 
(cf. Scheme 57) and may prove equally or even more useful when incorporated into a 
chiral glycine equivalent. 
Solvent-free mechanochemical conditions proved applicable for derivatization 
reactions of complex 206. With regard to the reactions performed in these studies, 
three possible follow-up projects are particularly interesting. Firstly, the increased 
formation of bis-alkylated side products was observed at higher milling frequencies 
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and with strong bases (sees section 2.2.6). The adjustment of process and chemical 
parameters for a selective formation of those disubstituted amino acid-
derivatives may be possible. Secondly, aldol addition reactions to 206 under HSBM 
conditions should be explored to a greater extend. High selectivities in the formation 
of the thermodynamic products were obtained in these transformations after notably 
short reaction time, and may be further improved by fine-tuning of reaction 
conditions.  
 
Scheme 77. Mechanochemical synthesis Ni(II)-complex 226 as reported by Duarte. 
Thirdly, the preparation of a different type of Ni(II)-complexes in ball mills has been 
recently reported (Scheme 77),[260] and complexes 206 and 207 may also be 
accessible by a solvent-free pathway in a similar manner. 
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5. Experimental part 
5.1 General methods and chemicals 
Unless otherwise stated, all commercial reagents and solvents were used without 
additional purification. All air- or moisture sensitive reactions were carried out under 
argon atmosphere in dried glassware using standard Schlenk and vacuum line 
techniques. Sensitive chemicals were kept under argon in a refrigerator or freezer. 
Solvents: Solvents for column chromatography were distilled before use. Solvents for 
anhydrous reactions were either purchased or dried according to standard 
procedures. 
Diethyl ether distilled over Solvona®. 
Dichloromethane  distilled over calcium hydride. 
Ethanol   distilled over magnesiumethanolate. 
Methanol   distilled over magnesiummethanolate. 
THF    distilled over Solvona®. 
Toluene   distilled over Solvona®. 
Chromatography and TLC: Flash column chromatography was undertaken on 
MERCK silica gel 60 (40-63 μm) with application of a light pressure (0.1-0.5 bar). 
Analytical thin layer chromatography (TLC) was performed on MERCK precoated 
silica gel 60 F254 plates. Visualization on TLC was achieved by the use of UV light 
(254 nm) or treatment with basic aqueous solution of KMnO4 or acidic ninhydrine-
solution in aceton followed by heating.  
Ball milling: HSBM experiments were carried out in air. Vessels and balls were 
typically made of Zr2O. FRITSCH Planetary micro mills Pulverisette 7 classic line and 
Pulverisette 7 premium line or a RETSCH Mixer Mill MM400 were used.  
Microwave heating: Epimerization reactions were performed in a CEM Discover 
laboratory microwave apparatus. 
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Ultrasound irradiation: Epimerization reactions were performed in a Fisher Scientific 
FB15048 ultrasonic bath. 
 
5.2 Determination of the physical data 
Melting points: Melting points were measured with a Büchi Melting Point B-540 
apparatus.  
HPLC analysis: HPLC analysis was performed with an Agilent 1200- or an Agilent 
1100-series system and chiral stationary phases from Chiral Technologies Inc or 
Astec.  
Optical rotation: Optical rotations were determined on a Perkin Elmer PE-241 
instrument or an Auto pol V PLVS matic polarimeter and are given in 
deg•cm3•g-1•dm-1. Measurements were carried out at room temperature using a light 
wave length of 589 nm in a cuvette (d= 1 dm, concentration c is given in g/100 mL).  
NMR Spectroscopy: 1H NMR, 13C NMR, 19F NMR and 31P NMR spectra were 
recorded on a Varian Mercury 300, a Varian Inova 400, a Varian VNMR 400 or a 
Varian VNMR 600 spectrometer. Chemical shifts are quoted in parts per million (ppm) 
referenced to the appropriate solvent peak or 0.00 ppm for tetramethylsilane (1H and 
13C NMR). The following abbreviations were used to describe peak splitting patterns 
when appropriate: br= broad, s= singlet, d= doublet, t= triplet, q= quartet, 
m= multiplet. Coupling constants are given in Hertz (Hz) to the nearest 0.1 Hz. 
All NMR spectra were recorded at room temperature. 
IR Spectroscopy: Infrared (IR) spectra were recorded on a Perkin Elmer Spectrum 
100 FT-IR spectrometer or on a Bruker TENSOR 27 FT-IR spectrophotometer. Wave 
numbers are given in reciprocal centimeters (cm–1) and only absorption bands with 
intensity >35% are reported. 
Mass spectrometry: Mass spectra were acquired on a Finnigan SSQ7000 
spectrometer. Peaks are given in m/z and the intensity is given as a percentage of 
the base peak. High resolution mass spectra were recorded on a Thermo Scientific 
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LTQ Orbitrap XL spectrometer or an Agilent Synapt G2 and a TOF (timeof-flight) 
detector or a Micromass Ultra Q-TOF spectrometer. 
Elemental analysis: Elemental analyses were performed on an Elemantar Vario EL 
instrument. All values are given as mass percentages 
X-ray structure analysis: Suitable crystals of 188c for single crystal X-ray structure 
analysis were obtained by recrystallization from Et2O. Crystallographic data of 188c 
were collected with a Bruker Kappa APEX II CCD-diffractometer (Mo–K = 0.71073 Å) and a CCD detector. The structure was solved by direct methods 
using SHELXS-97 and refined against F2 on all data by full-matrix least-squares 
methods using SHELXL-97.[261] 
Suitable crystals of 206, 207, and 208p for single crystal X-ray structure analysis 
were obtained by recrystallization from DCM. Suitable crystals of 216a were obtained 
by recrystallization from MeOH. Intensity data for analysis were collected at 100 K 
with a BrukerD8 goniometer with an APEX area detector equipped with an Incoatec 
microsource (Mo-Kα, = 0.71073 Å, multilayer optics). Temperature was controlled 
using an Oxford Cryostream 700 instrument. Intensities were integrated with 
SAINT+[262] and corrected for absorption by multiscan methods using SADABS.[263] 
 
5.3 Synthesis of substrates 
The following compounds were synthesized according to literature procedures 
 - Takemoto catalyst 36[46]   
- (S)-benzyl proline (103)[232]  
- achiral Ni(II)-complex 113[264] 
- benzyl azide (151a)[265] 
 - Phenyl isoselenocyanate (192)[215c] 
 - [2-(bromomethyl)phenyl]diphenyl-phosphine oxide (210k)[266] 
 - 3,4-bis(benzyloxy)benzyl bromide (210x)[112c, 238]   
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5.4 Synthesis and analytical data of compounds 
5.4.1 Synthesis of N-Boc-protected diols 
General procedure A:  
A flask equipped with a magnetic stirrer bar was charged with MeOH (250 mL) and 
the natural amino acid (100 mmol, 1 equiv.). Thionylchloride (16.06 mL, 220 mmol, 
2.2 equiv.) was added over 30 min with a syringe pump at 0 °C and the reaction was 
stirred at room temperature for 16 h, followed by concentration in vacuo. The crude 
dimethylester-HCl salt 183 was afforded in quantitative yield and used without further 
purification.  
A flame-dried flask equipped with a magnetic stirrer bar was charged with dry DCM 
(180 mL) and the dimethylester-HCl salt 183 (100 mmol, 1 equiv.). Et3N (27.88 mL, 
200 mmol, 2 equiv.) and di-tert-butyldicarbonate (22.51 g, 100 mmol, 1 equiv.) were 
added over 15 min each with a syringe pump at 0 °C and the reaction was stirred at 
room temperature for 10 h. The mixture was washed with sat. aq. Na2CO3 (100 mL) 
and the separated aqueous layer was extracted twice with DCM (2 x 60 mL). The 
combined organic phases were dried over MgSO4, filtered, and concentrated in 
vacuo to afford the N-Boc-protected dimethylester 184 in quantitative yield, which 
was used without further purification. 
In a flame-dried flask equipped with a magnetic stirrer bar, powdered NaBH4 (2.19 g, 
57.9 mmol, 4 equiv.) was added to a suspension of powdered CaCl2 (6.44 g, 
58.0 mmol, 4 equiv.) in dry EtOH (44 mL) and stirred for 15 min. The N-Boc-
protected dimethylester 184 (14.5 mmol, 1 equiv.) was solved in dry EtOH (2 mL) 
and added to the suspension. The reaction was stirred for 4 h and then stopped by 
adding citric acid (10% aq.), adjusting the pH of the mixture to 5-6. EtOH was 
removed in vacuo and the aqueous layer extracted with EtOAc (3 x 25 mL). Column 
chromatography of the crude product (gradient: pure Et2O to Et2O/MeOH 9:1) gave 
the N-Boc-protected diol 177. 
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(S)-tert-Butyl 1,4-dihydroxybutane-2-ylcarbamate (177a) 
 
Prepared from L-aspartic acid (79) according to the general procedure A and 
obtained as a white solid in 84% yield after column chromatography.  
Mp.: 62 °C. 
Optical rotation:       = –9.9 (c= 1.67, CHCl3). 
1H NMR (300 MHz, CDCl3) = 5.39-5.22 (m, 1H), 3.95 (br s, 2H), 3.82 (br s, 1H), 3.69 
(br s, 4H), 1.90-1.75 (m, 1H), 1.71-1.55 (m, 1H), 1.47 (s, 9H). 
13C NMR (75 MHz, CDCl3) = 157.0, 79.9, 65.0, 58.7, 49.5, 34.7, 28.4. 
MS (ESI): m/z (%)= 228 ([M+Na]+, 100), 206 ([M+H]+, 3), 178 (21), 176 (19), 172 (5), 
162 (16). 
IR (ATR): = 3373, 2971, 2941, 1686, 1512, 1365, 1292, 1242, 1167, 1088, 1044, 
970, 875, 779, 757.  
CHN-Analysis: for C9H19NO4, calc.: C: 52.67, H: 9.33, N: 6.82; found: C: 52.36, 
H: 9.62, N: 6.78. 
HRMS (ESI): m/z calculated for C9H19NO4Na [M+Na]
+: 228.1206, found 228.1205. 
NMR and IR data correspond to those given in the literature.[267] 
 
(S)-tert-Butyl 1,5-dihydroxypentane-2-ylcarbamate (177b) 
 
Prepared from L-glutamic acid (72) according to the general procedure A and 
obtained as a white solid in 78% yield after column chromatography.  
Mp.: 57 °C. 
Optical rotation:       = –14.1 (c= 1.79, CHCl3). 
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1H NMR (400 MHz, CDCl3) = 5.09 (d, J= 8.1 Hz, 1H), 3.77-3.42 (m, 7H), 1.66-1.42 
(m, 4H), 1.39 (s, 9H). 
13C NMR (101 MHz, CDCl3) = 156.6, 79.6, 65.0, 62.2, 52.4, 28.8, 28.5, 28.0. 
MS (CI): m/z (%)= 220 ([M+H]+, 10), 192 (4), 164 (75), 160 (7), 148 (18), 146 (13), 
132 (16), 120 (100), 102 (14), 85 (7). 
IR (ATR): = 3345, 2918, 2866, 1679, 1528, 1448, 1367, 1296, 1250, 1165, 1073, 
11003, 988, 903, 870 780, 748, 661. 
CHN-Analysis: for C10H21NO4, calc.: C: 54.77, H: 9.65, N: 6.39; found: C: 54.41, 
H: 9.85, N: 6.23. 
All spectral data correspond to those given in the literature.[268] 
5.4.2 Synthesis of N-Boc-protected 3-amino cyclic amines 
General procedure B:  
A flame-dried flask equipped with a magnetic stirrer bar was charged with dry DCM 
(36 mL) and N-Boc-protected diol 177 (10.5 mmol, 1 equiv.). Et3N (7.30 mL, 
52.4 mmol, 5 equiv.) and MsCl (1.95 mL, 25.2 mmol, 2.4 equiv.) were added 
consecutively at 0 °C. The reaction mixture was stirred for 2 h at room temperature 
after which it was quenched with sat. aq. NaHCO3 (30 mL). The phases were 
separated, and the aqueous layer was extracted with DCM (2 x 30 mL). The 
combined organic phases were dried over MgSO4, filtered, and concentrated in 
vacuo to afford the corresponding dimesylate 185, which was used without further 
purification. 
A flask equipped with a magnetic stirrer bar was charged with 1.00 mmol of the 
mesylated diol 185. An excess of amine (15.0 mmol, 15 equiv.) was added and the 
reaction was stirred for 16 h after which it was quenched with sat. aq. Na2CO3 
(2 mL). The mixture was extracted with DCM (3 x 2.5 mL), the combined organic 
phases were dried over K2CO3, filtered, concentrated in vacuo and then subjected to 
column chromatography (Et2O + 2% Et3N) to afford the N-Boc-protected 3-amino 
cyclic amine 178. 
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(S)-tert-Butyl 1-methylpyrrolidin-3-ylcarbamate (178a) 
 
Prepared from (S)-tert-butyl 1,4-dihydroxybutane-2-ylcarbamate (177a) and 
methylamine, according to the general procedure B and obtained as a yellow-white 
solid in 84% yield after column chromatography.  
Mp.: 67 °C. 
Optical rotation:       = –12.7 (c= 1.30, EtOH). 
1H NMR (300 MHz, CDCl3) = 5.42 (br s, 1H), 4.15 (br s, 1H), 2.89-2.71 (m, 1H), 
2.64-2.54 (m, 1H), 2.51-2.41 (m, 1H), 2.32 (s, 3H), 2.30-2.13 (m, 2H), 1.68-1.48 (m, 
1H), 1.43 (s, 9H). 
13C NMR (75 MHz, CDCl3) = 155.6, 79.0, 63.4, 55.1, 50.5, 42.0, 33.1, 28.5. 
MS (CI): m/z (%)= 200 ([M+H]+, 4), 199 (14), 185 (5), 173 (17), 145 (100), 127 (9), 
116 (3), 101 (4), 85 (9), 83 (23). 
IR (ATR): = 3203, 2972, 2786, 1699, 1540, 1451, 1362, 1250, 1165, 1060, 983, 
921, 756.  
CHN-Analysis for C10H20N2O2, calc.: C: 59.97, H: 10.07, N: 13.99; found: C: 59.71, 
H: 10.41, N: 13.92. 
 
(S)-tert-Butyl 1-methylpiperidin-3-ylcarbamate (178b) 
 
Prepared from (S)-tert-butyl 1,5-dihydroxypentane-2-ylcarbamate (177b) and 
methylamine, according to the general procedure B and obtained as a yellow-white 
solid in 72% yield after column chromatography.  
Mp.: 96 °C. 
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Optical rotation:       = –22.1 (c= 1.60, EtOH). 
1H NMR (300 MHz, CDCl3) = 4.99 (br s, 1H), 3.73 (br s, 1H), 2.46 (br s, 1H), 
2.34 (br s, 1H), 2.29-2.13 (m, 2H), 2.22 (s, 3H), 1.76-1.62 (m, 1H), 1.62-1.49 (m, 2H), 
1.49-1.34 (m, 1H), 1.44 (s, 9H). 
13C NMR (75 MHz, CDCl3) = 155.3, 79.0, 60.9, 55.9, 46.6, 46.4, 29.3, 28.5, 22.5. 
MS (EI): m/z (%)= 157 (1), 141 (7), 98 (10), 97 (100), 96 (11), 82 (8), 70 (9), 58 (13), 
57 (35). 
IR (ATR): = 3181, 2969, 2788, 1696, 1553, 1446, 1362, 1308, 1248, 1170, 1124, 
1098, 1062, 1006, 954, 730. 
CHN-Analysis for C11H22N3O2, calc.: C: 61.65, H: 10.35, N: 13.07; found: C: 61.39, 
H: 10.63, N: 12.92. 
 
(S)-tert-Butyl 1-isopropylpiperidin-3-ylcarbamate (178c) 
 
Prepared from (S)-tert-butyl 1,5-dihydroxypentane-2-ylcarbamate (177b) and 
isopropylamine, according to the general procedure B and obtained as a yellow solid 
in 69% yield after column chromatography.  
Mp.: 45-47 °C. 
Optical rotation:       = –16.2 (c= 1.02, EtOH). 
1H NMR (300 MHz, CDCl3) = 5.08 (br s, 1H), 3.71 (br s, 1H), 2.70 (dq, J= 13.2, 
6.6 Hz, 1H), 2.63-2.52 (m, 1H), 2.52-2.19 (m, 3H), 1.78-1.49 (m, 4H), 1.45 (s, 9H), 
0.99 (d, J= 6.6 Hz, 6H). 
13C NMR (75 MHz, CDCl3) = 155.2, 78.8, 54.6, 53.7, 49.3, 46.5, 30.2, 28.5, 22.7, 
18.2, 17.9. 
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MS (EI): m/z (%)= MS (CI): m/z (%)= 242 ([M]+, 4), 227 (4), 171 (35), 169 (11), 153 
(10), 126 (15), 125 (100), 110 (77), 84 (15), 83 (15), 82 (11), 70 (26), 57 (60). 
IR (CHCl3): = 3364, 2966, 2929, 1681, 1524, 1452, 1365, 1305, 1238, 1166, 1094, 
1049, 952, 868, 769.  
HRMS (ESI) m/z calculated for C14H27N2O2 [M+H]
+: 243.2067, found 243.2067. 
 
(S)-tert-Butyl 1-tert-butylpiperidin-3-ylcarbamate (178d) 
 
Prepared from (S)-tert-butyl 1,5-dihydroxypentane-2-ylcarbamate (177b) and tert-
butylamine, according to the general procedure B and obtained as an orange glue in 
63% yield after column chromatography. 
Optical rotation:       = –6.8 (c= 1.01, CHCl3). 
1H NMR (300 MHz, CDCl3) = 5.03 (br s, 1H), 3.63 (br s, 1H), 2.64-2.36 (m, 3H), 
2.31-2.18 (m, 1H), 1.63-1.35 (m, 4H), 1.38 (s, 9H), 0.95 (s, 9H). 
13C NMR (75 MHz, CDCl3) = 155.2, 78.6, 53.6, 51.7, 46.8, 46.4, 30.1 28.5, 26.2, 
23.1. 
MS (EI): m/z (%)= MS (CI): m/z (%)= 256 ([M]+, 9), 241 (28), 199 (7), 185 (100), 
183 (10), 143 (19), 139 (74), 124 (75), 99 (9), 83 (19), 70 (30), 57 (64). 
IR (CHCl3): = 3434, 3345, 2973, 1707, 1491, 1366, 1310, 1243, 1172, 1065, 956, 
873, 780.  
HRMS (ESI) m/z calculated for C14H29N2O2 [M+H]
+: 257.2224, found 257.2223. 
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(S)-tert-Butyl 1-cyclohexylpiperidin-3-ylcarbamate (178e) 
 
Prepared from (S)-tert-butyl 1,5-dihydroxypentane-2-ylcarbamate (177b) and 
cyclohexylamine, according to the general procedure B and obtained as an off-white 
solid in 64% yield after column chromatography.  
Mp.: 81-82 °C. 
Optical rotation:       = –18.9 (c= 0.99, EtOH). 
1H NMR (300 MHz, CDCl3) = 5.03 (br s, 1H), 3.64 (br s, 1H), 2.59 (d, J= 10.4 Hz, 
1H), 2.52-2.27 (m, 3H), 2.26-2.14 (m, 1H), 1.80-1.44 (m, 9H), 1.40 (s, 9H), 
1.24-0.95 (m, 5H). 
13C NMR (75 MHz, CDCl3) = 155.2, 78.8, 63.9, 54.4, 49.8, 46.6, 30.2, 28.8, 28.5, 
26.5, 26.1, 22.9. 
MS (EI): m/z (%)= 282 ([M]+, 6), 239 (7), 225 (2), 209 (6), 183 (22), 166 (15), 
165 (100), 122 (22), 82 (6), 70 (8), 57(17). 
IR (ATR): = 3365, 2929, 2855, 1686, 1529, 1451, 1365, 1307, 1242, 1175, 1097, 
1049, 953, 882, 772, 3373, 2936, 1686, 1519, 1449, 1363, 1306, 1231, 1164, 1095, 
1047, 1021, 945, 862, 742, 695.  
HRMS (ESI) m/z calculated for C16H31N2O2 [M+H]
+: 283.2380, found 283.2379. 
 
(S)-tert-Butyl 1-phenylpiperidin-3-ylcarbamate (178f) 
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Prepared from (S)-tert-butyl 1,5-dihydroxypentane-2-ylcarbamate (177b) and 
benzylamine, according to the general procedure B and obtained as an off-white 
solid in 76% yield after column chromatography.  
Mp.: 78-80 °C. 
Optical rotation:       = –6.4 (c= 1.01, EtOH). 
1H NMR (300 MHz, CDCl3) = 7.29-7.12 (m, 5H), 4.93 (br s, 1H), 3.68 (br s, 1H), 
3.39 (s, 2H), 2.52-2.06 (m, 4H), 1.66-1.42 (m, 4H), 1.36 (s, 9H). 
13C NMR (75 MHz, CDCl3) = 155.2, 138.3, 129.0, 128.2, 127.0, 79.0, 63.1, 58.7, 
53.4, 46.4, 29.7, 28.4, 22.3. 
MS (EI): m/z (%)= 290 ([M]+, 4), 233 (3), 217 (5), 174 (16), 173 (100), 143 (4), 
91 (42), 82 (6), 70 (6), 57(17). 
IR (ATR): = 3373, 2936, 1686, 1519, 1449, 1363, 1306, 1231, 1164, 1095, 1047, 
1021, 945, 862, 742, 695.  
CHN-Analysis for C17H26N2O2, calc.: C: 70.31, H: 9.02, N: 9.65; found: C: 70.16, 
H: 8.80, N: 9.46. 
NMR and MS data correspond to those given in the literature.[198] 
5.4.3 Synthesis of thioureas 
General procedure C:  
A flask equipped with a magnetic stirrer bar was charged with N-Boc-protected 
3-amino cyclic amine 178 (0.5 mmol) in MeOH (2 mL), and conc. HCl (0.2 mL, 
3.5 equiv.) was added dropwise at 0 °C. The mixture was stirred at room temperature 
overnight, before the solvent was removed in vacuo to give the crude deprotected 
HCl-salt 186 which was used without further purification. 
A flame-dried flask with a magnetic stirrer bar was charged with 0.5 mmol of the 
deprotected 3-amino cyclic amine HCl-salt 186 in dry THF (2 mL). Et3N (1.25 mmol, 
2.5 equiv) and isothiocyanate (0.5 mmol, 1.0 equiv) were added consecutively at 
0 °C. The mixture was allowed to warm to room temperature and stirred for 16 h. 
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The solvent was removed in vacuo and the residue was dissolved in DCM. The 
mixture was washed with sat. aq. Na2CO3, the aqueous layer was extracted with 
DCM (2 x 2 mL) and the combined organic phases were dried over MgSO4, filtered, 
and concentrated in vacuo. The product was purified by column chromatography 
(ethyl acetate:MeOH:Et3N 100:4:4). 
 
(S)-1-[3,5-Bis-(trifluoromethyl)phenyl]-3-(1-methylpyrrolidine-3-yl)thiourea (182a) 
 
Prepared from (S)-tert-butyl 1-methylpyrrolidine-3-ylcarbamate (178a) and 3,5-bis-
(trifluoromethyl)phenyl isothiocyanate, according to the general procedure C and 
obtained as a white solid in 86% after column chromatography.  
Mp.: 141 °C. 
Optical rotation:       = –14.8 (c= 0.60, EtOH). 
1H NMR (400 MHz, CDCl3) = 12.94 (s, 1H), 8.13 (br s, 1H), 7.87 (br s, 2H), 
7.61 (s, 1H), 3.99 (s, 1H), 3.21 (d, J= 42.2 Hz, 2H), 2.59-2.29 (m, 5H), 
2.27-2.05 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 178.8, 141.7, 131.8 (q, J= 23.4 Hz), 123.2, 
123.0 (q, J= 272.4 Hz), 118.1, 61.0, 55.4, 54.3, 39.9, 31.3. 
19F NMR (282 MHz, CDCl3) = –63.4. 
MS (EI): m/z (%)= 372 ([M+H]+, 11), 352 (9), 327 (4), 289 (1), 272 (3), 229 (3), 
213 (4), 163 (3), 143 (2), 83 (100), 57 (24). 
IR (ATR): = 3252, 2800, 1560, 1533, 1464, 1381, 1270, 1177, 1126, 959, 884, 711, 
677. 
HRMS (ESI) m/z calculated for C14H15F6N3S [M]
+: 371.0885, found 371.0882. 
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(S)-1-[3,5-Bis-(trifluoromethyl)phenyl]-3-(1-methylpiperidine-3-yl)thiourea (182b) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 3,5-bis-
(trifluoromethyl)phenyl isothiocyanate, according to the general procedure C and 
obtained as a white solid in 81% yield after column chromatography.  
Mp.: 159-160 °C. 
Optical rotation:       = –21.5 (c= 1.00, EtOH). 
1H NMR (300 MHz, CDCl3) = 8.92 (br s, 1H), 7.74 (s, 2H), 7.61 (s, 1H), 7.33 (br s, 
1H), 4.48 (br s, 1H), 2.69-2.48 (m, 2H), 2.33-2.13 (m, 1H), 2.09 (s, 3H), 1.94 (br s, 
2H), 1.60-1.46 (m, 2H), 1.46-1.30 (m, 1H). 
13C NMR (75 MHz, CDCl3) = 178.5, 139.3, 133.1 (q, J= 33.2 Hz), 123.2, 
123.0 (q, J= 272.8 Hz), 119.0, 117.5, 59.7, 55.8, 50.8, 46.4, 27.0, 21.5. 
19F NMR (282 MHz, CDCl3) = –63.2. 
MS (CI): m/z (%)= 414 ([M+C2H5]
+, 18), 386 ([M+H]+, 100), 366 (51), 352 (11), 
332 (22), 157 (17), 115 (8), 98 (38), 97 (70), 70 (2). 
IR (ATR): = 3154, 2945, 2793, 2085, 1548, 1511, 1465, 1381, 1343, 1269, 1170, 
1124, 958, 886, 713, 679. 
CHN-Analysis for C15H17F6N3S, calc.: C: 46.75, H: 4.45, N: 10.90; found: C: 46.67, 
H: 4.39, N: 10.87. 
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(S)-1-[3,5-Bis-(trifluoromethyl)phenyl]-3-(1-isopropylpiperidine-3-yl)thiourea (182c) 
 
Prepared from (S)-tert-butyl 1-isopropylpiperidine-3-ylcarbamate (178c) and 3,5-bis-
(trifluoromethyl)phenyl isothiocyanate, according to the general procedure C and 
obtained as an orange glue in 66% yield after column chromatography. 
Optical rotation:       = –4.9 (c= 1.05, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.71 (s, 1H), 7.78 (s, 2H), 7.70 (s, 1H), 7.35 (s, 1H), 
4.54 (s, 1H), 2.79-2.56 (m, 3H), 2.43 (d, J= 10.1 Hz, 1H), 2.33-2.19 (m, 1H), 2.18-
2.05 (m, 1H), 1.68-1.36 (m, 3H), 1.00-0.61 (m, 6H). 
13C NMR (101 MHz, CDCl3) = 178.2, 138.9, 133.4 (d, J= 32.3 Hz), 123.6, 
122.9 (q, J= 273.1 Hz), 119.3, 54.8, 52.9, 50.9, 49.2, 27.9, 22.0, 18.1, 17.6. 
19F NMR (376 MHz, CDCl3) = –63.2. 
MS (EI): m/z (%)= 413 ([M]+, 1), 394 (4), 355 (4), 272 (1), 125 (100), 110 (63), 84 (6), 
82 (8), 70 (11), 56 (17). 
IR (CHCl3): = 3436, 3295, 2924, 2854, 2112, 1622, 1537, 1466, 1383, 1276, 1135, 
954, 886, 707, 681. 
CHN-Analysis for C17H21F6N3S, calc.: C: 49.39, H: 5.12, N: 10.16; found: C: 49.32, 
H: 4.86, N: 10.11. 
 
(S)-1-[3,5-Bis-(trifluoromethyl)phenyl]-3-(1-tert-butylpiperidine-3-yl)thiourea (182d) 
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Prepared from (S)-tert-butyl 1-tert-butylpiperidine-3-ylcarbamate (177d) and 3,5-bis-
(trifluoromethyl)phenyl isothiocyanate, according to the general procedure C and 
obtained as a yellow-white solid in 82% yield after column chromatography.  
Mp.: 89-91 °C. 
Optical rotation:       = –10.9 (c= 1.02, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.66 (br s, 1H), 7.80 (s, 2H), 7.73 (s, 1H), 7.33 (br s, 
1H), 4.57 (br s, 1H), 3.04-2.81 (m, 2H), 2.32 (d, J= 9.4 Hz, 1H), 2.21-1.98 (m, 2H), 
1.71-1.36 (m, 3H), 0.89 (s, 9H). 
13C NMR (101 MHz, CDCl3) = 178.5, 138.9, 133.4 (q, J= 30.0 Hz), 124.3, 
122.9 (q, J= 272.8 Hz), 119.6, 54.3, 50.9, 50.9, 46.6, 27.9, 26.1, 22.5. 
19F NMR (376 MHz, CDCl3) = –63.0. 
MS (CI): m/z (%)= 468 ([M+C3H5]
+, 7), 456 ([M+C2H5]
+, 30), 428 ([M+H]+, 100), 
408 (41), 394 (12), 374 (20), 338 (10), 318 (5), 230 (3), 210 (3), 199 (12), 140 (18), 
139 (21), 124 (2), 84 (5). 
IR (ATR): = 3288, 2976, 1660, 1504, 1470, 1380, 1273, 1172, 1129, 1055, 970, 
943, 881, 850, 678. 
CHN-Analysis for C18H23F6N3S, calc.: C: 50.58, H: 5.42, N: 9.83; found: C: 50.19, 
H: 5.11, N: 9.76. 
 
(S)-1-[3,5-Bis-(trifluoromethyl)phenyl]-3-(1-cyclohexylpiperidine-3-yl)thiourea (182e)  
 
Prepared from (S)-tert-butyl 1-cyclohexylpiperidine-3-ylcarbamate (178e) and 3,5-bis-
(trifluoromethyl)phenyl isothiocyanate, according to the general procedure C and 
obtained as a yellow-white solid in 92% yield after column chromatography.  
Mp.: 67-69 °C. 
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Optical rotation:       = +0.4 (c= 1.00, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.35 (s, 1H), 7.76 (s, 2H), 7.71 (s, 1H), 7.27 (s, 1H), 
4.52 (s, 1H), 2.84-2.62 (m, 2H), 2.49 (d, J= 10.6 Hz, 1H), 2.33 (t, J= 9.9 Hz, 1H), 
2.24-2.07 (m, 2H), 1.76-1.31 (m, 8H), 1.21-0.92 (m, 5H). 
13C NMR (101 MHz, CDCl3) = 178.3, 138.9, 133.4 (q, J= 35.9 Hz), 123.7, 
122.9 (q, J= 272.8 Hz), 119.4, 64.0, 53.5, 51.0, 50.0, 29.1, 28.5, 27.9, 26.3, 25.9, 
25.85, 22.2. 
19F NMR (376 MHz, CDCl3) = –63.2. 
MS (EI): m/z (%)= 453 ([M]+, 2), 434 (4), 355 (3), 165 (100), 122 (33), 96 (2), 83 (6), 
82 (6), 70 (6), 55 (21). 
IR (ATR): = 3276, 2932, 1512, 1453, 1380, 1273, 1171, 1129, 953, 885, 704, 679.  
CHN-Analysis for C27H25F6N3S, calc.: C: 52.97, H: 5.56, N: 9.27; found: C: 52.71, 
H: 5.61, N: 9.32. 
 
(S)-1-(1-Benzylpiperidine-3-yl)-3-[3,5-bis-(trifluoromethyl)phenyl]thiourea (182f) 
 
Prepared from (S)-tert-butyl 1-phenylpiperidine-3-ylcarbamate (178f) and 3,5-bis-
(trifluoromethyl)phenyl isothiocyanate, according to the general procedure C and 
obtained as a white solid in 94% yield after column chromatography.  
Mp.: 70 °C. 
Optical rotation:       = –6.2 (c= 1.00, CHCl3). 
1H NMR (300 MHz, CDCl3) = 9.11 (s, 1H), 7.80-7.55 (m, 3H), 7.31-6.92 (m, 4H), 
6.80 (s, 2H), 4.43 (s, 1H), 3.50-3.09 (m, 2H), 2.81-2.34 (m, 2H), 2.27-1.77 (m, 3H), 
1.62-1.31 (m, 3H). 
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13C NMR (75 MHz, CDCl3) = 178.1, 138.9, 137.5, 133.3 (q, J= 33.8 Hz), 
122.9 (q, J= 275.15 Hz), 128.8, 128.3, 127.4, 124.0, 119.3, 62.8, 57.0, 53.8, 50.7, 
27.6, 21.8. 
19F NMR (376 MHz, CDCl3) = –63.1. 
MS (EI): m/z (%)= 461 ([M]+, 4), 442 (2), 353 (2), 272 (1), 173 (100), 158 (3), 95 (6), 
91 (81), 82 (11), 65 (8), 55 (6). 
IR (ATR): = 3313, 3032, 2941, 2810, 1619,1514, 1468, 1378, 1274, 1173, 1131, 
1003, 887, 737, 699, 680.  
HRMS (ESI) m/z calculated for C21H22F6N3S [M+H]
+: 462.1433, found 462.1433. 
 
(S)-1-(1-Methylpiperidine-3-yl)-3-phenylthiourea (182g) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and phenyl 
isothiocyanate, according to the general procedure C and obtained as an off-white 
solid in 89% yield after column chromatography.  
Mp.: 103-104 °C. 
Optical rotation:       = –12.8 (c= 1.01, CHCl3). 
1H NMR (300 MHz, CDCl3) = 8.71 (br s, 1H), 7.34-7.37 (m, 2H), 7.34-7.19 (m, 3H), 
7.04 (br s, 1H), 4.56 (br s, 1H), 2.64-2.25 (m, 3H), 2.12 (s, 3H), 2.09-1.95 (m, 1H), 
1.80 (br s, 1H), 1.68-1.38 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 178.8, 137.0, 129.8, 126.5, 124.5, 59.8, 55.6, 50.6, 
46.5, 27.7, 21.9. 
MS (EI): m/z (%)= 250 ([M+H]+, 5), 217 (1), 157 (1), 136 (4), 98 (20), 97 (100), 
96 (40), 82 (22), 77 (13), 58 (7). 
Experimental part 
 
120 
 
IR (ATR): = 3362, 3161, 2779, 1593, 1517, 1450, 1319, 1293, 1245, 1146, 1023, 
931, 852, 798, 747, 694.  
CHN-Analysis for C13H19N3S, calc.: C: 62.61, H: 7.68, N: 16.85; found: C: 62.19, 
H: 7.90, N: 16.77. 
HRMS (ESI) m/z calculated for C13H20N3S [M+H]
+: 250.1372, found 250.1370. 
 
(S)-1-(1-Methylpiperidine-3-yl)-3-p-tolylthiourea (182h) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
p-methylphenyl isothiocyanate, according to the general procedure C and obtained 
as a colorless glue in 67% yield after column chromatography. 
Optical rotation:       = –10.3 (c= 1.02, CHCl3). 
1H NMR (300 MHz, CDCl3) = 8.11 (br s, 1H), 7.19 (d, J= 8.1 Hz, 2H), 
7.08 (d, J= 8.3 Hz, 2H), 6.83 (br s, 1H), 4.53 (br s, 1H), 2.52-2.27 (m, 3H), 
2.34 (s, 3H), 2.11 (s, 3H), 2.08-1.99 (m, 1H), 1.77 (br s, 1H), 1.61-1.38 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 179.1, 136.8, 134.0, 130.6, 124.8, 59.9, 55.7, 50.9, 
46.5, 27.9, 22.1, 21.1. 
MS (EI): m/z (%)= 264 ([M+H]+, 5), 231 (1), 167 (5), 150 (4), 107 (4), 106 (7), 98 (25), 
97 (100), 96 (39), 82 (22), 70 (13), 58 (6). 
IR (CHCl3): = 3265, 2934, 2852, 2786, 1527, 1318, 1252, 1160, 1103, 1021, 929, 
819, 727, 498.  
CHN-Analysis for C14H21N3S, calc.: C: 63.84, H: 8.04, N: 15.95; found: C: 63.43, 
H:8.08, N: 15.79. 
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(S)-1-(1-Methylpiperidine-3-yl)-3-[4-(trifluoromethyl)phenyl]thiourea (182i) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
p-(trifluoromethyl)phenyl isothiocyanate, according to the general procedure C and 
obtained as a white solid in 98% yield after column chromatography.  
Mp.: 114-115 °C. 
Optical rotation:       = –4.9 (c= 1.01, CHCl3). 
1H NMR (300 MHz, CDCl3) = 8.95 (br s, 1H), 7.56 (d, J= 8.3 Hz, 2H), 
7.34 (d, J= 8.3 Hz, 2H), 7.17 (br s, 1H), 4.50 (br s, 1H), 2.62-2.39 (m, 2H), 
2.36-2.17 (m, 1H), 2.08 (s, 3H), 2.05-1.89 (m, 1H), 1.89-1.68 (m, 1H), 
1.68-1.31 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 178.7, 140.7, 127.7 (q, J= 32.7 Hz), 127.0, 
123.9 (q, J= 271.9 Hz), 123.5, 59.7, 55.7, 50.8, 46.58, 27.5, 21.9. 
19F NMR (282 MHz, CDCl3) = –62.4. 
MS (EI): m/z (%)= 317 ([M]+, 1), 204 (2), 161 (2), 157 (3), 145 (6), 98 (15), 97 (100), 
96 (34), 82 (19), 70 (11), 58 (6). 
IR (ATR): = 3274, 2940, 2790, 1614, 1519, 1317, 1253, 1160, 1110, 1061, 1012, 
837, 710, 590, 535.  
CHN-Analysis for C14H18F3N3S, calc.: C: 52.98, H: 5.72, N: 13.24; found: C: 52.71, 
H: 5.62, N: 13.20. 
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(S)-1-(1-Methylpiperidine-3-yl)-3-(4-nitrophenyl)thiourea (182j) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
p-nitrophenyl isothiocyanate, according to the general procedure C and obtained as 
an orange solid in 99% yield after column chromatography. 
Optical rotation:       = +13.2 (c= 1.00, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.51 (br s, 1H), 8.25 (d, J= 9.0 Hz, 2H), 
7.49 (d, J= 8.5 Hz, 2H), 4.62 (br s, 1H), 2.72 (d, J= 9.4 Hz, 2H), 2.56-2.28 (m, 2H), 
2.24 (s, 3H), 2.15-1.92 (m, 2H), 1.74-1.43 (m, 3H). 
13C NMR (101 MHz, CDCl3) = 178.6, 144.2, 143.9, 125.5, 122.0, 59.6, 55.8, 50.8, 
46.5, 27.2, 21.7. 
MS (CI): m/z (%)= 323 ([M+C2H5]
+, 1), 295 ([M+H]+, 4), 279 (2), 261 (26), 231 (30), 
181 (5), 157 (9), 139 (7), 124 (5), 113 (4), 98 (100), 61 (22). 
IR (ATR): = 3284, 2937, 2788, 1593, 1501, 1325, 1253, 1166, 1106, 1012, 958, 
849, 730, 702.  
HRMS (ESI) m/z calculated for C13H19O2N4S [M+H]
+: 295.1223, found 295.1223. 
 
(S)-1-(4-Chlorophenyl)-3-(1-methylpiperidine-3-yl)thiourea (182k) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
p-chlorophenyl isothiocyanate, according to the general procedure C and obtained as 
a white solid in 95% yield after column chromatography.  
Mp.: 125-126 °C. 
Optical rotation:       = –5.1 (c= 1.00, CHCl3). 
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1H NMR (300 MHz, CDCl3) = 8.27 (br s, 1H), 7.36 (d, J= 8.7 Hz, 2H), 
7.19 (d, J= 8.7 Hz, 2H), 7.02 (br s, 1H), 4.56 (br s, 1H), 2.54 (br s, 2H), 
2.33 (d, J= 11.2 Hz, 1H), 2.15 (s, 3H), 2.10-1.99 (m, 1H), 1.93-1.73 (m, 1H), 
1.63-1.39 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 179.1, 135.6, 132.2, 130.1, 125.9, 59.8, 55.8, 50.8, 
46.5, 27.6, 21.9. 
MS (EI): m/z (%)= 283 ([M]+, 1), 170 (2), 157 (1), 127 (3), 126 (1), 111 (4), 98 (22), 
97 (100), 96 (41), 82 (21), 70 (11), 58 (6). 
IR (ATR): = 3257, 2938, 2786, 1489, 1318, 1247, 1156, 1089, 1011, 934, 823, 723, 
670.  
HRMS (ESI) m/z calculated for C13H19ClN3S [M+H]
+: 284.0983, found 284.0982. 
 
 (S)-1-(3,5-Dichlorophenyl)-3-(1-methylpiperidine-3-yl)thiourea (182l) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
3,5-dichlorophenyl isothiocyanate, according to the general procedure C and 
obtained as an off-white solid in 70% yield after column chromatography.  
Mp.: 122-123 °C. 
Optical rotation:       = +3.3 (c= 1.00, CHCl3). 
1H NMR (300 MHz, CDCl3) = 8.99 (br s, 1H), 7.39-7.23 (m, 1H), 7.18 (d, J= 1.6 Hz, 
2H), 7.10 (t, J= 1.7 Hz, 1H), 4.47 (br s, 1H), 2.55 (d, J= 9.8 Hz, 2H), 
2.37-2.16 (m, 1H), 2.12 (s, 3H), 2.05-1.92 (m, 1H), 1.90-1.72 (m, 1H), 
1.61-1.31 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 178.5, 139.6, 135.8, 125.8, 122.0, 59.7, 55.7, 50.6, 
46.5, 27.3, 21.7. 
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MS (CI): m/z (%)= 358 ([M+C3H5]
+, 5), 346 ([M+C2H5]
+, 17), 318 ([M+H]+, 100), 
284 (29), 250 (3), 204 (2), 157 (29), 115 (13), 98 (35), 97 (39). 
IR (ATR): = 3301, 3008, 2935, 2789, 1585, 1522, 1440, 1324, 1265, 1225, 1143, 
1103, 953, 846, 800, 710.  
CHN-Analysis for C13H17Cl2N3S, calc.: C: 49.06, H: 5.38, N: 13.20; found: C: 48.83, 
H: 5.08, N: 12.97. 
 
(S)-1-(4-Fluorophenyl)-3-(1-methylpiperidine-3-yl)thiourea (182m) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
p-fluorophenyl isothiocyanate, according to the general procedure C and obtained as 
a white solid in 96% yield after column chromatography.  
Mp.: 123-124 °C. 
Optical rotation:       = –9.4 (c= 1.01, CHCl3). 
1H NMR (300 MHz, CDCl3) = 8.76 (br s, 1H), 7.27-7.13 (m, 2H), 7.01 (t, J= 8.4 Hz, 
2H), 6.90 (br s, 1H), 4.47 (br s, 1H), 2.41 (br s, 2H), 2.27 (br s, 1H), 2.04 (s, 3H), 
2.01-1.87 (m, 1H), 1.72 (br s, 1H), 1.56-1.32 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 179.3, 161.0 (d, J= 246.9 Hz), 133.0, 
127.1 (d, J= 8.4 Hz), 116.6 (d, J= 22.7 Hz), 59.7, 55.6, 50.4, 46.4, 27.7, 21.8. 
19F NMR (282 MHz, CDCl3) = –114.50. 
MS (EI): m/z (%)= 268 ([M+H]+, 12), 235 (2), 171 (2), 154 (9), 127 (6), 111 (11), 
98 (35), 97 (100), 96 (73), 95 (17), 82 (42), 70 (23), 58(12). 
IR (ATR): = 3282, 3204, 3043, 2937, 2790, 1537, 1500, 1336, 1216, 1154, 934, 
834, 791, 722, 683.  
HRMS (ESI) m/z calculated for C13H19FN3S [M+H]
+: 268.1278, found 268.1276. 
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(S)-1-(1-Methylpiperidine-3-yl)-3-(naphthalen-1-yl)thiourea (182n) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and naphthyl 
isothiocyanate, according to the general procedure C and obtained as a white solid in 
97% yield after column chromatography.  
Mp.: 138-139 °C. 
Optical rotation:       = –16.2 (c= 1.00, CHCl3). 
1H NMR (300 MHz, CDCl3) = 8.74 (s, 1H), 8.03-7.90 (m, 1H), 7.84-7.68 (m, 2H), 
7.50-7.42 (m, 2H), 7.42-7.36 (m, 2H), 6.62 (s, 1H), 4.44 (s, 1H), 2.29-2.04 (m, 3H), 
1.92-1.83 (m, 1H), 1.81 (s, 3H), 1.64-1.44 (m, 1H), 1.40-1.20 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 180.0, 134.6, 132.5, 129.8, 128.4, 128.3, 127.0, 126.8, 
125.6, 124.7, 122.7, 59.7, 55.4, 50.6, 46.1, 27.8, 21.7. 
MS (EI): m/z (%)= 299 ([M]+, 1), 203 (2), 157 (1), 143 (5), 127 (4), 115 (4), 98 (14), 
97 (100), 82 (10), 70 (6), 58 (3). 
IR (ATR): = 3354, 3147, 2937, 2789, 1512, 1390, 1267, 1245, 1204, 1145, 1011, 
934, 875, 790, 766, 680. 
HRMS (ESI) m/z calculated for C17H22N3S [M+H]
+: 300.1529, found 300.1528. 
 
(S)-1-(2,6-Dimethylphenyl)-3-(1-methylpiperidine-3-yl)thiourea (182o) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
1,6-dimethylphenyl isothiocyanate, according to the general procedure C and 
obtained as a white solid in 79% yield after column chromatography.  
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Mp.: 118-119 °C. 
Optical rotation:       = –6.8 (c= 1.00, CHCl3). 
1H NMR (400 MHz, CDCl3) = 7.42 (s, 1H), 7.23-6.96 (m, 3H), 5.96 (s, 1H), 
4.52 (s, 1H), 2.49-2.33 (m, 1H), 2.29 (s, 7H), 2.12-1.95 (m, 4H), 1.61 (s, 1H), 
1.57-1.43 (m, 2H), 1.37 (s, 1H). 
13C NMR (101 MHz, CDCl3) = 179.6, 137.3, 133.1, 129.0, 60.2, 55.6, 50.6, 46.4, 
28.3, 22.1, 18.2. 
MS (EI): m/z (%)= 277 ([M]+, 1), 181 (2), 164 (1), 130 (1), 105 (2), 97 (100), 82 (9), 
70 (4), 58 (3). 
IR (ATR): = 3338, 3142, 2937, 2796, 1510, 1265, 1227, 1192, 1165, 1141, 1027, 
1008, 935, 853, 777, 732, 663.  
CHN-Analysis for C15H23N3S, calc.: C: 64.94, H: 8.36, N: 15.15; found: C: 64.79, 
H: 8.43, N: 15.11. 
 
(S)-1-Benzyl-3-(1-methylpiperidine-3-yl)thiourea (182p) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and benzyl 
isothiocyanate, according to the general procedure C and obtained as a yellow-white 
glue in 96% yield after column chromatography. 
Optical rotation:       = –2.0 (c= 1.00, CHCl3). 
1H NMR (300 MHz, CDCl3) = 7.30 (s, 5H), 7.45-7.07 (m, 1H), 6.81 (br s, 1H), 
4.56 (br s, 2H), 4.32 (br s, 1H), 2.58-2.20 (m, 3H), 2.15 (s, 3H), 2.10-1.95 (m, 1H), 
1.69 (br s, 1H), 1.44 (br s, 3H). 
13C NMR (75 MHz, CDCl3) = 180.2, 137.1, 128.7, 127.6, 127.5, 59.8, 55.6, 50.0, 
48.0, 46.3, 27.8, 21.5. 
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MS (EI): m/z (%)= 263 ([M]+, 1), 167 (1), 141 (1), 106 (2), 98 (13), 97 (100), 96 (22), 
91 (19), 82 (11), 70 (7), 65 (4), 58(4). 
IR (CHCl3): = 3259, 3060, 2939, 2790, 1542, 1454, 1375, 1345, 1310, 1253, 1161, 
957, 754, 698, 604.  
HRMS (ESI) m/z calculated for C14H22N3S [M+H]
+: 264.1529, found 264.1527. 
 
(S)-1-Isobutyl-3-(1-methylpiperidine-3-yl)thiourea (182q) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and isobutyl 
isothiocyanate, according to the general procedure C and obtained as a hygroscopic 
yellow solid in 94% yield after column chromatography. 
Optical rotation:       = –7.1 (c= 0.63, CHCl3). 
1H NMR (400 MHz, CDCl3) = 6.54 (s, 1H), 6.28 (s, 1H), 4.38 (br s, 1H), 3.17 (br s, 
1H), 3.08-2.87 (m, 1H), 2.74-2.31 (m, 3H), 2.24 (s, 3H), 2.11 (br s, 1H), 1.90 (dq, 
J= 6.8, 20.3 Hz, 1H), 1.84-1.76 (m, 1H), 1.76-1.63 (m, 1H), 1.64-1.37 (m, 2H), 
0.97 (d, J= 6.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) = 180.4, 60.1, 55.8, 51.5, 50.1, 46.6, 28.2, 28.0, 21.9, 
20.38, 20.37. 
MS (EI): m/z (%)= 230 ([M+H]+, 2), 197 (1), 171 (1), 157 (2), 133 (2), 98 (13), 
97 (100), 96 (27), 82 (15), 70 (8), 58 (5), 57(6). 
IR (CHCl3): = 3664, 2923, 2857, 1644, 1548, 1450, 1383, 1251, 1074, 876, 824, 
523. 
HRMS (ESI) m/z calculated for C11H24N3S [M+H]
+: 230.1686, found 230.1685. 
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(S)-1-(Cyclohexylmethyl)-3-(1-methylpiperidine-3-yl)thiourea (182r) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and 
cyclohexylmethyl isothiocyanate, according to the general procedure C and obtained 
as a white solid in 99% yield after column chromatography.  
Mp.: 122-123 °C. 
Optical rotation:       = –4.8 (c= 0.99, CHCl3). 
1H NMR (300 MHz, CDCl3) = 6.44 (s, 1H), 6.07 (s, 1H), 4.37 (br s, 1H), 3.18 (br s, 
2H), 2.71-2.45 (m, 2H), 2.45-2.30 (m, 1H), 2.24 (s, 3H), 2.20-2.03 (m, 1H), 
1.88-1.44 (m, 10H), 1.34-1.10 (m, 3H), 1.07-0.86 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 180.1, 60.0, 55.6, 50.3, 50.0, 46.4, 37.5, 31.0, 28.0, 
26.2, 25.7, 21.9. 
MS (EI): m/z (%)= 269 ([M]+, 1), 173 (3), 97 (100), 84 (2), 82 (12), 70 (9), 58 (5), 
55 (15). 
IR (CHCl3): = 3276, 2922, 2852, 2794, 2108, 1545, 1450, 1383, 1101, 945, 729.  
HRMS (ESI) m/z calculated for C14H28N3S [M+H]
+: 270.1999, found 270.1998. 
 
(S)-1-Benzyl-3-(1-tert-butylpiperidine-3-yl)thiourea (182s) 
 
Prepared from (S)-tert-butyl 1-tert-butylpiperidin-3-ylcarbamate (178d) and benzyl 
isothiocyanate, according to the general procedure C and obtained as an orange 
glue in 97% yield after column chromatography. 
Optical rotation:       = +6.6 (c= 1.00, CHCl3). 
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1H NMR (400 MHz, CDCl3) = 7.42-7.22 (m, 5H), 7.18-6.88 (m, 1H), 6.73 (s, 1H), 
4.45 (s, 3H), 2.73 (s, 2H), 2.31 (s, 1H), 2.07 (s, 1H), 1.83 (s, 1H), 1.57-1.16 (m, 3H), 
0.95 (s, 9H). 
13C NMR (101 MHz, CDCl3) = 179.4, 136.6, 128.8, 127.8, 127.2, 53.7, 50.9, 50.5, 
47.5, 46.3, 28.4, 26.1, 22.0. 
MS (EI): m/z (%)= 305 ([M]+, 1), 256 (5), 214 (1), 139 (100), 124 (73), 106 (2), 
91 (25), 83 (17), 82 (9), 71 (2), 68 (6), 57 (9). 
IR (CHCl3): = 3268, 2968, 1536, 1364, 1310, 1216, 1078, 958, 754, 698, 663, 606.  
HRMS (ESI) m/z calculated for C17H28N3S [M+H]
+: 306.1999, found 306.1996.  
5.4.4 Michael addition reactions of -nitrocyclohexanone to nitroalkenes  
General procedure D 
A solution of -nitrocyclohexanone (187, 0.4 mmol) and thiourea 182d (0.04 mmol, 
0.1 equiv.) in DCM (2 mL) was cooled to 0 °C under argon atmosphere. The mixture 
was stirred for 15 min, before nitroalkene 40 (0.6 mmol, 1.5 equiv) was added. After 
17 h, water was added and the reaction mixture was allowed to warm to room 
temperature. The phases were separated and the aqueous layer was extracted with 
DCM (3 x 3 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The product was purified by column chromatography 
(gradient: pentane:ethyl acetate 9:1 to 8:2, diastereomers could be separated under 
these conditions but were combined to determine the yield). 
General procedure E 
Thiourea 182s (0.01 mmol, 0.025 equiv.) was frozen with liquid nitrogen under argon 
atmosphere and transferred to a clean, dry ball milling vessel loaded with 7.8 g of 
grinding balls, together with -nitrocyclohexanone (187, 0.4 mmol) and nitroalkene 
40 (0.6 mmol, 1.5 equiv.). The vessel was placed in a FRITSCH planetary mill 
Pulverisette 7 classic line and milling was started (milling cycle: 15 min of milling 
followed by a 15 minutes pause). The mixture was obtained by washing the vessel 
and the balls with DCM or EtOAc (3 x 3-5 mL). The resulting solution was 
concentrated in vacuo, and the product was purified by column chromatography 
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(gradient: pentane:ethyl acetate 9:1 to 8:2, diastereomers could be separated under 
these conditions but were combined to determine the yield). 
 
(S)-2-[(S)-1-(2-Fluorophenyl)-2-nitroethyl]-2-nitrocyclohexanone (7a)  
 
Prepared from -nitrocyclohexanone (187) and 2-fluoro--nitrostyrene (40a) 
according to general procedures D or E and obtained as a yellowish-white solid after 
column chromatography.  The compound could be recrystallized from Et2O to give 
white crystals. 
Mp.: 127 °C. 
HPLC-analysis: Chiralpak OD-H, n-heptane:i-PrOH= 95:5, 0.8 mL/min, tret: 17.5 (anti, 
major), 20.1, 24.1, 34.1 (anti, minor) min. 
1H NMR (300 MHz, CDCl3) anti: = 7.39-7.30 (m, 1H), 7.18-6.97 (m, 3H), 5.22 (dd, 
J= 13.5, 2.8 Hz, 1H), 4.78 (dd, J= 11.2, 2.3 Hz, 1H), 4.66 (dd, J= 13.5, 11.1 Hz, 1H), 
2.71-2.46 (m, 2H), 2.39-2.27 (m, 1H), 2.13-1.98 (m, 1H), 1.87  1.65 (m, 3H), 
1.65-1.45 (m, 1H). 
1H NMR (300 MHz, CDCl3) syn: = 7.45-7.24 (m, 2H), 7.18-6.97 (m, 2H), 5.36 (dd, 
J= 15.5, 11.3 Hz, 1H), 4.82-4.60 (m, 2H), 2.98-2.86 (m, 1H), 2.70-2.47 (m, 2H), 
2.13-1.98 (m, 1H), 1.87-1.65 (m, 1H), 1.65-1.45 (m, 3H). 
13C NMR (75 MHz, CDCl3) anti: = 200.0, 161.3 (d, J= 247.6 Hz), 
131.0 (d, J= 8.7 Hz), 129.0, 124.9 (d, J= 3.7 Hz), 120.2 (d, J= 13.9 Hz), 
116.1 (d, J= 22.9 Hz), 97.1, 74.9 (d, J= 1.7 Hz), 39.9, 39.2, 36.4, 27.5, 21.2  
13C NMR (75 MHz, CDCl3) syn: = 199.8, 161.5 (d, J= 247.9 Hz), 
130.9 (d, J= 8.8 Hz), 130.6, 125.2 (d, J= 3.6 Hz), 120.9 (d, J= 13.2 Hz), 
116.2 (d, J= 23.1 Hz), 98.6, 75.1 (d, J= 1.6 Hz), 40.3, 39.2, 34.8, 25.6, 21.0. 
19F NMR (376 MHz, CDCl3) anti: = –114.9,  syn = –113.7. 
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MS (EI): m/z (%)= 310 ([M]+, 17), 217 (23), 147 (29), 146 (30), 133 (27), 122 (100), 
109 (90), 84 (30), 67 (34), 55 (94). 
IR (ATR): = 2932, 1724, 1549, 1491, 1431, 1381, 1303, 1229, 1103, 821, 762, 694. 
CHN-Analysis for C14H15N2O5F, calc.: C: 54.19, H: 4.87, N: 9.03; found: C: 54.09, 
H: 4.87, N: 8.72. 
 
(S)-2-Nitro-2-[(S)-2-nitro-1-phenylethyl]cyclohexanone (7b)  
 
Prepared from -nitrocyclohexanone (187) and -nitrostyrene (40b) according to 
general procedures D or E and obtained as a white solid after column 
chromatography. The compound could be recrystallized from Et2O to give white 
crystals. 
Mp.: 93-94 °C. 
HPLC-analysis: Chiralpak OD-H, n-heptane:i-PrOH= 90:10, 0.8 mL/min, tret: 36.0 
(anti, major), 39.4, 49.1, 66.4 (anti, minor) min. 
1H NMR (400 MHz, CDCl3) anti: = 7.34-7.29 (m, 3H), 7.10-7.04 (m, 2H), 5.12 (dd, 
J= 13.7, 3.2 Hz, 1H), 4.69 (dd, J= 13.7, 11.0 Hz, 1H), 4.28 (dd, J= 11.0, 3.1 Hz, 1H), 
2.68-2.49 (m, 2H), 2.28 (ddd, J= 14.7, 6.2, 3.3 Hz, 1H), 2.08-1.97 (m, 1H), 1.80-1.48 
(m, 4H). 
1H NMR (400 MHz, CDCl3) syn: = 7.34-7.29 (m, 3H), 7.28-7.23 (m, 2H), 5.26 (dd, 
J= 14.0, 10.7 Hz, 1H), 4.69 (dd, J= 14.0, 3.0 Hz, 1H), 4.25 (dd, J= 10.7, 3.1 Hz, 1H), 
2.80-2.69 (m, 1H), 2.67-2.50 (m, 2H), 2.08-1.97 (m, 1H), 1.80-1.48 (m, 4H). 
13C NMR (75 MHz, CDCl3) anti: = 200.3, 132.6, 129.34, 129.22, 129.1, 97.6, 76.3, 
46.9, 39.9, 37.4, 27.6, 21.3 
13C NMR (75 MHz, CDCl3) syn: = 199.9, 133.4, 129.7, 129.30, 129.20, 98.5, 76.1, 
49.6, 40.4, 35.3, 25.7, 21.0. 
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MS (EI): m/z (%)= 292 ([M]+, 18), 199 (76), 143 (17), 141 (19), 129 (53), 128 (46), 
115 (43), 104 (100), 91 (97), 77 (45), 55 (70). 
IR (ATR): = 2944, 1735, 1540, 1433, 1378, 1331, 1212, 1119, 826, 753, 701. 
CHN-Analysis for C14H16N2O5, calc.: C: 57.53, H: 5.52, N: 9.58; found: C: 57.30, 
H: 5.54, N: 9.54. 
 
(S)-2-[(S)-1-(2-Chlorophenyl)-2-nitroethyl]-2-nitrocyclohexanone (7c)  
 
Prepared from -nitrocyclohexanone (187) and 2-chloro--nitrostyrene (40c) 
according to general procedures D or E and obtained as a yellowish-white solid after 
column chromatography, white crystals after recrystallization from Et2O.  
Mp.: 152 °C. 
HPLC-analysis: Chiralpak AS-H, n-heptane:i-PrOH= 98:2, 0.8 mL/min, tret: 26.6 (anti, 
minor), 35.2 (anti, major), 38.7, 45.9 min. 
1H NMR (400 MHz, CDCl3) anti: = 7.39-7.33 (m, 1H), 7.20 (dt, J= 5.5, 2.9 Hz, 2H), 
6.92-6.87 (m, 1H), 5.17 (dd, J= 13.8, 3.4 Hz, 1H), 5.11 (dd, J= 11.0, 3.4 Hz, 1H), 
4.47 (dd, J= 13.7, 11.0 Hz, 1H), 2.62-2.54 (m, 1H), 2.48 (td, J= 13.4, 5.9 Hz, 1H), 
2.18 (ddd, J= 15.3, 6.2, 3.0 Hz, 1H), 2.04-1.94 (m, 1H), 1.92-1.81 (m, 1H), 
1.73-1.58 (m, 2H), 1.50-1.35 (m, 1H). 
1H NMR (400 MHz, CDCl3) syn: = 7.50-7.44 (m, 1H), 7.37-7.30 (m, 1H), 
7.23-7.13 (m, 2H), 5.38 (dd, J= 14.5, 10.6 Hz, 1H), 4.95 (dd, J= 10.6, 2.6 Hz, 1H), 
4.59 (dd, J= 14.5, 2.7 Hz, 1H), 2.99-2.84 (m, 1H), 2.63-2.42 (m, 2H), 
1.95-1.78 (m, 1H), 1.73-1.58 (m, 1H), 1.52-1.28 (m, 3H). 
13C NMR (100 MHz, CDCl3): = anti: 199.8, 136.1, 131.2, 130.4, 130.3, 128.1, 127.7, 
97.5, 75.7, 41.0, 39.8, 35.7, 27.5, 21.1. 
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13C NMR (100 MHz, CDCl3): syn: = 200.5, 136.6, 130.6, 130.1, 129.8, 128.0, 127.6, 
99.2, 76.4, 44.8, 40.5, 35.1, 25.5, 20.9. 
MS (EI): m/z (%)= 326 ([M]+, 7), 280 (48), 233 (8), 163 (10), 138 (72), 125 (56), 
112 (36), 100 (45), 84 (35), 77 (28), 67 (31), 55 (100). 
IR (ATR): = 2927, 1723, 1548, 1434, 1378, 1341, 1205, 1116, 1043, 825, 758, 685.  
CHN-Analysis for C14H15N2O5Cl, calc.: C: 51.46, H: 4.63, N: 8.57; found: C: 51.35, 
H: 4.56, N: 8.58. 
 
 (S)-2-[(S)-1-(4-Fluorophenyl)-2-nitroethyl]-2-nitrocyclohexanone (7d) 
 
Prepared from -nitrocyclohexanone (187) and 4-fluoro--nitrostyrene (40d) 
according to general procedures D or E and obtained as a yellow-white solid after 
column chromatography.  
Mp.: 86 °C. 
HPLC-analysis: Chiralpak AD-H, n-heptane:i-PrOH= 90:10, 0.8 mL/min, tret: 20.3, 
22.1, 36.6 (anti, minor), 29.1 (anti, major) min. 
1H NMR (300 MHz, CDCl3) anti: = 7.12-6.97 (m, 4H), 5.11 (dd, J= 13.7, 3.2 Hz, 1H), 
4.65 (dd, J= 13.7, 11.1 Hz, 1H), 4.28 (dd, J= 11.1, 3.2 Hz, 1H), 2.71-2.47 (m, 2H), 
2.38-2.22 (m, 1H), 2.13-1.96 (m, 1H), 1.85-1.44 (m, 4H),  
1H NMR (300 MHz, CDCl3) syn: = 7.32-7.24 (m, 2H), 7.07-6.98 (m, 2H), 5.24 (dd, 
J= 14.0, 10.8 Hz, 1H), 4.68 (dd, J= 14.0, 3.1 Hz, 1H), 4.25 (dd, J= 10.8, 3.1 Hz, 1H), 
2.75 (dt, J= 11.6, 2.8 Hz, 1H), 2.65-2.55 (m, 2H), 2.07-1.93 (m, 1H), 
1.87-1.75 (m, 1H), 1.64-1.46 (m, 3H). 
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13C NMR (75 MHz, CDCl3) anti: = 200.2, 163.2 (d, J= 249.0 Hz), 
131.0 (d, J= 8.3 Hz), 128.5 (d, J= 2.7 Hz), 116.3 (d, J= 21.7 Hz), 97.5, 76.3, 46.4, 
40.0, 37.4, 27.5, 21.3. 
13C NMR (75 MHz, CDCl3) syn: = 199.9, 163.1 (d, J= 249.3 Hz), 
131.6 (d, J= 8.2 Hz), 129.2 (d, J= 3.1 Hz), 116.4 (d, J= 21.6 Hz), 98.5, 76.1, 48.9, 
40.4, 35.5, 25.8, 21.1. 
19F NMR (282 MHz, CDCl3): = anti: 111.9, syn: = 112.1. 
MS (EI): m/z (%)= 310 ([M]+, 17), 217 (69), 147 (42), 146 (32), 133 (33), 122 (100), 
109 (90), 84 (17), 67 (23), 55 (78). 
IR (ATR): = 2940, 1726, 1605, 1550, 1508, 1428, 1379, 1229, 1163, 1107, 851, 
819, 738, 692. 
CHN-Analysis for C14H15N2O5F, calc.: C: 54.19, H: 4.87, N: 9.03; found: C: 54.28, 
H: 4.75, N: 8.66. 
 
(S)-2-[(S)-1-(4-Chlorophenyl)-2-nitroethyl]-2-nitrocyclohexanone (7e)  
 
Prepared from -nitrocyclohexanone (187) and 4-chloro--nitrostyrene (40e) 
according to general procedures D or E and obtained as a yellow oil after column 
chromatography. 
HPLC-analysis: Chiralpak AD-H, n-heptane:i-PrOH= 95:5, 0.8 mL/min, tret: 31.9, 38.2 
(anti, minor), 33.9, 81.5 (anti, major) min. 
1H NMR (600 MHz, CDCl3) anti: = 7.25 (d, J= 8.3 Hz, 2H), 6.97 (d, J= 8.4 Hz, 2H), 
5.05 (dd, J= 13.9, 3.1 Hz, 1H), 4.58 (dd, J= 13.8, 11.2 Hz, 1H), 4.21 (dd, J= 11.1, 
3.0 Hz, 1H), 2.62-2.55 (m, 1H), 2.55-2.47 (m, 1H), 2.25 (dd, J= 15.0, 2.7 Hz, 1H), 
2.03-1.95 (m, 1H), 1.79-1.55 (m, 3H), 1.55-1.41 (m, 1H). 
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1H NMR (600 MHz, CDCl3) syn: = 7.25 (d, J= 8.3 Hz, 2H), 7.17 (d, J= 8.4 Hz, 2H), 
5.17 (dd, J= 14.0, 10.9 Hz, 1H), 4.62 (dd, J= 14.1, 3.0 Hz, 1H), 4.17 (dd, J= 11.0, 
2.7 Hz, 1H), 2.71-2.65 (m, 1H), 2.61-2.55 (m, 2H), 1.95-1.90 (m, 1H), 
1.77-1.67 (m, 1H), 1.55-1.41 (m, 3H). 
13C NMR (150 MHz, CDCl3) anti: = 200.1, 135.5, 131.2, 130.6, 129.4, 97.2, 76.0, 
46.5, 39.9, 37.4, 27.5, 21.3  
13C NMR (150 MHz, CDCl3) syn: = 199.8, 135.4, 131.9, 131.1, 129.5, 98.2, 75.9, 
49.0, 40.3, 35.5, 25.8, 21.0. 
MS (EI): m/z (%)= 326 ([M]+, 19), 280 (6), 233 (69), 163 (19), 138 (82), 125 (73), 
115 (31), 103 (27), 84 (19), 77 (32), 67 (29), 55 (100). 
IR (ATR): = 2953, 1728, 1548, 1493, 1430, 1377, 1095, 1015, 906, 826, 731. 
CHN-Analysis for C14H15N2O5Cl, calc.: C: 51.46, H: 4.63, N: 8.57; found: C: 51.31, 
H: 4.44, N: 8.43. 
 
 (S)-2-[(S)-1-(4-Bromophenyl)-2-nitroethyl]-2-nitrocyclohexanone (7f)  
 
Prepared from -nitrocyclohexanone (187) and 4-bromo--nitrostyrene (40f) 
according to general procedures D or E and obtained as a yellow-white solid after 
column chromatography.  
Mp.: 112-113 °C. 
HPLC-analysis: Chiralpak AD-H, n-heptane:i-PrOH= 95:5, 0.8 mL/min, tret: 34.7, 41.9 
(anti, minor), 48.0, 89.9 (anti, major) min. 
1H NMR (400 MHz, CDCl3) anti: = 7.47 (dt, J= 4.7, 2.6 Hz, 2H), 7.02-6.95 (m, 2H), 
5.11 (dd, J= 13.8, 3.2 Hz, 1H), 4.64 (dd, J= 13.8, 11.1 Hz, 1H), 4.26 (dd, J= 11.1, 
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3.2 Hz, 1H), 2.69-2.50 (m, 2H), 2.36-2.26 (m, 1H), 2.10-1.96 (m, 1H), 
1.84-1.48 (m, 4H). 
1H NMR (400 MHz, CDCl3) syn: = 7.49-7.45 (m, 2H), 7.19-7.14 (m, 2H), 5.23 (dd, 
J= 14.0, 10.8 Hz, 1H), 4.68 (dd, J= 14.1, 3.1 Hz, 1H), 4.22 (dd, J= 10.8, 3.0 Hz, 1H), 
2.79-2.70 (m, 1H), 2.69-2.50 (m, 2H), 2.36-2.26 (m, 1H), 2.10-1.96 (m, 1H), 
1.84-1.47 (m, 3H). 
13C NMR (100 MHz, CDCl3) anti: = 200.0, 132.3, 131.8, 130.9, 123.7, 97.3, 76.0, 
46.5, 39.9, 37.4, 27.5, 21.3. 
13C NMR (100 MHz, CDCl3) syn: = 199.8, 132.49, 132.46, 131.4, 123.6, 98.3, 75.8, 
49.1, 40.3, 35.5, 25.7, 21.0. 
MS (EI): m/z (%)= 370 ([M]+, 17), 277 (43), 198 (22), 181 (46), 169 (40), 155 (24), 
141 (39), 128 (63), 115 (40), 102 (29), 77 (48), 67 (31), 55 (100). 
IR (CHCl3): = 3094, 2924, 1910, 1730, 1545, 1490, 1432, 1378, 1340, 1217, 1119, 
1075, 1011, 908, 829, 733, 646, 548.  
CHN-Analysis for C14H15N2O5Br, calc.: C: 45.30, H: 4.07, N: 7.55; found: C: 45.62, 
H: 4.12, N: 7.15. 
 
(S)-2-[(S)-1-(4-Methoxyphenyl)-2-nitroethyl]-2-nitrocyclohexanone (7g)  
 
Prepared from -nitrocyclohexanone (187) and 4-methoxy--nitrostyrene (40g) 
according to general procedures D or E and obtained as a yellow oil after column 
chromatography. 
HPLC-analysis: Chiralpak OT+, n-heptane:i-PrOH= 97:3, 0.8 mL/min, tret: 18.0 (anti, 
major), 22.0, 25.3, 40.1 (anti, minor) min. 
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1H NMR (400 MHz, CDCl3) anti: = 7.03-6.98 (dm, J= 8.8 Hz 2H), 6.87-6.82 (dm, 
J= 8.8 Hz, 2H), 5.09 (dd, J= 13.6, 3.2 Hz, 1H), 4.66 (dd, J= 13.6, 11.1 Hz, 1H), 
4.24 (dd, J= 11.1, 3.2 Hz, 1H), 3.78 (s, 3H), 2.69-2.50 (m, 2H), 2.33 (ddd, 
J= 14.6, 6.0, 3.2 Hz, 1H), 2.09-1.93 (m, 1H), 1.83-1.47 (m, 4H). 
1H NMR (400 MHz, CDCl3) syn: = 7.22-7.15 (dm, J= 8.8 Hz, 2H), 6.87-6.82 (dm, 
J= 8.8 Hz, 2H), 5.23 (dd, J= 13.8, 10.9 Hz, 1H), 4.66 (dd, J= 14.0, 2.8 Hz, 1H), 
4.20 (dd, J= 10.9, 3.0 Hz, 1H), 3.77 (s, 3H), 2.78-2.71 (m, 1H), 2.64-2.52 (m, 2H), 
2.09-1.93 (m, 1H), 1.83-1.47 (m, 4H). 
13C NMR (100 MHz, CDCl3) anti: = 200.4, 160.2, 130.3, 124.3, 114.5, 97.9, 76.4, 
55.4, 46.4, 39.9, 37.3, 27.6, 21.3. 
13C NMR (100 MHz, CDCl3) syn: = 200.0, 160.1, 130.9, 125.0, 114.6, 98.6, 76.3, 
55.4, 49.1, 40.4, 35.4, 25.7, 21.0. 
MS (EI): m/z (%)= 322 ([M]+, 45), 229 (39), 215 (16), 211 (14), 201 (16), 187 (14), 
179 (11), 173 (10), 159 (21), 134 (100), 121 (55), 115 (21), 102 (11), 91 (50), 77 (43), 
57 (34), 55 (72). 
IR (CHCl3): = 3440, 2922, 1730, 1613, 1543, 1515, 1435, 1381, 1302, 1253, 1184, 
1120, 1032, 904, 819, 731, 636, 567. 
CHN-Analysis for C15H18N2O6, calc.: C: 55.90, H: 5.63, N: 8.69; found: C: 56.07, 
H: 6.01, N: 8.53. 
 
(S)-2-Nitro-2-[(S)-2-nitro-1-p-tolylethyl]cyclohexanone (7h) 
 
Prepared from -nitrocyclohexanone (187) and 4-methyl--nitrostyrene (40h) 
according to general procedures D or E and obtained as a yellow oil after column 
chromatography. 
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HPLC-analysis: Chiralpak AD-H, n-heptane:i-PrOH= 98:2, 0.8 mL/min, tret: 30.3, 34.1 
(anti, minor), 36.6, 58.7 (anti, major) min. 
1H NMR (400 MHz, CDCl3) anti: = 7.13 (d, J= 7.7 Hz, 2H), 6.97 (d, J= 8.1 Hz, 2H), 
5.11 (dd, J= 13.6, 3.1 Hz, 1H), 4.68 (dd, J= 13.6, 11.1 Hz, 1H), 4.26 (dd, J= 11.1, 
3.1 Hz, 1H), 2.69-2.52 (m, 2H), 2.32 (s, 3H), 2.36-2.26 (m, 1H), 2.10-1.97 (m, 1H), 
1.82-1.47 (m, 4H). 
1H NMR (400 MHz, CDCl3) syn: = 7.17-7.09 (m, 4H), 5.25 (dd, J= 13.8, 10.8 Hz, 
1H), 4.69 (dd, J= 13.9, 3.3 Hz, 1H), 4.23 (dd, J= 10.9, 3.1 Hz, 1H), 2.79-2.73 (m, 1H), 
2.69-2.52 (m, 2H), 2.31 (s, 3H), 2.10-1.97 (m, 1H), 1.82-1.45 (m, 4H). 
13C NMR (100 MHz, CDCl3) anti: = 200.4, 139.3, 129.8, 129.5, 129.1, 97.7, 76.4, 
46.7, 39.9, 37.3, 27.6, 21.3, 21.2. 
13C NMR (100 MHz, CDCl3) syn: = 200.0, 139.1, 130.0, 129.6, 129.5, 98.6, 76.2, 
49.4, 40.4, 35.3, 25.7, 21.2, 21.0. 
MS (EI): m/z (%)= 306 ([M]+, 28), 242 (7), 213 (98), 185 (19), 171 (17), 157 (17), 
143 (44), 129 (38), 128 (41), 118 (100), 105 (84), 91 (53), 77 (44), 65 (25), 55 (79). 
IR (CHCl3): = 2950, 1729, 1552, 1433, 1377, 1219, 1120, 757, 563. 
HRMS (ESI) m/z calculated for C15H18N2O5Na [M+Na]
+: 329.1108, found 329.1107. 
 
(S)-2-[(S)-1-(Furan-2-yl)-2-nitroethyl]-2-nitrocyclohexanone (7i) 
 
Prepared from -nitrocyclohexanone (187) and 2-(2-nitrovinyl)furane (40i) according 
to general procedures D or E, and obtained as a brown oil after column 
chromatography. 
HPLC-analysis: Chiralpak AD-H, n-heptane:i-PrOH= 95:5, 0.8 mL/min, tret: 21.7 (anti, 
minor), 24.8, 57.5, 61.5 (anti, major) min. 
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1H NMR (300 MHz, CDCl3) anti: = 7.38 (dd, J= 1.9, 0.7 Hz, 1H), 6.35-6.32 (m, 1H), 
6.28-6.26 (m, 1H), 4.98 (dd, J= 13.6, 2.8 Hz, 1H), 4.64 (dd, J= 13.6, 10.8 Hz, 1H), 
4.50 (dd, J= 10.9, 2.8 Hz, 1H), 2.69-2.39 (m, 3H), 2.11-1.98 (m, 1H), 
1.89-1.52 (m, 4H). 
1H NMR (300 MHz, CDCl3) syn: = 7.37-7.36 (m, 1H), 6.32-6.30 (m, 2H), 5.10 (dd, 
J= 13.7, 10.4 Hz, 1H), 4.61 (dd, J= 13.6, 3.1 Hz, 1H), 4.57 (dd, J= 10.2, 3.1 Hz, 1H), 
2.94-2.81 (m, 1H), 2.67-2.52 (m, 2H), 2.11-1.97 (m, 1H), 1.89-1.51 (m, 4H). 
13C NMR (75 MHz, CDCl3) anti: = 199.8, 146.7, 143.75, 111.0, 110.9, 97.1, 74.5, 
40.9, 39.7, 36.5, 27.3, 21.3. 
13C NMR (75 MHz, CDCl3) syn: = 199.0, 146.7, 143.69, 111.4, 111.1, 97.6, 74.3, 
42.7, 40.0, 34.7, 25.8, 21.0. 
MS (EI): m/z (%)= 282 ([M]+, 2), 189 (50), 161 (18), 133 (11), 123 (16), 105 (16), 
94 (64), 91 (50), 83 (100), 81 (46), 77 (32), 65 (45), 55 (84). 
IR (ATR): = 3126, 2953, 2874, 1729, 1556, 1501, 1432, 1379, 1150, 1119, 1078, 
1017, 915, 821, 749, 691, 598, 536. 
CHN-Analysis for C12H14N2O6, calc.: C: 51.06, H: 5.00 N: 9.93; found: C: 51.22, 
H: 4.95, N: 9.95. 
5.4.5 Synthesis of catalysts 
(S)-N-(1-methylpiperidine-3-yl)-3,5-bis-(trifluoromethyl)benzenesulfonamide (189) 
 
A flame-dried flask with a magnetic stirrer bar was charged with 4 mmol of the 
deprotected (S)-1-methylpiperidin-3-amin HCl-salt (183b-HCl-salt) in dry DCM 
(30 mL). Et3N (30 mmol, 4 equiv.) and 3,5-bis-(trifluoromethyl)-benzenesulfonyl 
chloride (4.2 mmol, 1.05 equiv. in 5 mL DCM) were added consecutively at 0 °C. The 
mixture was allowed to warm to room temperature and stirred for 16 h. The mixture 
was diluted with DCM and washed with 1N NaOH, the organic phase was dried over 
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MgSO4, filtered, and concentrated in vacuo. The product was purified by column 
chromatography (Et2O:MeOH 9:1) and received in 91% yield as a white solid.  
Mp.: 146 °C. 
Optical rotation:       = –31.4 (c= 1.47, EtOH). 
1H NMR (400 MHz, CDCl3) = 8.35 (s, 2H), 8.06 (s, 1H), 5.49 (brs, 1H), 
3.59-3.49 (m, 1H), 2.45 (br s, 1H), 2.37-2.25 (m, 1H), 2.25-2.04 (m, 2H), 2.16 (s, 3H), 
1.76-1.60 (m, 1H), 1.57-1.39 (m, 3H). 
13C NMR (101 MHz, CDCl3) = 144.6, 133.0 (q, J= 34.5 Hz), 127.3, 126.1, 
122.6 (q, J= 273.3 Hz), 60.6, 55.4, 50.0, 46.4, 29.7, 21.6. 
19F NMR (376 MHz, CDCl3) = 63.04. 
MS (EI): m/z (%)= 391 ([M+H]+, 0.3), 213 (7), 194 (1), 163 (3), 113 (19), 96 (3), 
84 (26), 70 (100), 57 (11). 
IR (ATR): = 2935, 1496, 1356, 1333, 1273, 1163, 1128, 1077, 1020, 918, 895, 782, 
694, 680. 
CHN-Analysis for C14H16 F6N2O2S, calc.: C: 43.08, H: 4.13, N: 7.18; found: C: 43.35, 
H: 4.12, N: 7.16. 
 
(S)-N-(1-methylpiperidine-3-yl)-P,P-diphenylphosphinthioic amide (190) 
 
A flame-dried flask with a magnetic stirrer bar was charged with 7.5 mmol of the 
deprotected (S)-1-methylpiperidin-3-amine HCl-salt (183b-HCl-salt) in dry DCM 
(10 mL). Et3N (30 mmol, 4 equiv.) and P,P-diphenyl-phosphinothioic chloride 
(7.5 mmol, 1.0 equiv. in 5 ml CH2Cl2) were added consecutively at 0 °C. The mixture 
was allowed to warm to room temperature and stirred for 16 h. The mixture was 
diluted with DCM and washed with 1N NaOH, the organic phase was dried over 
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MgSO4, filtered, and concentrated in vacuo. The product was purified by column 
chromatography (Et2O:MeOH 98:2) and received in 94% yield as a white solid.  
Mp.: 64 °C. 
Optical rotation:       = –17.6 (c= 2.99, CHCl3). 
1H NMR (300 MHz, CDCl3) = 8.08-7.94 (m, 4H), 7.51-7.37 (m, 6H), 
3.51-3.30 (m, 1H), 3.11 (br s, 1H), 2.55-2.26 (m, 3H), 2.22-2.09 (m, 1H), 2.19 (s, 3H), 
1.84-1.70 (m, 1H), 1.68-1.40 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 135.5 (d, J= 2.6 Hz), 134.1 (d, J= 3.7 Hz), 131.8, 
131.6 (d, J= 1.9 Hz), 131.49 (d, J= 5.1 Hz), 131.46 (d, J= 4.6 Hz), 
128.4 (d, J= 4.5 Hz), 128.2 (d, J= 4.6 Hz), 62.4, 55.6, 47.7, 46.5, 31.3, 22.3. 
31P NMR (121 MHz, CDCl3) = 57.51. 
MS (EI): m/z (%)= 331 ([M]+, 2), 234 (20), 217 (30), 202 (4), 183 (6), 139 (15), 
97 (100), 82 (8), 77 (4), 70 (17). 
IR (ATR): = 3254, 2938, 2785, 1434, 1302, 1100, 1069, 1021, 983, 859, 751, 700.  
CHN-Analysis for C18H23N2PS, calc.: C: 65.43, H: 7.02, N: 8.48; found: C: 65.43, 
H: 7.36, N: 8.56. 
 
(S)-1-(1-methylpiperidine-3-yl)-3-phenylselenourea (193) 
 
Prepared from (S)-tert-butyl 1-methylpiperidine-3-ylcarbamate (178b) and phenyl 
isoselenocyanate (192), according to the general procedure C and obtained as a 
brown solid in 91% yield after column chromatography (ethyl acetate:MeOH:Et3N 
100:4:4). 
Mp.: 126-128 °C.  
Optical rotation:       = –16.1 (c= 0.82, CHCl3). 
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1H NMR (300 MHz, CDCl3) = 9.08 (s, 1H), 7.43 (t, J= 7.7 Hz, 2H), 
7.37-7.02 (m, 4H), 4.64 (s, 1H), 2.51 (d, J= 9.1 Hz, 2H), 2.31 (d, J= 11.9 Hz, 1H), 
2.12 (s, 3H), 2.07-1.96 (m, 1H), 1.92 (s, 1H), 1.67-1.34 (m, 3H). 
13C NMR (75 MHz, CDCl3) = 175.9, 136.4, 130.0, 127.0, 124.5, 59.5, 55.5, 53.2, 
46.3, 27.6, 21.7. 
MS (EI): m/z (%)= 297 ([M]+, 12), 184 (1), 119 (3), 98 (17), 97 (100), 96 (32), 82 (17), 
77 (11), 70 (10), 58 (5). 
IR (ATR): = 3344, 3141, 2935, 2781, 1592, 1526, 1446, 1244, 1148, 1011, 926, 
855, 761, 693.  
CHN-Analysis for C13H19N3Se, calc.: C: 52.70, H: 6.46, N: 14.18; found: C: 52.57, 
H: 6.47, N: 14.13. 
 
(S)-1-(1-methylpiperidine-3-yl)-3-phenylurea (194) 
 
Prepared from (S)-tert-Butyl 1-tert-butylpiperidin-3-ylcarbamate (178d) and phenyl 
isocyanate according to the general procedure C and obtained as a white solid in 
quantitative yield after column chromatography (first pentane:ethyl acetate 7:3, then 
ethyl acetate:MeOH:Et3N 100:4:4). 
Mp.: 195-196 °C. 
Optical rotation:       = –17.9 (c= 1.00, EtOH). 
1H NMR (600 MHz, CD3OD): = 7.31-7.34 (m, 2H), 7.23 (t, J= 8.0 Hz, 2H), 6.96 
(t, J= 7.3 Hz, 1H), 3.86-3.79 (m, 1H), 2.83 (br s, 1H), 2.58 (br s, 1H), 2.27 (s, 3H), 
2.16 (br s, 1H), 2.01 (br s, 1H), 1.84 (br s, 1H), 1.80-1.71 (m, 1H), 1.69-1.58 (m, 1H), 
1.28 (br s, 1H). 
13C NMR (151 MHz, CD3OD):  = 157.5, 140.9, 129.8, 123.4, 120.1, 62.0, 56.4, 47.3, 
46.5, 30.9, 24.3. 
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MS (EI): m/z (%)= 234 ([M+H]+, 1), 141 (2), 119 (1), 98 (6), 97 (100), 96 (8), 82 (10), 
77 (2), 70 (7), 58 (5). 
IR (ATR): = 3300, 2932, 2779, 2469, 2433, 2061, 1631, 1567, 1442, 1305, 1232, 
1148, 1101, 1061, 1017, 855, 762, 726, 670. 
CHN-Analysis for C13H19N3O, calc.: C: 66.92, H: 8.21, N: 18.01; found:  C: 66.50, 
H: 8.07, N: 18.06. 
HRMS (ESI) m/z calculated for C13H20N3O [M+H]
+: 234.16009, found 234.15964. 
5.4.6 Preparation of the chiral ligand (S)-205 
(S)-1-benzyl-N-[4-chloro-2-(2-chlorobenzoyl)phenyl]pyrrolidine-2-carboxamide 
[(S)-205)] 
 
In a flask equipped with a magnetic stirrer bar (S)-N-benzylproline (103, 3.08 g, 
15.0 mol) was suspended in dry DCM (18 mL) under an argon atmosphere. The 
mixture was cooled with a NaCl/ice bath and SOCl2 (1.65 ml, 2.7 g, 22.5 mmol, 
1.5 equiv.) was added dropwise. The mixture was stirred for 10 min and a solution of 
2-amino-2‟,5-dichlorobenzophenone (204, 3.05 g, 11.25 mmol, 0.75 equiv.) in dry 
DCM (15 mL) was added dropwise. The resulting mixture was heated to 45 °C and 
stirred for 15 h. The reaction mixture was washed with sat. aq. NaHCO3 (30 mL) and 
the separated aqueous layer was extracted with DCM (3 x 20 mL). The combined 
organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The 
residue was purified by column chromatography (DCM:pentane 3:1) to afford the 
product in 88% yield as a brownish glue. 
Optical rotation:       = +24.0 (c= 0.31, CHCl3). 
1H NMR (400 MHz, CDCl3) = 12.37 (br s, 1H), 8.76 (d, J= 9.1 Hz, 1H), 
7.51-7.43 (m, 3H), 7.43-7.34 (m, 4H), 7.29 (d, J= 2.5 Hz, 1H), 7.25-7.12 (m, 3H), 
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3.81 (dd, J= 105.5, 12.9 Hz, 2H), 3.36 (dd, J= 10.2, 4.6 Hz, 1H), 3.33-3.27 (m, 1H), 
2.46 (td, J= 9.5, 6.4 Hz, 1H), 2.35-2.23 (m, 1H), 2.05-1.95 (m, 1H), 1.95-1.86 (m, 1H), 
1.85-1.75 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 196.9, 175.4, 139.5, 138.4, 138.0, 135.0, 133.0, 
131.5, 131.0, 130.3, 129.2, 128.7, 128.2, 127.2, 127.1, 126.9, 123.8, 122.3, 68.3, 
59.8, 53.9, 31.2, 24.2. 
IR (CHCl3): = 3445, 3235, 2952, 2816, 1657, 1566, 1495, 1394, 1280, 1236, 1157, 
1107, 1031, 942, 832, 748, 700.  
HRMS (ESI) m/z calculated for C25H23N2O2Cl2 [M+H]
+: 453.1131, found: 453.1130. 
5.4.7 Preparation of chiral Ni(II)-complexes 206 and 207 
In a Schlenk flask equipped with a magnetic stirrer bar (S)-1-benzyl-N-[4-chloro-2-(2-
chlorobenzoyl)phenyl]pyrrolidine-2-carboxamide ((S)-205, 4.19 g, 10.03 mol), 
nickel(II) nitrate hexahydrate (6.01 g, 20.05 mmol, 2 equiv.) and glycine (75, 2.31 g, 
30.09 mmol, 3 equiv.) were dissolved in MeOH (200 mL) under an argon atmosphere 
at 50 °C. To the solution solid K2CO3 (20.8 g, 150.5 mmol, 15 equiv.) was added in 
one portion and the mixture was stirred at 60 °C. The reaction mixture turned red 
after 10 min, and the conversion was followed by TLC (DCM:acetone 4:1) until 
completion. After 1 h the starting material was consumed, and the reaction mixture 
was neutralized with 5% AcOH. The product was extracted with DCM (4 x 30 mL). 
The combined organic phases were dried over Na2SO4, filtered, and concentrated in 
vacuo. The product was purified by column chromatography (DCM:acetone 7:1 to 
2:1) to afford the two diastereomers 6 and 7 (the latter is eluted first) as red solids in 
22% and 45% yield, respectively.  
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Nickel complex 206 (minor) 
 
Mp: 160-162 °C 
Optical rotation:       = +2030 (c= 0.105, CHCl3). 
1H NMR (600 MHz, CDCl3): = 8.30 (d, J= 9.3 Hz, 1H), 8.21 (d, J= 7.3 Hz, 2H), 
7.57 (d, J= 8.1 Hz, 1H), 7.50 (td, J= 7.9, 1.5 Hz, 1H), 7.45-7.38 (m, 3H), 
7.28-7.25 (m, 1H), 7.12 (dd, J= 9.3, 2.5 Hz, 1H), 6.95 (dd, J= 7.6, 1.2 Hz, 1H), 
6.60 (d, J= 2.5 Hz, 1H), 4.42 (t, J= 17.1 Hz, 1H), 3.71 (t, J= 8.3 Hz, 1H), 3.65 (dd, 
J= 54.0, 20.0 Hz, 2H), 3.50 (d, J= 12.6 Hz, 1H), 3.44 (dd, J= 10.7, 5.6 Hz, 1H), 
3.35-3.25 (m, 1H), 2.57-2.39 (m, 2H), 2.19-2.05 (m, 2H). 
13C NMR (151 MHz, CDCl3): = 181.6, 176.8, 167.6, 141.5, 133.9, 132.9, 132.2, 
131.7, 131.6, 130.7, 130.6, 130.5, 129.3, 129.1, 128.3, 127.2, 125.7, 125.6, 125.0, 
70.4, 64.1, 60.8, 58.2, 30.9, 23.7. 
IR (CHCl3): = 3049, 2970, 1741, 1668, 1530, 1459, 1316, 1244, 1168, 1028, 953, 
823, 748, 703. 
HRMS (ESI) m/z calculated for C27H23N3O3Cl2NiNa [M+Na]
+: 588.0362, found: 
588.0356. 
 
Nickel complex 207 (major): 
 
Mp: 261-263 °C 
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Optical rotation:       = +1650 (c= 0.1, CHCl3). 
1H NMR (600 MHz, CDCl3): = 8.35 (d, J= 9.3 Hz, 1H), 8.08 (d, J= 7.2 Hz, 2H), 
7.55-7.45 (m, 3H), 7.43 (t, J= 7.7 Hz, 2H), 7.32 (t, J= 7.5 Hz, 1H), 7.14 (dd, J= 9.3, 
2.6 Hz, 1H), 7.05 (dd, J= 7.3, 1.6 Hz, 1H), 6.66 (d, J= 2.5 Hz, 1H), 
4.49 (d, J= 12.7 Hz, 1H), 3.81 (d, J= 20.0 Hz, 1H), 3.79-3.73 (m, 1H), 
3.57 (dd, J= 25.5, 16.3 Hz, 2H), 3.47-3.40 (m, 1H), 3.39-3.27 (m, 1H), 
2.55-2.47 (m, 1H), 2.46-2.36 (m, 1H), 2.24-2.14 (m, 1H), 2.12-2.04 (m, 1H). 
13C NMR (151 MHz, CDCl3): = 181.9, 176.8, 167.8, 141.7, 133.5, 132.7, 132.2, 
131.69, 131.67, 130.9, 130.53, 130.50, 129.3, 129.0, 128.00, 127.7, 125.69, 125.63, 
125.0, 70.0, 63.3, 60.8, 58.1, 30.9, 23.7. 
IR (CHCl3) major: = 2937, 1740, 1656, 1585, 1529, 1457, 1332, 1239, 1166, 1051, 
972, 930, 828, 748, 701. 
5.4.8 Alkylation of Ni(II)-complexes 
General procedure D 
In a Schlenk flask equipped with a magnetic stirrer bar the Ni(II)-complex (206 or 
207, 37.8 mg, 0.07 mmol), TBAI (2.5 mg, 0.007 mmol, 0.1 equiv.) and crushed NaOH 
(106.7 mg, 2.7 mmol, 40 equiv.) were dissolved in 1,2-dichloroethane (0.7 mL) under 
an argon atmosphere. The alkylation reagent (0.17 mmol, 2.5 equiv.) was added to 
the reaction mixture (liquid alkyl halides were dissolved in a small amount of 
1,2-dichloroethane). The reaction was followed by TLC (DCM:acetone 4:1) until 
completion (30-60 min). The reaction mixture was washed with AcOH (5% aq. sol., 
5 mL) and the separated aqueous layer was extracted with DCM (3 x 5 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated in 
vacuo. The product was purified by column chromatography (gradient: DCM:acetone 
9:1 to 2:1). 
General procedure E 
Procedure E1: 
Ni(II)-complex 206 (56.7 mg, 0.1 mmol), the alkylating agent (0.15 mmol, 1.5 equiv.), 
NaOMe (108.0 mg, 2.0 mmol, 20 equiv.) and MgSO4 (12,0 mg, 0.1 mmol, 1 equiv.) 
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were transferred to a clean, dry ZrO2 ball milling vessel loaded with 3 milling balls 
(⌀= 10.0 mm, ZrO2). The vessel was placed in a RETSCH Mixer Mill MM400 and 
milling was started at 20 Hz. After 30 min of milling the vessel was removed, opened, 
and a sample was analyzed by TLC (DCM:acetone 4:1). If the conversion was 
incomplete, the vessel was placed back into the mixer mill for additional cycles of 
15 min (each milling cycle was followed by a 10 minutes pause). The mixture was 
obtained by washing the vessel and the balls with 5 mL of acetic acid (5% in H2O) 
and 3 x 3-5 mL of DCM. The phases were separated and the aqueous phase washed 
3 times with 5 mL of DCM. The organic phase was dried with Na2SO4, concentrated 
in vacuo, and the product was purified by column chromatography (gradient: 
DCM:acetone 9:1 to 2:1). 
Procedure E2: 
Performed as procedure E1, but using Cs2CO3 (162.9 mg, 0.5 mmol, 5 equiv.) 
instead of NaOMe and MgSO4. 
 
Nickel complex 208a  
 
Prepared from 206 and benzyl bromide (210a) according to the general procedures 
D or E and obtained as a red solid after column chromatography. The product has 
S-configuration at the newly formed stereogenic center. 
Mp.: 104-106 °C 
Optical rotation:       = +2277 (c= 0.095, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.30-8.12 (m, 3H), 7.56 (dd, J= 8.2, 0.9 Hz, 1H), 
7.48 (td, J= 7.8, 1.6 Hz, 1H), 7.43-7.33 (m, 3H), 7.33-7.21 (m, 3H), 7.17 (dd, J= 6.5, 
2.9 Hz, 2H), 7.12-6.97 (m, 2H), 6.62 (dd, J= 7.7, 1.4 Hz, 1H), 6.45 (d, J= 2.6 Hz, 1H), 
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4.19 (d, J= 12.4 Hz, 1H), 3.87 (t, J= 5.1 Hz, 1H), 3.31-3.19 (m, 2H), 
3.19-3.09 (m, 2H), 2.85 (dd, J= 13.8, 5.2 Hz, 1H), 2.50-2.25 (m, 3H), 1.99-1.88 (m, 
1H), 1.81-1.68 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.5, 177.8, 166.9, 141.9, 135.6, 134.2, 132.3, 
132.1, 131.6, 131.3, 131.2, 130.9, 130.6, 130.4, 129.3, 129.0, 128.9, 128.8, 127.6, 
127.3, 125.8, 125.2, 124.5, 72.1, 71.0, 64.3, 58.2, 40.6, 30.9, 23.2.  
IR (CHCl3): = 3849, 2438, 2941, 2656, 2320, 2098, 1998, 1652, 1530, 1457, 1337, 
1242, 1166, 1059, 829, 751, 699. 
HRMS (ESI) m/z calculated for C34H30N3O3Cl2Ni [M+H]
+: 656.1012, found: 656.1027. 
 
Nickel complex 219a 
 
Obtained as a side-product in the formation of Ni(II)-complex 208a according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (600 MHz, CDCl3) = 8.15 (d, J= 9.3 Hz, 1H), 8.03 (d, J= 7.1 Hz, 2H), 
7.54-7.50 (m, 1H), 7.46-7.42 (m, 2H), 7.42-7.26 (m, 12H), 7.25-7.21 (m, 1H), 
7.08 (dd, J= 9.3, 2.4 Hz, 2H), 6.46 (d, J= 2.5 Hz, 1H), 4.13 (d, J= 12.9 Hz, 1H), 
3.40-3.36 (m, 1H), 3.32-3.23 (m, 3H), 3.09 (dd, J= 119.5, 15.6 Hz, 2H), 
2.79 (d, J=  16.2 Hz, 1H), 2.10-1.99 (m, 4H), 1.60-1.55 (m, 1H). 
13C NMR (151 MHz, CDCl3) = 181.0, 178.9, 168.3, 141.4, 136.8, 136.4, 135.3, 
133.5, 133.4, 132.0, 131.6, 131.6, 131.5, 130.8, 130.4, 129.7, 129.4, 128.9, 128.4, 
128.2, 127.3, 127.0, 126.7, 126.5, 125.4, 125.2, 81.9, 69.5, 63.3, 57.8, 47.0, 44.8, 
30.6, 23.0. 
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HRMS (ESI) m/z calculated for C41H35N3O3Cl2NaNi [M+Na]
+: 768.1301, found: 
768.1296. 
 
Nickel complex 208b  
 
Prepared from 206 and 4-(trifluoromethyl)benzyl bromide (210b) according to the 
general procedures D or E and obtained as a red solid after column chromatography. 
The product has S-configuration at the newly formed stereogenic center. 
Mp.: 95-98 °C 
Optical rotation:       = +2653 (c= 0.1, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.24-8.15 (m, 3H), 7.68 (d, J= 8.1 Hz, 2H), 7.62-
7.58 (m, 1H), 7.53 (td, J= 7.9, 1.5 Hz, 1H), 7.37 (td, J= 7.5, 1.0 Hz, 1H), 7.31-7.21 
(m, 4H), 7.07-7.00 (m, 2H), 6.84 (dd, J= 7.6, 1.4 Hz, 1H), 6.47 (d, J= 2.6 Hz, 1H), 
4.17 (d, J= 12.4 Hz, 1H), 3.92 (t, J= 4.9 Hz, 1H), 3.25 (dd, J= 10.6, 6.0 Hz, 1H), 3.18-
3.12 (m, 2H), 3.11-3.05 (m, 1H), 2.81 (dd, J= 13.7, 5.4 Hz, 1H), 2.42-2.30 (m, 1H), 
2.25-2.13 (m, 2H), 1.93-1.83 (m, 1H), 1.77-1.69 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.5, 177.3, 167.4, 142.0, 139.7, 134.2, 132.6, 
132.1, 131.9, 131.3, 131.1, 130.9, 130.7, 130.2, 129.9, 129.1, 129.0, 128.8, 127.4, 
125.8, 125.8, 125.6, 125.5, 125.3, 124.6, 71.5, 70.8, 64.4, 58.1, 39.8, 30.8, 22.9. 
19F NMR (376 MHz, CDCl3) = –62.5. 
IR (CHCl3): = 2927, 2868, 2241, 2166, 2114, 1980, 1638, 1588, 1530, 1460, 1396, 
1323, 1241, 1163, 1115, 1065, 1016, 971, 912, 866, 825, 729, 700. 
HRMS (ESI) m/z calculated for C35H29N3O3Cl2F3Ni [M+H]
+: 724.0886, found: 
724.0893. 
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Nickel complex 219b 
 
Obtained as a side-product in the formation of Ni(II)-complex 208b according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (600 MHz, CDCl3) = 8.17 (d, J= 9.3 Hz, 1H), 8.09 (d, J= 7.6 Hz, 2H), 
7.74 (d, J= 8.0 Hz, 2H), 7.63-7.57 (m, 3H), 7.48 (d, J= 7.9 Hz, 2H), 7.44-
7.39 (m, 2H), 7.38-7.32 (m, 4H), 7.28-7.22 (m, 1H), 7.20 (d, J= 7.6 Hz, 1H), 7.11 (dd, 
J= 9.3, 2.3 Hz, 1H), 6.47 (d, J= 2.3 Hz, 1H), 4.25 (d, J= 12.9 Hz, 1H), 
3.33 (d, J= 12.9 Hz, 1H), 3.29-3.07 (m, 5H), 2.77 (d, J= 16.6 Hz, 1H), 2.22-
2.12 (m, 1H), 2.04-1.95 (m, 2H), 1.94-1.87 (m, 1H), 1.66-1.58 (m, 1H). 
HRMS (ESI) m/z calculated for C43H33N3O3Cl2F6NaNi [M+Na]
+: 904.1049, 
found: 904.1046. 
 
Nickel complex 208c  
 
Prepared from 206 and 4-bromobenzyl bromide (210c) according to the general 
procedures D or E and obtained as a red solid in after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 93-95 °C 
Optical rotation:       = +2297 (c= 0.1, CHCl3). 
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1H NMR (400 MHz, CDCl3) = 8.19 (dd, J= 8.2, 5.4 Hz, 3H), 7.60-7.46 (m, 4H), 7.39-
7.32 (m, 1H), 7.26-7.20 (m, 2H), 7.07-6.97 (m, 4H), 6.82 (dd, J= 7.6, 1.4 Hz, 1H), 
6.45 (d, J= 2.6 Hz, 1H), 4.15 (d, J= 12.4 Hz, 1H), 3.86 (t, J= 4.8 Hz, 1H), 3.26 (dd, 
J= 10.0, 6.5 Hz, 1H), 3.17-3.00 (m, 3H), 2.70 (dd, J= 13.8, 5.3 Hz, 1H), 2.46-
2.23 (m, 3H), 2.03-1.90 (m, 1H), 1.84-1.73 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.6, 177.5, 167.1, 141.9, 134.5, 134.2, 132.4, 
132.3, 132.1, 132.0, 131.8, 131.2, 131.1, 130.9, 130.6, 129.2, 129.0, 128.8, 127.4, 
125.6, 125.2, 124.6, 122.0, 71.6, 70.9, 64.5, 58.4, 39.5, 30.9, 23.1. 
IR (CHCl3): = 3028, 2957, 2870, 2238, 1640, 1531, 1459, 1337, 1240, 1166, 1067, 
1010, 908, 822, 722. 
HRMS (ESI) m/z calculated for C34H29N3O3Cl2BrNi [M+H]
+: 734.0117, found: 
734.0109. 
 
Nickel complex 219c 
 
Obtained as a side-product in the formation of Ni(II)-complex 208c according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (400 MHz, CDCl3) = 8.14 (d, J= 9.3 Hz, 1H), 8.08 (d, J= 7.1 Hz, 2H), 7.60-
7.31 (m, 90H), 7.27-7.18 (m, 3H), 7.13 (d, J= 8.5 Hz, 3H), 7.08 (dd, J= 9.3, 2.5 Hz, 
1H), 6.44 (d, J= 2.4 Hz, 1H), 4.17 (d, J= 12.7 Hz, 1H), 3.36-3.24 (m, 3H), 3.10 (dd, 
J= 15.5, 11.4 Hz, 2H), 3.00-2.93 (m, 1H), 2.65 (d, J= 16.3 Hz, 1H), 2.25-1.93 (m, 3H), 
1.72-1.60 (m, 1H), 1.40 (d, J= 5.6 Hz, 1H). 
HRMS (ESI) m/z calculated for C41H33N3O3Br2Cl2NaNi [M+Na]
+: 923.9511, 
found: 923.9514. 
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Nickel complex 208d  
 
Prepared from 206 and 4-nitrobenzyl bromide (210d) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 87-89 °C 
Optical rotation:       = +1989 (c= 0.1, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.23-8.14 (m, 5H), 7.63-7.58 (m, 1H), 7.54 (td, J= 7.8, 
1.5 Hz, 1H), 7.39 (td, J= 7.5, 1.2 Hz, 1H), 7.29-7.20 (m, 4H), 7.06-6.99 (m, 2H), 
6.88 (dd, J= 7.6, 1.4 Hz, 1H), 6.47 (d, J= 2.5 Hz, 1H), 4.17 (d, J= 12.4 Hz, 1H), 
3.88 (dd, J= 6.1, 4.4 Hz, 1H), 3.28 (dd, J= 10.0, 6.3 Hz, 1H), 3.20-3.08 (m, 3H), 
2.94 (dd, J= 13.6, 6.1 Hz, 1H), 2.42-2.29 (m, 2H), 2.27-2.16 (m, 1H), 1.96-
1.85 (m, 1H), 1.82-1.70 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.5, 176.9, 167.5, 147.7, 143.2, 141.9, 134.1, 
132.7, 132.0, 132.0, 131.4, 131.33, 131.27, 131.1, 130.9, 130.8, 129.0, 128.9, 127.5, 
125.5, 125.4, 124.7, 123.8, 71.2, 70.7, 64.4, 58.2, 40.2, 30.8, 23.1. 
IR (CHCl3): = 3069, 2925, 2861, 2235, 2177, 2110, 2005, 1639, 1519, 1459, 1395, 
1340, 1241, 1166, 1112, 1053, 967, 909, 870, 826, 727, 700. 
HRMS (ESI) m/z calculated for C34H29N4O5Cl2Ni [M+H]
+: 701.0863, found: 701.0876. 
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Nickel complex 219d 
 
Obtained as a side-product in the formation of Ni(II)-complex 208c according to the 
general procedure E. The product was obtained as a red solid. 
HRMS (ESI) m/z calculated for C41H34N5O7Cl2Ni [M+H]
+: 836.1183, found: 836.1182. 
 
Nickel complex 208e 
 
Prepared from 206 and 4-bromomethyl benzyl bromide (210e) according to the 
general procedure D and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 142-144 °C 
Optical rotation:       = +2041 (c= 0.115, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.24-8.18 (m, 3H), 7.58-7.52 (m, 1H), 7.47 (td, J= 7.8, 
1.5 Hz, 1H), 7.39 (d, J= 8.1 Hz, 2H), 7.30 (td, J= 7.5, 1.1 Hz, 1H), 7.25 (t, J= 7.7 Hz, 
2H), 7.11 (d, J= 8.1 Hz, 1H), 7.06-6.99 (m, 2H), 6.59 (dd, J= 7.6, 1.4 Hz, 1H), 
6.43 (d, J= 2.6 Hz, 1H), 4.50 (s, 2H), 4.20 (d, J= 12.4 Hz, 1H), 3.89-3.83 (m, 1H), 
3.31-3.14 (m, 4H), 2.86 (dd, J= 13.8, 5.2 Hz, 1H), 2.61-2.47 (m, 1H), 2.46-
2.30 (m, 2H), 1.94-1.80 (m, 2H). 
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13C NMR (101 MHz, CDCl3) = 180.5, 177.6, 167.0, 141.9, 137.1, 135.9, 134.2, 
132.4, 131.9, 131.7, 131.3, 131.1, 131.0, 130.9, 130.4, 129.6, 129.3, 129.0, 128.8, 
127.4, 125.8, 125.3, 124.5, 72.0, 71.0, 64.2, 58.0, 40.4, 33.0, 31.1, 23.3. 
IR (CHCl3): = 2951, 2109, 2047, 1743, 1637, 1588, 1530, 1459, 1395, 1335, 1239, 
1165, 1119, 1052, 968, 918, 874, 823, 754, 699. 
HRMS (ESI) m/z calculated for C35H31N3O3Cl2BrNi [M+H]
+: 748.0274, found: 
748.0272. 
 
Nickel complex 208f  
 
Prepared from 206 and 3,5-difluorobenzyl bromide (210f) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 247 °C (decomp.) 
Optical rotation:       = +2317 (c= 0.11, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.24 (d, J= 9.4 Hz, 1H), 8.20 (d, J= 7.1 Hz, 2H), 7.62-
7.58 (m, 1H), 7.54 (td, J= 7.8, 1.5 Hz, 1H), 7.38 (td, J= 7.5, 1.2 Hz, 1H), 
7.27 (t, J= 7.7 Hz, 2H), 7.10-7.01 (m, 2H), 6.86-6.79 (m, 2H), 6.68-6.62 (m, 2H), 
6.47 (d, J= 2.6 Hz, 1H), 4.22 (d, J= 12.5 Hz, 1H), 3.85 (dd, J= 5.8, 4.6 Hz, 1H), 3.35-
3.23 (m, 2H), 3.21 (d, J= 12.5 Hz, 1H), 3.07 (dd, J= 13.8, 4.5 Hz, 1H), 2.83 (dd, 
J= 13.8, 5.9 Hz, 1H), 2.72-2.60 (m, 1H), 2.51-2.36 (m, 2H), 2.03-1.87 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 180.5, 177.2, 167.4, 164.4 (d, J= 12.7 Hz), 
161.9 (d, J= 12.6 Hz), 142.0, 139.3 (t, J= 9.1 Hz), 134.1, 132.6, 132.0, 131.9, 131.3, 
131.2, 130.9, 130.7, 129.1, 129.0, 128.9, 127.4, 125.6, 125.4, 124.7, 113.3 (dd, 
J= 18.1, 6.6 Hz), 103.1 (t, J= 25.1 Hz), 71.3, 71.0, 64.3, 58.2, 40.2, 30.9, 23.3. 
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19F NMR (376 MHz, CDCl3) = –109.0 (t, J= 109.0 Hz). 
IR (CHCl3): = 3078, 2961, 2869, 2695, 2316, 2069, 1648, 1592, 1533, 1456, 1339, 
1243, 1165, 1114, 1080, 1010, 968, 875, 833, 751, 694. 
HRMS (ESI) m/z calculated for C34H28N3O3Cl2F2Ni [M+H]
+: 692.0824, found: 
692.0812. 
 
Nickel complex 219f 
 
Obtained as a side-product in the formation of Ni(II)-complex 208f according to the 
general procedure E. The product was obtained as a red solid. 
 
1H NMR (600 MHz, CDCl3) = 8.19 (d, J= 9.3 Hz, 1H), 8.02 (d, J= 7.1 Hz, 2H), 
7.58 (td, J= 8.1, 1.5 Hz, 1H), 7.46 (dd, J= 8.2, 0.9 Hz, 1H), 7.40-7.33 (m, 3H), 7.25-
7.21 (m, 1H), 7.11 (dd, J= 9.3, 2.5 Hz, 1H), 7.07 (dd, J= 7.7, 1.4 Hz, 1H), 
6.97 (d, J= 5.9 Hz, 2H), 6.89 (tt, J= 8.8, 2.2 Hz, 1H), 6.82 (d, J= 6.3 Hz, 2H), 6.73 (tt, 
J= 8.8, 2.2 Hz, 1H), 6.47 (d, J= 2.5 Hz, 1H), 4.41 (d, J= 12.9 Hz, 1H), 3.45-
3.38 (m, 2H), 3.31 (dd, J= 9.9, 6.7 Hz, 1H), 3.19 (d, J= 15.1 Hz, 1H), 
3.10 (d, J= 16.4 Hz, 1H), 2.93 (d, J= 15.1 Hz, 1H), 2.71 (d, J= 16.4 Hz, 1H), 2.39-
2.18 (m, 3H), 2.09-2.02 (m, 1H), 1.83-1.74 (m, 1H). 
13C NMR (151 MHz, CDCl3) = 181.1, 178.3, 169.2, 164.0, 163.7, 163.6, 162.4, 
162.3, 162.1, 162.0, 141.6, 140.1, 139.8, 135.1, 133.4, 132.9, 132.6, 132.1, 131.5, 
131.1, 129.2, 129.1, 129.1, 126.8, 126.4, 125.7, 125.5, 113.4, 113.4, 113.2, 112.6, 
112.4, 103.2, 103.1, 102.9, 102.5, 102.3, 102.2, 80.6, 69.3, 63.6, 57.8, 46.4, 44.3, 
30.7, 22.9. 
19F NMR (564 MHz, CDCl3) = 108.59 (t, J= 7.9 Hz), 110.08 (t, J= 8.2 Hz). 
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HRMS (ESI) m/z calculated for C41H33N3O3Cl2F4Ni [M+H]
+: 818.1105, found: 
818.1105. 
 
Nickel complex 208g  
 
Prepared from 206 and 3,5-dimethoxybenzyl bromide (210g) according to the 
general procedures D or E and obtained as a red solid after column chromatography. 
The product has S-configuration at the newly formed stereogenic center. 
Mp.: 130-132 °C 
Optical rotation:       = +1935 (c= 0.105, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.21 (dd, J= 8.2, 4.4 Hz, 3H), 7.54-7.50 (m, 1H), 
7.44 (td, J= 7.9, 1.5 Hz, 1H), 7.24 (t, J= 7.7 Hz, 3H), 7.05-6.96 (m, 2H), 6.51 (dd, 
J= 7.6, 1.4 Hz, 1H), 6.45 (t, J= 2.2 Hz, 1H), 6.42 (d, J= 2.6 Hz, 1H), 
6.27 (d, J= 2.2 Hz, 2H), 4.18 (d, J= 12.4 Hz, 1H), 3.82 (t, J= 5.3 Hz, 1H), 3.60 (s, 6H), 
3.32-3.19 (m, 2H), 3.17 (d, J= 12.4 Hz, 1H), 2.85-2.78 (m, 1H), 2.74-2.63 (m, 1H), 
2.49-2.33 (m, 2H), 2.01-1.93 (m, 1H), 1.87-1.79 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.4, 177.7, 166.6, 161.0, 141.8, 137.6, 134.3, 
132.3, 131.9, 131.6, 131.3, 131.1, 130.9, 130.3, 129.5, 129.0, 128.7, 127.1, 125.7, 
125.1, 124.5, 108.0, 100.3, 72.0, 71.1, 64.3, 58.3, 55.2, 41.2, 30.9, 23.3. 
IR (CHCl3): = 3460, 2930, 2282, 2106, 2060, 194, 1741, 1674, 1643, 1591, 1529, 
1459, 1347, 1235, 1207, 1154, 1062, 932, 828, 754, 698, 532. 
HRMS (ESI) m/z calculated for C36H33N3O5Cl2NiNa [M+Na]
+: 738.1043, found: 
738.1041. 
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Nickel complex 208h 
 
Prepared from 206 and 2,3,4,5,6-pentafluorobenzyl bromide (210h) according to the 
general procedures D or E and obtained as a red solid after column chromatography. 
The product has S-configuration at the newly formed stereogenic center. 
Mp.: 99-101 °C 
Optical rotation:       = +2352 (c= 0.1, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.22 (d, J= 7.4 Hz, 2H), 8.12 (d, J= 9.3 Hz, 1H), 7.62-
7.53 (m, 2H), 7.41 (t, J= 6.7 Hz, 1H), 7.32 (t, J= 7.6 Hz, 2H), 7.11 (t, J= 7.4 Hz, 1H), 
7.06 (dd, J= 9.3, 2.5 Hz, 1H), 6.91 (d, J= 7.4 Hz, 1H), 6.50 (d, J= 2.5 Hz, 1H), 
4.33 (d, J= 12.5 Hz, 1H), 3.84-3.75 (m, 1H), 3.56 (ddd, J= 16.9, 10.6, 5.6 Hz, 2H), 
3.64-3.49 (m, 2H), 3.31 (d, J= 12.4 Hz, 1H), 2.97 (dd, J= 12.9, 4.9 Hz, 1H), 2.71-
2.52 (m, 2H), 2.31-2.21 (m, 1H), 2.14-2.03 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.6, 176.0, 167.2, 141.7, 134.1, 132.6, 132.1, 
131.5, 131.3, 131.2, 130.9, 130.60, 129.1, 129.0, 128.8, 127.6, 125.9, 125.6, 125.1, 
70.9, 69.0, 64.0, 58.2, 30.9, 28.7, 23.8. 
19F NMR (376 MHz, CDCl3) = –142.3 (dd, J= 22.5, 7.9 Hz. 2F), –154.9 (t, 
J= 20.8 Hz, 1F), –161.8 (td, J= 22.2, 8.0 Hz, 2F). 
IR (CHCl3): = 3787, 3328, 3070, 2971, 2169, 2107, 1976, 1644, 1595, 1507, 1456, 
1396, 1335, 1239, 1168, 1122, 1042, 940, 824, 729. 
HRMS (ESI) m/z calculated for C34H25N3O3Cl2F5Ni [M+H]
+: 746.0541, found: 
746.0538. 
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Nickel complex 219h 
 
Obtained as a side-product in the formation of Ni(II)-complex 208h according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (600 MHz, CDCl3) = 8.31-8.28 (m, 2H), 8.11 (d, J= 9.3 Hz, 1H), 7.60 (td, 
J= 8.0, 1.5 Hz, 1H), 7.50 (t, J= 7.2 Hz, 1H), 7.47-7.40 (m, 2H), 7.29 (dd, J= 7.7, 
1.4 Hz, 1H), 7.27-7.23 (m, 1H), 7.08 (dd, J= 9.3, 2.4 Hz, 1H), 6.52 (d, J= 2.4 Hz, 1H), 
4.36 (d, J= 12.6 Hz, 1H), 3.84 (d, J= 14.4 Hz, 1H), 3.64-3.58 (m, 1H), 3.45-
3.34 (m, 3H), 2.94-2.84 (m, 1H), 2.77-2.69 (m, 2H), 2.55-2.45 (m, 1H), 2.42-
2.34 (m, 1H), 2.05 (dt, J= 10.7, 6.0 Hz, 2H). 
HRMS (ESI) m/z calculated for C41H26N3O3Cl2F10NaNi [M+Na]
+: 923.9511, 
found: 923.9514. 
 
Nickel complex 208i  
 
Prepared from 206 and 2-bromobenzyl bromide (210i) according to the general D or 
E and obtained as a red solid after column chromatography. The product has 
S-configuration at the newly formed stereogenic center. 
Mp.: 223-235 °C 
Optical rotation:       = +2481 (c= 0.1, CHCl3). 
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1H NMR (600 MHz, CDCl3) = 8.28-8.21 (m, 3H), 7.59 (d, J= 7.7 Hz, 1H), 
7.53 (d, J= 8.1 Hz, 1H), 7.47-7.42 (m, 1H), 7.32-7.22 (m, 4H), 7.22-7.18 (m, 2H), 
7.07-7.02 (m, 1H), 7.00 (d, J= 9.3 Hz, 1H), 6.50 (d, J= 7.4 Hz, 1H), 6.40 (s, 1H), 
4.23 (d, J= 12.5 Hz, 1H), 3.97-3.91 (m, 1H), 3.52-3.45 (m, 1H), 3.42-3.31 (m, 2H), 
3.26-3.21 (m, 1H), 3.19 (d, J= 11.9 Hz, 1H), 2.90-2.81 (m, 1H), 2.59-2.45 (m, 2H), 
2.04-1.97 (m, 1H), 1.93 (s, 1H). 
13C NMR (151 MHz, CDCl3) = 180.3, 177.1, 167.0, 141.8, 135.6, 134.2, 133.2, 
132.9, 132.3, 131.7, 131.5, 131.4, 131.1, 131.06, 130.2, 129.22, 129.16, 129.0, 
128.8, 128.0, 127.4, 126.1, 126.0, 125.1, 124.5, 71.8, 71.2, 64.2, 58.2, 41.2, 31.1, 
23.6 
IR (CHCl3): = 2959, 1655, 1595, 1459, 1396, 1338, 1243, 1082, 1033, 974, 871, 
817, 746, 705.  
HRMS (ESI) m/z calculated for C34H28N3O3BrCl2INiNa [M+Na]
+: 755.9937, 
found: 755.9937. 
 
Nickel complex 219i 
 
Obtained as a side-product in the formation of Ni(II)-complex 208i according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (600 MHz, CDCl3) = 8.30 (d, J= 7.1 Hz, 2H), 8.22 (d, J= 9.3 Hz, 1H), 
7.74 (ddd, J= 18.0, 7.9, 1.2 Hz, 2H), 7.54-7.49 (m, 2H), 7.48-7.41 (m, 2H), 7.40-
7.35 (m, 6H), 7.35-7.29 (m, 1H), 7.29-7.22 (m, 1H), 7.10-7.02 (m, 2H), 
6.37 (d, J= 2.5 Hz, 1H), 4.37 (d, J= 12.8 Hz, 1H), 3.49 (dd, J= 56.2, 13.9 Hz, 2H), 
3.40-3.30 (m, 3H), 3.26 (d, J= 15.0 Hz, 1H), 2.71 (d, J= 17.5 Hz, 1H), 2.36-2.24 (m, 
2H), 2.22-2.10 (m, 2H), 1.78-1.67 (m, 1H). 
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13C NMR (151 MHz, CDCl3) = 180.7, 177.7, 169.1, 141.4, 136.1, 135.8, 134.9, 
134.0, 133.4, 133.1, 132.8, 132.6, 132.0, 131.9, 131.8, 131.3, 130.4, 129.1, 129.1, 
129.0, 128.6, 127.9, 127.2, 127.1, 126.9, 126.5, 125.3, 124.9, 81.7, 70.4, 64.3, 58.5, 
47.2, 45.1, 30.9, 23.2. 
HRMS (ESI) m/z calculated for C41H32N3O3Br2Cl2NaNi [M+Na]
+: 923.9511, 
found: 923.9514. 
 
Nickel complex 208j  
 
Prepared from 206 and 2-iodobenzyl bromide (210j) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 150-152 °C 
Optical rotation:       = +2099 (c= 0.105, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.26-8.20 (m, 3H), 7.84 (d, J= 7.9 Hz, 1H), 7.52-
7.48 (m, 1H), 7.41 (td, J= 7.9, 1.5 Hz, 1H), 7.28-7.20 (m, 4H), 7.12 (td, J= 7.6, 
1.0 Hz, 1H), 7.06-6.95 (m, 3H), 6.37 (d, J= 2.6 Hz, 1H), 6.32 (dd, J= 7.6, 1.2 Hz, 1H), 
4.23 (d, J= 12.4 Hz, 1H), 3.92 (dd, J= 7.9, 3.9 Hz, 1H), 3.71-3.61 (m, 1H), 3.41-
3.30 (m, 2H), 3.30-3.22 (m, 1H), 3.17 (d, J= 12.4 Hz, 1H), 3.10-2.95 (m, 1H), 2.67-
2.45 (m, 2H), 2.05-1.92 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 180.2, 177.0, 166.9, 141.8, 139.9, 139.1, 134.3, 
132.3, 132.0, 131.6, 131.5, 131.1, 130.07, 129.2, 129.1, 129.0, 128.8, 128.7, 127.3, 
126.1, 125.1, 124.5, 102.3, 72.0, 71.3, 64.2, 58.3, 45.7, 31.1, 23.7. 
IR (CHCl3): = 3433, 2960, 2323, 2058, 1742, 1645, 1529, 1460, 1339, 1239, 1165, 
1120, 1054, 1012, 874, 824, 750, 701, 656, 598, 549. 
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HRMS (ESI) m/z calculated for C34H28N3O3Cl2INiNa [M+Na]
+: 803.9798, found: 
803.9799. 
 
Nickel complex 219j 
 
Obtained as a side-product in the formation of Ni(II)-complex 208j according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (400 MHz, CDCl3) = 8.27 (d, J= 7.1 Hz, 2H), 8.22 (d, J= 9.3 Hz, 1H), 
8.00 (dd, J= 7.9, 1.2 Hz, 1H), 7.80 (dd, J= 7.8, 1.5 Hz, 1H), 7.75 (dd, J= 7.9, 1.1 Hz, 
1H), 7.54-7.48 (m, 1H), 7.47-7.32 (m, 7H), 7.28-7.18 (m, 2H), 7.07-7.01 (m, 2H), 
6.89 (td, J= 7.7, 1.5 Hz, 1H), 6.33 (d, J= 2.5 Hz, 1H), 4.34 (d, J= 12.7 Hz, 1H), 3.52-
3.24 (m, 6H), 2.83 (d, J= 16.9 Hz, 1H), 2.42-2.24 (m, 2H), 2.20-2.10 (m, 1H), 1.86-
1.74 (m, 1H). 
HRMS (ESI) m/z calculated for C41H34N3O3Cl2I2Ni [M+H]
+: 997.9415, found: 
997.9413. 
 
Nickel complex 208k  
 
Prepared from 206 and [2-(bromomethyl)phenyl]diphenyl-phophine oxide according 
to the general procedures D or E and obtained as a red solid after column 
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chromatography. The product has S-configuration at the newly formed stereogenic 
center. 
Mp.: 160-162 °C 
Optical rotation:       = +1859 (c= 0.145, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.30-8.20 (m, 3H), 7.54-7.34 (m, 13H), 7.33-7.19 (m, 
4H), 7.11-7.00 (m, 3H), 6.96 (dd, J= 9.3 Hz, 2.6 Hz, 1H), 6.88 (d, J= 7.5 Hz, 1H), 
6.39 (d, J= 2.6 Hz, 1H), 4.23 (d, J= 12.3 Hz, 1H), 4.06-3.94 (m, 2H), 3.48 (dd, 
J= 13.7 Hz, 5.5 Hz, 1H), 3.32 (dd, J= 10.3 Hz, 6.6 Hz, 1H), 3.21-3.15 (m, 1H), 
3.12 (d, J= 12.4 Hz, 1H), 3.00-2.85 (m, 1H), 2.48-2.32 (m, 2H), 2.00-1.89 (m, 1H), 
1.89-1.78 (m, 1H). 
13C NMR (151 MHz, CDCl3) = 180.5, 177.9, 167.5, 141.9, 141.8 (d, J= 7.1 Hz), 
134.3, 133.9 (d, J= 13.2 Hz), 133.3 (d, J= 39.4 Hz), 132.56 (d, J= 41.8 Hz), 
132.55 (d, J= 9.8 Hz), 132.3, 132.20 (d, J= 1.6 Hz), 132.15, 132.1, 132.0, 131.9, 
131.85 (d, J= 2.2 Hz), 131.8, 131.7, 131.6, 131.3, 131.2, 131.1, 131.1, 130.2, 129.9, 
129.0, 128.7, 128.64, 128.62, 128.56, 128.54, 127.2, 126.6, 126.5, 125.1, 124.4, 
72.6, 71.2, 64.1, 58.3, 39.1, 31.0, 23.9. 
31P NMR (243 MHz, CDCl3) = 31.6. 
IR (CHCl3): = 3442, 3058, 2959, 2658, 2323, 2092 1644, 1454, 1331, 1246, 1176, 
1113, 823, 700. 
HRMS (ESI) m/z calculated for C46H39N3O4Br2Cl2NiP [M+H]
+: 856.1403, found: 
856.1402. 
 
Nickel complex 208l  
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Prepared from 206 and 3-fluorobenzyl bromide (210l) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 235-237 °C 
Optical rotation:       = +2674 (c= 0.095, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.24-8.17 (m, 3H), 7.60-7.56 (m, 1H), 7.51 (td, J= 7.8, 
1.5 Hz, 1H), 7.39-7.31 (m, 2H), 7.28-7.24 (m, 2H), 7.12-7.00 (m, 3H), 6.93-
6.85 (m, 2H), 6.72 (dd, J= 7.6, 1.3 Hz, 1H), 6.46 (d, J= 2.5 Hz, 1H), 
4.21 (d, J= 12.4 Hz, 1H), 3.87 (t, J= 5.1 Hz, 1H), 3.29 (dd, J= 10.1, 6.9 Hz, 1H), 3.23-
3.13 (m, 3H), 2.84 (dd, J= 13.8, 5.5 Hz, 1H), 2.59-2.48 (m, 1H), 2.46-2.29 (m, 2H), 
2.01-1.91 (m, 1H), 1.88-1.78 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.5, 177.5, 167.1, 141.9, 138.0 (d, J= 7.1 Hz), 
134.2, 132.5, 132.0, 131.8, 131.3, 131.2, 130.9, 130.6, 130.3, 130.2, 129.2, 129.0, 
128.8, 127.3, 126.2, 125.7, 125.3, 124.6, 117.4 (d, J= 21.1 Hz), 
114.5 (d, J= 20.7 Hz), 71.7, 71.0, 64.3, 58.2, 40.2, 30.9, 23.2. 
19F NMR (376 MHz, CDCl3) = –112.3 (td, J= 9.0, 6.2 Hz). 
IR (CHCl3): = 2964, 2131, 1660, 1588, 1458, 1397, 1340, 1245, 1166, 1140, 1081, 
879, 813, 754, 704.  
HRMS (ESI) m/z calculated for C34H29N3O3Cl2FNi [M+H]
+: 674.0918, found: 
674.0916. 
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Nickel complex 219l 
 
Obtained as a side-product in the formation of Ni(II)-complex 208l according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (600 MHz, CDCl3) = 8.16 (d, J= 9.3 Hz, 1H), 8.04 (d, J= 7.1 Hz, 2H), 
7.55 (td, J= 8.2, 1.5 Hz, 1H), 7.44-7.37 (m, 2H), 7.35 (t, J= 7.6 Hz, 3H), 7.32-
7.27 (m, 1H), 7.24-7.19 (m, 2H), 7.15-7.05 (m, 5H), 7.03-6.95 (m, 2H), 
6.47 (d, J= 2.5 Hz, 1H), 4.30 (d, J= 12.9 Hz, 1H), 3.41-3.33 (m, 2H), 3.28 (dd, 
J= 9.5, 6.5 Hz, 1H), 3.22 (d, J= 15.0 Hz, 1H), 3.16 (d, J= 16.4 Hz, 1H), 
2.99 (d, J= 14.9 Hz, 1H), 2.72 (d, J= 16.4 Hz, 1H), 2.23-2.02 (m, 4H), 1.74-
1.66 (m, 1H). 
19F NMR (564 MHz, CDCl3) = –111.95 (dd, J= 15.4, 9.0 Hz), –113.41 (dd, J= 15.9, 
9.0 Hz). 
HRMS (ESI) m/z calculated for C41H34N3O3Cl2F2Ni [M+H]
+: 782.1293, found: 
782.1293. 
 
Nickel complex 208m  
 
Prepared from 206 and 3-methoxybenzyl bromide (210m) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
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Mp.: 130-132 °C 
Optical rotation:       = +2487 (c= 0.095, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.23-8.18 (m, 3H), 7.56-7.51 (m, 1H), 7.45 (td, J= 7.9, 
1.5 Hz, 1H), 7.28-7.21 (m, 4H), 7.06-6.96 (m, 2H), 6.90 (dd, J= 8.2, 2.0 Hz, 1H), 
6.72 (d, J= 7.5 Hz, 1H), 6.65 (s, 1H), 6.53 (dd, J= 7.6, 1.4 Hz, 1H), 6.42 (d, J= 2.6 Hz, 
1H), 4.18 (d, J= 12.4 Hz, 1H), 3.84 (t, J= 5.2 Hz, 1H), 3.64 (s, 3H), 3.31-3.12 (m, 4H), 
2.88-2.81 (m, 1H), 2.63-2.51 (m, 1H), 2.46-2.31 (m, 2H), 2.01-1.91 (m, 1H), 1.85-
1.75 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.5, 177.7, 166.7, 160.0, 141.8, 136.9, 134.2, 
132.3, 132.0, 131.6, 131.3, 131.1, 130.9, 130.3, 129.8, 129.4, 129.0, 128.7, 127.2, 
125.8, 125.2, 124.5, 122.8, 115.1, 113.9, 72.1, 71.1, 64.3, 58.3, 55.0, 40.9, 30.9, 
23.3. 
IR (CHCl3): = 3436, 2953, 2322, 2140, 1741, 1641, 1530, 1458, 1394, 1338, 1242, 
1163, 1048, 875, 826, 754, 697, 568, 526.  
HRMS (ESI) m/z calculated for C35H32N3O4Cl2Ni [M+H]
+: 686.1118, found: 686.1118. 
 
Nickel complex 208n  
 
Prepared from 206 and 3-nitrobenzyl bromide (210n) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 88-90 °C 
Optical rotation:       = +2280 (c= 0.11, CHCl3). 
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1H NMR (400 MHz, CDCl3) = 8.23-8.13 (m, 4H), 7.72 (t, J= 1.8 Hz, 1H), 7.63-
7.54 (m, 2H), 7.49 (t, J= 7.9 Hz, 1H), 7.41-7.36 (m, 2H), 7.29-7.22 (m, 2H), 7.09-
7.00 (m, 2H), 6.83 (dd, J= 7.6, 1.4 Hz, 1H), 6.48 (d, J= 2.6 Hz, 1H), 
4.23 (d, J= 12.4 Hz, 1H), 3.82 (dd, J= 6.7, 4.8 Hz, 1H), 3.36-3.07 (m, 5H), 2.84-
2.69 (m, 1H), 2.50-2.30 (m, 2H), 2.01-1.88 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 180.5, 176.9, 167.3, 148.5, 141.9, 137.6, 136.2, 
134.1, 132.7, 132.2, 131.9, 131.4, 131.1, 130.9, 130.8, 129.5, 129.0, 127.5, 125.6, 
125.4, 124.8, 124.7, 122.5, 71.4, 70.7, 64.2, 58.1, 40.8, 30.8, 23.5. 
IR (CHCl3): = 3837, 3459, 3073, 2932, 2643, 2323, 2072, 1986, 1738, 1647, 157, 
1459, 1345, 1238, 1167, 1079, 882, 821, 750, 697. 
HRMS (ESI) m/z calculated for C34H29N4O5Cl2Ni [M+H]
+: 701.0863, found: 701.0862. 
 
Nickel complex 219n 
 
Obtained as a side-product in the formation of Ni(II)-complex 208n according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (400 MHz, CDCl3) = 8.30-8.26 (m, 3H), 8.22 (s, 2H), 8.14-8.04 (m, 2H), 
7.98-7.92 (m, 3H), 7.67-7.54 (m, 4H), 7.50-7.39 (m, 2H), 7.33-7.27 (m, 1H), 7.25-
7.21 (m, 2H), 7.17-7.11 (m, 1H), 6.47 (d, J= 2.4 Hz, 1H), 4.41 (d, J= 13.0 Hz, 1H), 
3.55 (d, J= 13.0 Hz, 1H), 3.41-3.21 (m, 4H), 3.12 (d, J= 14.8 Hz, 1H), 
2.80 (d, J= 16.3 Hz, 1H), 2.23-2.10 (m, 2H), 2.09-1.96 (m, 2H), 1.77-1.62 (m, 1H). 
HRMS (ESI) m/z calculated for C41H33N5O7Cl2NaNi [M+Na]
+: 858.1003, found: 
858.1005. 
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Nickel complex 208o  
 
Prepared from 206 and allyl bromide (210o) according to the general procedures D 
or E and obtained as a red solid after column chromatography. The product has S-
configuration at the newly formed stereogenic center. 
Mp.: 275 °C (decomp.) 
Optical rotation:       = +3143 (c= 0.11, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.22 (d, J= 7.1 Hz, 2H), 8.14 (d, J= 9.3 Hz, 1H), 7.58-
7.52 (m, 1H), 7.49 (td, J= 7.8, 1.5 Hz, 1H), 7.38 (td, J= 7.5, 1.2 Hz, 1H), 
7.30 (t, J= 7.7 Hz, 2H), 7.09 (t, J= 7.5 Hz, 1H), 7.02 (dd, J= 9.3, 2.6 Hz, 1H), 
6.91 (dd, J= 7.6, 1.4 Hz, 1H), 6.51-6.38 (m, 2H), 5.43 (d, J= 10.1 Hz, 1H), 5.20 (dd, 
J= 17.0, 1.2 Hz, 1H), 4.33 (d, J= 12.5 Hz, 1H), 3.66 (dd, J= 6.5, 3.8 Hz, 1H), 3.62-
3.51 (m, 2H), 3.41 (dd, J= 10.9, 5.9 Hz, 1H), 3.30 (d, J= 12.5 Hz, 1H), 2.74-
2.65 (m, 1H), 2.61-2.45 (m, 2H), 2.37-2.28 (m, 1H), 2.20-2.11 (m, 1H), 2.09-
1.99 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.6, 178.0, 166.5, 141.5, 134.2, 132.2, 132.1, 
131.9, 131.8, 131.2, 130.7, 130.5, 129.2, 129.0, 128.9, 127.3, 126.0, 125.4, 124.8, 
120.1, 70.9, 70.8, 64.1, 57.9, 38.9, 30.9, 23.4. 
IR (CHCl3): = 3060, 3017, 2926, 2864, 2059, 1677, 1634, 1533, 1460, 1395, 1353, 
1331, 1274, 1241, 1166, 1123, 1082, 1052, 1002, 940, 857, 826, 762, 701, 657.  
HRMS (ESI) m/z calculated for C30H28N3O3Cl2Ni [M+H]
+: 606.0856, found: 606.0864. 
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Nickel complex 208p  
 
Prepared from 206 and cinnamyl bromide (210p) according to the general D or E and 
obtained as a red solid after column chromatography. The product has S-
configuration at the newly formed stereogenic center. 
Mp.: 124-126 °C 
Optical rotation:       = +2907 (c= 0.095, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.21 (d, J= 7.1 Hz, 2H), 8.15 (d, J= 9.3 Hz, 1H), 7.58-
7.53 (m, 1H), 7.50 (td, J= 7.8, 1.6 Hz, 1H), 7.46-7.42 (m, 2H), 7.36 (td, J= 7.5, 
1.2 Hz, 1H), 7.34-7.20 (m, 5H), 7.09-7.00 (m, 2H), 6.95 (dd, J= 7.6, 1.4 Hz, 1H), 
6.76-6.67 (m, 1H), 6.54 (d, J= 15.8 Hz, 1H), 6.46 (d, J= 2.5 Hz, 1H), 
4.25 (d, J= 12.4 Hz, 1H), 3.76 (dd, J= 5.8, 4.0 Hz, 1H), 3.46-3.39 (m, 1H), 3.27 (dd, 
J= 10.2, 6.9 Hz, 1H), 3.21 (d, J= 12.4 Hz, 1H), 2.93-2.80 (m, 1H), 2.73-2.63 (m, 1H), 
2.47-2.36 (m, 1H), 2.27-2.10 (m, 2H), 1.99-1.88 (m, 1H), 1.61-1.50 (m, 1H). 
13C NMR (101 MHz, CDCl3) = 180.6, 178.1, 166.8, 141.7, 136.9, 134.9, 134.2, 
132.2, 132.1, 131.8, 131.2, 131.2 130.8, 130.0, 129.4, 129.0, 128.8, 128.6, 127.9, 
127.3, 126.5, 126.0, 125.3, 124.7, 123.2, 71.1, 71.0, 64.2, 58.3, 38.1, 30.8, 23.3. 
IR (CHCl3): = 3494, 2958, 2320, 2068, 1988, 1742, 1643, 1529, 1456, 1337, 1237, 
1166, 1057, 965, 878, 824, 749, 693, 589, 535. 
HRMS (ESI) m/z calculated for C36H32N3O3Cl2Ni [M+H]
+: 682.1169, found: 682.1172. 
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Nickel complex 219p 
 
Obtained as a side-product in the formation of Ni(II)-complex 208p according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (600 MHz, CDCl3) = 8.07 (d, J= 7.1 Hz, 2H), 7.97 (d, J= 9.2 Hz, 1H), 7.59-
7.52 (m, 4H), 7.46-7.41 (m, 3H), 7.35 (t, J= 7.6 Hz, 2H), 7.32-7.24 (m, 5H), 7.18 (dt, 
J= 14.0, 7.4 Hz, 2H), 7.07 (dd, J= 9.2, 2.5 Hz, 1H), 6.88-6.80 (m, 1H), 
6.72 (d, J= 15.8 Hz, 1H), 6.60 (d, J= 2.5 Hz, 1H), 6.46-6.43 (m, 2H), 
4.25 (d, J= 12.5 Hz, 1H), 3.60-3.55 (m, 1H), 3.27-3.20 (m, 2H), 2.75 (dd, J= 14.7, 
8.8 Hz, 1H), 2.66-2.56 (m, 1H), 2.52-2.39 (m, 3H), 2.14-2.06 (m, 1H), 2.06-
1.99 (m, 1H), 1.91 (td, J= 10.9, 6.1 Hz, 1H), 1.49-1.41 (m, 1H). 
13C NMR (151 MHz, CDCl3) = 181.2, 179.7, 168.7, 141.0, 137.6, 137.0, 135.2, 
135.1, 134.2, 133.6, 133.5, 131.9, 131.7, 131.4, 131.3, 130.5, 129.3, 129.0, 128.9, 
128.7, 128.5, 127.9, 127.4, 127.3, 126.69, 126.5, 126.4, 125.6, 125.5, 124.0, 123.0, 
83.7, 70.3, 64.1, 58.6, 42.6, 41.6, 30.8, 22.9. 
HRMS (ESI) m/z calculated for C45H40N3O3Cl2Ni [M+H]
+: 798.1795, found: 798.1793. 
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Nickel complex 208q  
 
Prepared from 206 and propargyl bromide (210q) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 275 °C (decomp.). 
Optical rotation:       = +3339 (c= 0.105, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.22 (d, J= 7.3 Hz, 2H), 8.18 (d, J= 9.3 Hz, 1H), 7.58-
7.53 (m, 1H), 7.53-7.47 (m, 1H), 7.39 (t, J= 7.5 Hz, 1H), 7.31 (t, J= 7.7 Hz, 2H), 
7.11 (t, J= 7.5 Hz, 1H), 7.05 (dd, J= 9.3, 2.6 Hz, 1H), 6.97 (dd, J= 7.6, 1.2 Hz, 1H), 
6.44 (d, J= 2.5 Hz, 1H), 4.34 (d, J= 12.5 Hz, 1H), 3.74-3.56 (m, 3H), 3.41 (dd, 
J= 10.7, 6.2 Hz, 1H), 3.35 (d, J= 12.5 Hz, 1H), 2.75-2.65 (m, 2H), 2.60-2.50 (m, 2H), 
2.24 (ddd, J= 17.2, 6.6, 2.7 Hz, 1H), 2.13-2.01 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 180.6, 177.8, 167.6, 141.8, 134.1, 132.4, 132.1, 
131.9, 131.3, 131.0, 130.8, 130.5, 129.1, 129.0, 128.9, 127.5, 125.9, 125.4, 124.9, 
78.7, 74.0, 71.0, 67.9, 64.2, 58.0, 30.9, 23.9, 23.2. 
IR (CHCl3): = 3456, 2972, 2924, 2872, 2319, 1743, 1633, 1591, 1531, 1461, 1338, 
1240, 1165, 1058, 970, 880, 823, 755, 698, 590, 545. 
HRMS (ESI) m/z calculated for C30H26N3O3Cl2Ni [M+H]
+: 604.0699, found: 604.0724. 
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Nickel complex 208r  
 
Prepared from 206 and 1-bromo-2-pentyne (210r) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 209-211 °C 
Optical rotation:       = +3053 (c= 0.105, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.22 (d, J= 7.1 Hz, 2H), 8.18 (d, J= 9.3 Hz, 1H), 7.57-
7.52 (m, 1H), 7.52-7.46 (m, 1H), 7.38 (td, J= 7.5, 1.3 Hz, 1H), 7.31 (t, J= 7.7 Hz, 2H), 
7.11 (t, J= 7.5 Hz, 1H), 7.04 (dd, J= 9.3, 2.6 Hz, 1H), 6.99 (dd, J= 7.6, 1.4 Hz, 1H), 
6.45 (d, J= 2.5 Hz, 1H), 4.35 (d, J= 12.5 Hz, 1H), 3.80-3.67 (m, 1H), 3.66-
3.58 (m, 2H), 3.43 (dd, J= 10.9, 6.0 Hz, 1H), 3.35 (d, J= 12.5 Hz, 1H), 2.77-
2.63 (m, 2H), 2.55 (dt, J= 13.2, 9.8 Hz, 1H), 2.39-2.24 (m, 3H), 2.18-2.01 (m, 2H), 
1.15 (t, J= 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) = 180.6, 178.2, 167.3, 141.6, 134.1, 132.3, 132.2, 
131.8, 131.3, 131.0, 130.8, 130.4, 129.3, 129.0, 128.9, 127.4, 126.0, 125.3, 124.9, 
87.0, 73.7, 70.8, 68.6, 64.1, 58.0, 31.0, 24.5, 23.4, 14.0, 13.1. 
IR (CHCl3):= 3781, 3663, 3473, 3064, 2978, 2931, 2163, 2057, 1981, 1631, 1533, 
1463, 1395, 1336, 1273, 1245, 1167, 1051, 973, 883, 825, 755, 699. 
HRMS (ESI) m/z calculated for C32H30N3O3Cl2Ni [M+H]
+: 632.1012, found: 632.1011. 
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Nickel complex 208s 
 
Prepared from 206 and methyl bromoacetate (210s) according to the general 
procedure D and obtained as a red solid after column chromatography. The product 
has S-configuration at the newly formed stereogenic center. 
Mp.: 83-85 °C 
Optical rotation:       = +2666 (c= 0.115, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.26 (d, J= 7.1 Hz, 2H), 8.16 (d, J= 9.3 Hz, 1H), 7.59-
7.54 (m, 1H), 7.53-7.48 (m, 1H), 7.39 (td, J= 7.5, 1.2 Hz, 1H), 7.30 (t, J= 7.7 Hz, 2H), 
7.09 (t, J= 7.5 Hz, 1H), 7.02 (dd, J= 9.3, 2.6 Hz, 1H), 6.91 (dd, J= 7.6, 1.4 Hz, 1H), 
6.42 (d, J= 2.5 Hz, 1H), 4.31 (d, J= 12.4 Hz, 1H), 3.82 (dd, J= 7.0, 3.1 Hz, 1H), 
3.74 (s, 3H), 3.71-3.60 (m, 2H), 3.41 (dd, J= 10.6, 6.3 Hz, 1H), 3.30 (d, J= 12.4 Hz, 
1H), 2.84-2.72 (m, 2H), 2.61-2.48 (m, 1H), 2.44 (dd, J= 16.1, 7.0 Hz, 1H), 2.15-
2.01 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 180.7, 177.9, 169.6, 167.7, 141.9, 134.4, 132.4, 
132.2, 131.9, 131.3, 131.0, 130.7, 130.6, 129.2, 129.0, 128.8, 127.5, 126.0, 125.2, 
124.9, 71.2, 66.4, 64.4, 58.4, 52.2 38.2, 30.9, 23.1.  
IR (CHCl3): = 2952, 2238, 1737, 1671, 1637, 1589, 1530, 1460, 1396, 1336, 1240, 
1165, 1053, 1010, 967, 909, 824, 728, 701. 
HRMS (ESI) m/z calculated for C30H28N3O5Cl2Ni [M+H]
+: 638.0754, found: 638.0764. 
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Nickel complex 208t  
 
Prepared from 206 and 2-(bromomethyl)naphthalene (210t) according to the general 
procedures D or E and obtained as a red solid after column chromatography. The 
product has S-configuration at the newly formed stereogenic center. 
Mp.: 152-154 °C 
Optical rotation:       = +2488 (c= 0.105, CHCl3). 
1H NMR (600 MHz, CDCl3) = 8.22-8.17 (m, 3H), 7.89 (t, J= 7.7 Hz, 2H), 7.82-
7.78 (m, 1H), 7.71 (s, 1H), 7.62-7.59 (m, 1H), 7.53-7.47 (m, 3H), 7.32-7.22 (m, 4H), 
7.07-7.02 (m, 2H), 6.87 (dd, J= 7.6, 1.3 Hz, 1H), 6.50 (d, J= 2.5 Hz, 1H), 
4.10 (d, J= 12.5 Hz, 1H), 3.98 (t, J= 4.8 Hz, 1H), 3.12 (ddd, J= 19.1, 13.8, 4.8 Hz, 
2H), 3.11 (dd, J= 10.2, 7.1 Hz, 1H), 3.03 (d, J= 12.5 Hz, 1H), 2.82 (ddd, J= 10.7, 6.2, 
4.3 Hz, 1H), 2.02-1.94 (m, 1H), 1.78-1.72 (m, 1H), 1.59 (dt, J= 12.9, 7.9 Hz, 1H), 
1.49-1.41 (m, 1H), 1.12-1.04 (m, 1H). 
13C NMR (151 MHz, CDCl3) = 180.5, 177.8, 166.9, 142.0, 134.2, 133.8, 133.0, 
133.0, 132.3, 132.2, 131.8, 131.3, 131.2, 130.9, 130.5, 129.4, 129.3, 128.9, 128.8, 
128.7, 128.3, 127.9, 127.6, 127.3, 126.5, 126.2, 125.8, 125.2, 124.6, 72.1, 70.8, 
64.4, 58.3, 40.2, 30.3, 22.5. 
IR (CHCl3): = 3047, 2951, 2306, 2197, 2095, 1646, 1530, 1456, 1335, 1240, 1162, 
1060, 966, 821, 749, 697. 
HRMS (ESI) m/z calculated for C38H31N3O3Cl2NiNa [M+Na]
+: 728.0988, found: 
728.0988. 
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Nickel complex 219t 
 
Obtained as a side-product in the formation of Ni(II)-complex 208t according to the 
general procedure E. The product was obtained as a red solid. 
1H NMR (400 MHz, CDCl3) = 8.20 (d, J= 9.3 Hz, 1H), 7.90 (dd, J= 12.4, 7.6 Hz, 6H), 
7.80 (d, J= 8.5 Hz, 4H), 7.55 (s, 1H), 7.50 (dd, J= 6.6, 2.9 Hz, 2H), 7.41 (dd, J= 6.1, 
3.3 Hz, 2H), 7.38-7.06 (m, 9H), 6.46 (d, J= 2.6 Hz, 1H), 3.92 (d, J= 13.1 Hz, 1H), 
3.53-3.41 (m, 2H), 3.22-3.07 (m, 3H), 3.06-2.96 (m, 1H), 2.91 (d, J= 16.3 Hz, 1H), 
2.03-1.92 (m, 1H), 1.46-1.22 (m, 3H). 
HRMS (ESI) m/z calculated for C49H39N3O3Cl2KNi [M+K]
+: 884.1354, found: 
884.1353. 
 
Nickel complex 208u  
 
Prepared from 206 and methyl iodide (210u) according to the general procedures D 
or E and obtained as a red solid after column chromatography. The major product 
has S-configuration at the newly formed stereogenic center. 
Mp. (major): 92-94 °C 
Optical rotation:        (major)= +2083 (c= 0.115, CHCl3). 
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1H NMR (600 MHz, CDCl3) major = 8.23 (d, J= 7.2 Hz, 2H), 8.10 (d, J= 9.3 Hz, 1H), 
7.59-7.54 (m, 1H), 7.50 (td, J= 7.9, 1.5 Hz, 1H), 7.39 (td, J= 7.5, 1.0 Hz, 1H), 
7.33 (t, J= 7.7 Hz, 2H), 7.13 (t, J= 7.5 Hz, 1H), 7.04 (dd, J= 9.3, 2.6 Hz, 1H), 
6.93 (dd, J= 7.6, 1.4 Hz, 1H), 6.45 (d, J= 2.5 Hz, 1H), 4.36 (d, J= 12.5 Hz, 1H), 3.77-
3.67 (m, 1H), 3.61-3.55 (m, 2H), 3.47-3.44 (m, 1H), 3.33 (d, J= 12.5 Hz, 1H), 2.71-
2.64 (m, 1H), 2.61-2.53 (m, 1H), 2.27-2.20 (m, 1H), 2.11-2.05 (m, 1H), 
1.58 (d, J= 7.1 Hz, 3H). 
13C NMR (151 MHz, CDCl3) major = 180.6, 179.7, 166.0, 141.1, 134.2, 132.1, 
131.8, 131.7, 131.3, 131.3, 130.6, 130.4, 129.1, 129.0, 129.0, 127.4, 126.1, 125.5, 
125.1, 70.8, 67.0, 63.9, 58.1, 30.9, 24.1, 22.0. 
1H NMR (600 MHz, CDCl3) minor = 8.56 (d, J= 9.4 Hz, 1H), 8.12 (d, J= 7.2 Hz, 2H), 
7.59-7.49 (m, 4H), 7.49-7.42 (m, 2H), 7.21-7.14 (m, 2H), 6.57 (d, J= 2.5 Hz, 1H), 
4.19 (ddd, J= 11.6, 6.9, 4.8 Hz, 1H), 3.92 (dd, J= 608.7, 12.9 Hz, 2H), 
3.89 (q, J= 7.1 Hz, 1H), 3.67-3.61 (m, 1H), 2.71-2.61 (m, 1H), 2.61-2.52 (m, 1H), 
2.27-2.19 (m, 2H), 2.03-1.93 (m, 1H), 1.44 (d, J= 7.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) minor = 182.3, 180.4, 167.4, 141.7, 133.8, 132.5, 
132.4, 132.1, 131.8, 131.6, 131.3, 130.8, 130.7, 129.4, 129.2, 128.9, 127.8, 125.7, 
125.2, 69.2, 67.3, 62.0, 59.3, 30.5, 23.3, 19.2. 
IR (CHCl3) (major): = 3827, 2956, 2705, 2478, 2287, 2183, 2057, 1986, 1739, 1673, 
1532, 1458, 1361, 1220, 1069, 959, 886, 823, 750, 704. 
HRMS (ESI) (major) m/z calculated for C28H26N3O3Cl2Ni [M+H]
+: 580.0699, 
found: 580.0715. 
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Nickel complex 208x  
: 
Prepared from 206 and 3,4-bis(benzyloxy)benzyl bromide (210x) according to the 
general procedure D and obtained as a red solid mixture of diastereomers (dr 93:7) 
after column chromatography. The major product has S-configuration at the newly 
formed stereogenic center. 
Mp. (major): 120-123 °C 
Optical rotation:        (major)= +2091 (c= 0.1, CHCl3). 
1H NMR (600 MHz, CDCl3) major = 8.30 (d, J= 9.4 Hz, 1H), 8.21 (d, J= 7.3 Hz, 2H), 
7.51 (d, J= 8.1 Hz, 1H), 7.46 (d, J= 7.3 Hz, 2H), 7.41 (td, J= 8.4, 1.3 Hz, 1H), 
7.35 (t, J= 7.4 Hz, 2H), 7.31-7.19 (m, 6H), 7.13-7.10 (m, 3H), 7.08-7.03 (m, 2H), 
6.95 (d, J= 8.1 Hz, 1H), 6.68 (dd, J= 8.1, 1.8 Hz, 1H), 6.58 (d, J= 1.8 Hz, 1H), 
6.42 (d, J= 2.5 Hz, 1H), 6.14 (dd, J= 7.5, 0.9 Hz, 1H), 5.19 (q, J= 12.4 Hz, 2H), 
5.03 (d, J= 12.9 Hz, 1H), 4.77 (d, J= 12.9 Hz, 1H), 4.20 (d, J= 12.5 Hz, 1H), 
3.80 (t, J= 5.1 Hz, 1H), 3.28 (dd, J= 10.4, 6.8 Hz, 1H), 3.19-3.14 (m, 2H), 3.12 (dd, 
J= 14.0, 4.9 Hz, 1H), 2.66 (dd, J= 13.9, 5.2 Hz, 1H), 2.53-2.44 (m, 1H), 2.41-
2.29 (m, 2H), 1.88 (td, J= 10.8, 6.3 Hz, 1H), 1.69-1.63 (m, 1H). 
13C NMR (151 MHz, CDCl3) major = 180.5, 177.9, 166.5, 149.1, 148.2, 141.8, 
137.2, 137.2, 134.3, 132.3, 132.0, 131.5, 131.2, 131.1, 131.1, 130.3, 129.4, 129.0, 
128.8, 128.54, 128.4, 127.9, 127.4, 127.4, 127.1, 126.6, 125.9, 125.2, 124.7, 123.1, 
116.4, 114.9, 72.0, 71.1, 71.0, 70.6, 64.3, 58.2, 39.9, 30.9, 22.0. 
IR (CHCl3) (major): = 3038, 2935, 1650, 1511, 1455, 1335, 1243, 1143,1011, 825, 
703.. 
HRMS (ESI) (major) m/z calculated for C48H41N3O5Cl2NiNa [M+Na]
+: 890.1669, 
found: 890.1636. 
Experimental part 
 
177 
 
Nickel complex 209  
 
Prepared from 207 (170.2 mg, 0.3 mmol) and benzyl bromide (210a, 130.9 mg, 
0.75 mmol, 2.5 equiv.) as 43:57 mixture of diastereomers (a ratio of 45:55 was 
determined by 1H NMR spectroscopy of the crude reaction mixture) according to the 
general procedure D but using 30% aq NaOH. The products were obtained as red 
solids in 99% yield after column chromatography. The relative configurations 
remained undetermined. 
Major diastereomer of 209: 
Mp.: 260-262 °C. 
Optical rotation:       = +2308 (c= 0.115, CHCl3). 
1H NMR (600 MHz, CDCl3) = 8.23 (d, J= 9.3 Hz, 1H), 8.01 (d, J= 7.2 Hz, 2H), 7.57-
7.50 (m, 3H), 7.48-7.39 (m, 5H), 7.30-7.25 (m, 3H), 7.13 (t, J= 7.5 Hz, 1H), 7.07 (dd, 
J= 9.3, 2.5 Hz, 1H), 6.55 (d, J= 2.5 Hz, 1H), 4.25 (t, J= 4.5 Hz, 1H), 
4.18 (d, J= 12.6 Hz, 1H), 3.27 (d, J= 12.6 Hz, 1H), 3.23 (t, J= 8.7 Hz, 1H), 2.93-
2.79 (m, 3H), 2.30-2.19 (m, 2H), 1.94-1.83 (m, 2H), 1.54-1.45 (m, 1H). 
13C NMR (151 MHz, CDCl3) = 180.6, 177.7, 167.7, 141.8, 135.7, 133.5, 132.3, 
132.2, 132.0, 131.9, 131.4, 131.3, 131.1, 130.3, 129.4, 128.9, 128.8, 128.8, 128.0, 
127.5, 125.9, 125.5, 125.0, 72.2, 70.5, 63.7, 57.8, 38.0, 30.7, 23.0. 
IR (CHCl3): = 3844, 3057, 2939, 2319, 2101, 1895, 1645, 1454, 1335, 1246, 1162, 
1065, 967, 886, 822, 745, 694. 
HRMS (ESI): m/z calculated for C34H30N3O3Cl2Ni [M+H]
+: 656.1012, found: 656.1020. 
Minor diastereomer of 209: 
Mp.: 262-263 °C. 
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Optical rotation:       = 2260 (c= 0.11, CHCl3). 
1H NMR (600 MHz, CDCl3) = 8.53 (d, J= 9.3 Hz, 1H), 7.58-7.51 (m, 2H), 7.45-
7.36 (m, 9H), 7.27-7.22 (m, 3H), 6.93 (dd, J= 7.6, 1.0 Hz, 1H), 6.64 (d, J= 2.5 Hz, 
1H), 3.93 (dd, J= 5.6, 4.5 Hz, 1H), 3.87-3.80 (m, 2H), 3.46 (d, J= 13.8 Hz, 1H), 
3.40 (dd, J= 9.4, 3.8 Hz, 1H), 2.99 (ddd, J= 19.5, 13.7, 5.0 Hz, 2H), 2.54-
2.45 (m, 1H), 2.34-2.22 (m, 1H), 1.98-1.89 (m, 1H), 1.61-1.50 (m, 1H). 
13C NMR (151 MHz, CDCl3) = 182.2, 177.8, 166.9, 142.3, 135.8, 132.7, 132.2, 
132.1, 131.8, 131.7, 131.4, 131.2, 130.9, 130.6, 129.6, 129.0, 128.9, 127.7, 127.2, 
126.1, 125.6, 125.2, 72.3, 68.5, 60.0, 56.2, 40.4, 31.1, 23.6. 
IR (CHCl3): = 3841, 3069, 2956, 2319, 2109, 1910, 1679, 1637, 1533, 1459, 1393, 
1347, 1307, 1240, 1166, 1117, 1084, 1042, 988, 930, 821, 753, 697.  
HRMS (ESI): m/z calculated for C34H30N3O3Cl2Ni [M+H]
+: 656.1012, found: 656.1026. 
5.4.9 Degradation of Ni(II)-complex 208a 
(S)-Phenylalanine ((S)-81) 
 
Complex 208a (1 g, 1.52 mmol) was dissolved in 1,4-dioxane/water (v/v= 2:1, 
150 mL), followed by addition of 6N HCl (30 mL). The mixture was stirred at 60 °C. 
After the degradation of the complex was completed (monitored by TLC, 
disappearance of the red color), the mixture was concentrated in vacuo, treated with 
concentrated ammonium hydroxide, and extracted with DCM (3 x 30 mL) to recover 
(S)-205 (650 mg, 95% yield). The aqueous solution was concentrated in vacuo, 
dissolved in a minimum amount of water, and then separated by column 
chromatography on C18-reversed phase (230-400 mesh) silica gel. Pure water as an 
eluent was employed to remove the green NiCl2. MeOH/water (v/v= 1:1) was then 
used to give pure product (S)-81 in 72% yield (180 mg, 95% ee).  
HPLC analysis: Astec CHIROBIOTIC T, MeOH:H2O= 70:30, 0.5 mL/min, tret: 12.1 
min (major), 15.5 (minor) min. 
Optical rotation:       = 33 (c= 1.3, H2O). 
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1H NMR (500 MHz, D2O) = 7.46-7.22 (m, 5H), 4.12 (dd, J= 7.8, 5.3 Hz, 1H), 
3.29 (dd, J= 14.6, 5.4 Hz, 1H), 3.13 (dd, J= 14.6, 7.8 Hz, 1H).  
13C NMR (125 MHz, D2O) = 172.2, 134.0, 128.8, 128.6, 127.3, 54.6, 35.4 ppm. 
HRMS (ESI) m/z calculated for C9H12N1O2 [M+H]
+ 166.0868, found: 166.0860. 
5.4.10 Synthesis of aryl-bridged dinickel complex 212 
Nickel complex 212 
 
In a Schlenk flask equipped with a magnetic stirrer bar 4-bromomethyl benzyl 
bromide (210e, 20.4 mg, 0.075 mmol), nickel complex 206 (85.1 mg, 0.15 mmol, 
2 equiv.), TBAI (7.1 mg, 0.2 mmol, 0.25 equiv.), and crushed NaOH (120.0 mg, 
3 mmol, 40 equiv.) were dissolved in 1,2-dichloroethane (1.5 mL) under an argon 
atmosphere. The reaction was followed by TLC (DCM:acetone 4:1) until completion 
(2 h). The reaction mixture was washed with AcOH (5% aq. sol., 5 mL) and the 
separated aqueous layer was extracted with DCM (3 x 5 mL). The combined organic 
phases were dried over Na2SO4, filtered, and concentrated in vacuo. The product 
was purified by column chromatography (DCM:acetone, gradient 7:1 to 4:1) and 
obtained as a red solid in 89% yield. 
Mp.: 151-153 °C 
Optical rotation:       = +2541 (c= 0.095, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.19 (d, J= 7.2 Hz, 4H), 8.15 (d, J= 9.4 Hz, 2H), 7.61-
7.57 (m, 2H), 7.52 (td, J= 7.9, 1.4 Hz, 2H), 7.37 (td, J= 7.5, 0.9 Hz, 2H), 
7.25 (t, J= 7.7 Hz, 4H), 7.14 (s, 4H), 7.05 (t, J= 7.5 Hz, 2H), 7.01 (dd, J= 9.4, 2.6 Hz, 
2H), 6.85 (dd, J= 7.6, 1.2 Hz, 2H), 6.46 (d, J= 2.5 Hz, 2H), 4.20 (d, J= 12.5 Hz, 2H), 
Experimental part 
 
180 
 
3.88 (dd, J= 6.2, 4.1 Hz, 2H), 3.29-3.10 (m, 8H), 2.87 (dd, J= 13.6, 6.3 Hz, 2H), 2.47-
2.25 (m, 4H), 2.21-2.10 (m, 2H), 1.93 (td, J= 10.4, 6.4 Hz, 2H), 1.79-1.68 (m, 2H). 
13C NMR (101 MHz, CDCl3) = 180.4, 177.6, 167.0, 141.7, 134.9, 134.1, 132.4, 
132.1, 131.97, 131.3, 131.2, 130.9, 130.9, 130.6, 129.3, 129.0, 128.8, 127.5, 125.8, 
125.4, 124.5, 71.7, 70.9, 64.3, 58.1, 39.9, 30.7, 23.1. 
IR (CHCl3): = 2965, 2116, 1742, 1638, 1589, 1529, 1459, 1394, 1334, 1239, 1165, 
1051, 914, 877, 822, 753, 728, 700. 
HRMS (ESI) m/z calculated for C62H52N6O6Cl4Ni2Na [M+Na]
+: 1255.1302, 
found: 1255.1273. 
5.4.11 Derivatization of Ni(II)-complex 206 by Michael addition reaction 
Nickel complex 214 
 
Method 1 
In a Schlenk flask equipped with a magnetic stirrer bar the nickel complex 206 
(56.7 mg, 0.1 mmol) was dissolved in MeCN (0.5 mL) under argon atmosphere. DBU 
(31.1 mg, 0.2 mmol, 2 equiv) was dissolved in MeCN (0.2 mL) and added to the 
stirred solution. Crotonic acid methyl ester (213, 20.2 mg, 0.2 mmol, 2 equiv.) was 
dissolved in MeCN (0.3 mL) and added dropwise to the reaction mixture. The 
reaction was followed by TLC (DCM:acetone 4:1) until completion (150 min). The 
reaction mixture was washed with AcOH (5% aq. sol., 5 mL) and the separated 
aqueous layer was extracted with DCM (3 x 5 mL). The combined organic phases 
were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was 
purified by column chromatography (DCM:acetone 7:1) to afford the product in 91% 
as a red solid. The product has S,S-configuration at the newly formed stereogenic 
centers. 
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Method 2 
Ni(II)-complex 206 (56.7 mg, 0.1 mmol), Crotonic acid methyl ester (213, 20.2 mg, 
0.2 mmol, 2 equiv.), NaOMe (108.0 mg, 2.0 mmol, 20 equiv.) and MgSO4 (12,0 mg, 
0.1 mmol, 1 equiv.) were transferred to a clean, dry ZrO2 ball milling vessel loaded 
with 3 milling balls (⌀= 10.0 mm, ZrO2). The vessel was placed in the RETSCH Mixer 
Mill MM400 and milling was conducted for 60 min (2 cycles consisting of 30 min of 
milling followed by a 10 minutes pause, TLC analysis was carried out after each 
cycle). The product was obtained by washing the vessel and the balls with 5 mL of 
acetic acid (5% in H2O) and 3 times with 3-5 mL of DCM. The phases were 
separated and the aqueous phase washed 3 times with 5 mL of DCM. The organic 
phase was dried with Na2SO4, concentrated in vacuo, and the product was purified 
by column chromatography (DCM:acetone 7:1) to afford the product in 13% as a red 
solid mixture of diastereomers (dr of 86:14).  
Mp.: 223-225 °C 
Optical rotation:       = +2737 (c= 0.11, CHCl3). 
1H NMR (400 MHz, CDCl3) major = 8.24 (d, J= 7.1 Hz, 2H), 8.18 (d, J= 9.3 Hz, 1H), 
7.57-7.53 (m, 1H), 7.49 (td, J= 7.8, 1.5 Hz, 1H), 7.39 (td, J= 7.5, 1.1 Hz, 1H), 
7.27 (t, J= 7.7 Hz, 2H), 7.06 (t, J= 7.5 Hz, 1H), 7.01 (dd, J= 9.3, 2.6 Hz, 1H), 
6.95 (dd, J= 7.6, 1.4 Hz, 1H), 6.44 (d, J= 2.6 Hz, 1H), 4.33 (d, J= 12.4 Hz, 1H), 3.59-
3.52 (m, 2H), 3.49 (s, 3H), 3.46-3.35 (m, 2H), 3.27 (d, J= 12.4 Hz, 1H), 2.76-
2.66 (m, 1H), 2.62-2.49 (m, 1H), 2.34-2.23 (m, 1H), 2.17-2.01 (m, 4H), 
1.97 (d, J= 6.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) major = 180.5, 176.6, 172.0, 167.3, 141.6, 134.3, 
132.3, 131.8, 131.7, 131.2, 131.0, 130.9, 130.3, 129.5, 129.0, 128.8, 127.5, 126.0, 
125.3, 124.6, 74.1, 71.0, 64.4, 58.0, 51.5, 37.9, 35.3, 30.8, 23.2, 16.1. 
IR (CHCl3): = 2958, 2069, 1733, 1673, 1635, 1535, 1459, 1393, 1324, 1274, 1240, 
1166, 1054, 1004, 966, 915, 882, 830, 753, 697. 
HRMS (ESI) m/z calculated for C32H32N3O5Cl2Ni [M+H]
+: 666.1067, found: 666.1078. 
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5.4.12 Derivatization of Ni(II)-complex 206 by aldol addition reaction 
General procedure F  
In a Schlenk flask equipped with a magnetic stirrer bar nickel complex 206 (37.8 mg, 
0.07 mmol) was dissolved in methanol (0.5 mL) under argon atmosphere. NaOMe 
(37.8 mg, 0.7 mmol, 10 equiv) was added to the stirred solution. The aldehyde 
(0.7 mmol, 10 equiv.) was dissolved in methanol (0.2 mL) and added dropwise to the 
reaction mixture. The reaction was followed by TLC (DCM:acetone 4:1) until 
completion (over night). The reaction mixture was washed with AcOH (5% aq. sol., 
5 mL) and the separated aqueous layer was extracted with DCM (3 x 5 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated in 
vacuo. The product was purified by column chromatography (DCM:acetone 7:1). 
General procedure G  
Ni(II)-complex 1 (56.7 mg, 0.1 mmol), the aldehyde (1.0 mmol, 10 equiv) and NaOMe 
(108.0 mg, 2.0 mmol, 20 equiv.) were transferred to a clean, dry ZrO2 ball milling 
vessel loaded with 3 milling balls (⌀= 10.0 mm, ZrO2). The vessel was placed in the 
RETSCH Mixer Mill MM400 and milling was conducted for 90 min (3 cycles 
consisting of 30 min of milling followed by a 10 minutes pause, TLC analysis was 
carried out after each cycle). The product was obtained by washing the vessel and 
the balls with 5 mL of acetic acid (5% in H2O) and 3 times with 3-5 mL of DCM. The 
phases were separated and the aqueous phase washed 3 times with 5 mL of DCM. 
The organic phase was dried with Na2SO4, concentrated in vacuo, and the product 
was purified by column chromatography (gradient: DCM:acetone 9:1 to 1:1). 
 
Nickel complex 216a  
 
Experimental part 
 
183 
 
Prepared from 206 and n-butyraldehyde according to the general procedures F or G 
and obtained as a red solid after column chromatography. The product has 
R,S-configuration at the newly formed stereogenic centers. 
Mp.: 179-181 °C 
Optical rotation:       = 495 (c= 0.1, CHCl3). 
1H NMR (400 MHz, CDCl3) = 8.54 (d, J= 9.3 Hz, 1H), 7.81-7.77 (m, 2H), 7.55-
7.41 (m, 6H), 7.24 (d, J= 7.3 Hz, 1H), 7.21 (dd, J= 9.4, 2.6 Hz, 1H), 
6.63 (d, J= 2.5 Hz, 1H), 4.81 (d, J= 13.2 Hz, 1H), 4.14 (d, J= 5.1 Hz, 1H), 4.03-
3.97 (m, 1H), 3.87 (d, J= 13.3 Hz, 1H), 3.72-3.66 (m, 1H), 3.60-3.52 (m, 2H), 2.85-
2.75 (m, 1H), 2.65-2.49 (m, 2H), 2.18-2.09 (m, 1H), 1.98 (ddd, J= 18.1, 13.3, 8.5 Hz, 
1H), 1.87-1.63 (m, 3H), 1.56-1.42 (m, 1H), 1.06 (t, J= 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) = 182.5, 179.1, 169.4, 141.8, 132.8, 132.6, 132.4, 
132.2, 131.9, 131.8, 131.2, 131.2, 129.3, 129.1, 128.4, 128.1, 125.9, 125.3, 125.2, 
73.8, 70.4, 68.1, 61.2, 57.2, 35.3, 30.7, 23.4, 19.4, 14.4. 
IR (CHCl3): = 3416, 2961, 2180, 2076, 2007, 1744, 1640, 1531, 1463, 1395, 1337, 
1273, 1239, 1170, 1088, 1050, 983, 826, 750, 711. 
HRMS (ESI) m/z calculated for C31H32N3O4Cl2Ni [M+H]
+: 668.1118, found: 668.1124. 
 
Nickel complex 216b 
  
Prepared from 206 and iso-butyraldehyde according to the general procedures F or 
G and obtained as a red solid after column chromatography. The product has R,S-
configuration at the newly formed stereogenic centers. Slow decomposition of the 
product in solution was observed. 
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Mp.: 120-122 °C 
Optical rotation:       = 1137 (c= 0.105, CHCl3). 
1H NMR (600 MHz, CDCl3) = 8.60 (d, J= 9.3 Hz, 1H), 7.72-7.67 (m, 2H), 
7.53 (d, J= 3.8 Hz, 2H), 7.51-7.43 (m, 4H), 7.26-7.21 (m, 2H), 6.68 (d, J= 2.5 Hz, 
1H), 4.81 (d, J= 13.5 Hz, 1H), 4.16 (d, J= 6.0 Hz, 1H), 4.07-4.00 (m, 1H), 
3.96 (d, J= 13.5 Hz, 1H), 3.65 (dd, J= 9.8, 4.0 Hz, 1H), 3.59 (s, 1H), 3.40 (br s, 1H), 
2.70-2.59 (m, 2H), 2.49-2.40 (m, 1H), 2.12 (ddd, J= 12.2, 7.9, 3.8 Hz, 1H), 1.94-
1.86 (m, 1H), 1.78-1.71 (m, 1H), 1.38 (d, J= 6.8 Hz, 3H), 0.96 (d, J= 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) = 182.3, 178.9, 169.3, 141.8, 132.8, 132.7, 132.5, 
132.1, 131.8, 131.8, 131.4, 131.3, 129.2, 129.0, 128.9, 127.9, 125.9, 125.5, 125.1, 
75.6, 73.5, 68.2, 60.8, 57.0, 30.8, 30.3, 23.4, 22.0, 16.3. 
IR (CHCl3): = 3855, 3392, 3079, 2957, 2704, 2486, 2290, 2071, 1980, 1920, 1739, 
1643, 1533, 1460, 1357, 1226, 1167, 1054, 990, 915, 825, 735. 
HRMS (ESI) m/z calculated for C31H32N3O4Cl2Ni [M+H]
+: 668.1118, found: 668.1129. 
5.4.13 Alkylation of Ni(II)-complex 113 under HSBM conditions 
Nickel complex 217 
 
Ni(II)-complex 113 (48.0 mg, 0.1 mmol), 2-iodobenzyl bromide  (71,0 mg, 0.24 mmol, 
2.4 equiv.), base and additive were transferred to a clean, dry ZrO2 ball milling vessel 
loaded with 3 milling balls (⌀= 10.0 mm, ZrO2). The vessel was placed in the 
RETSCH Mixer Mill MM400  and the milling was started. After one milling cycle the 
vessel was removed, opened, and a sample was analyzed by TLC (DCM:acetone 
7:1). If the conversion was incomplete, the vessel was placed back into the Mixer Mill 
for additional cycles (each milling cycle was followed by a 10 minutes pause). The 
mixture was obtained by washing the vessel and the balls with 5 mL of acetic acid 
(5% in H2O) and 3 x 3-5 mL of DCM. The phases were separated, and the aqueous 
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phase was washed 3 times with 5 mL of DCM. The organic phase was dried with 
Na2SO4, concentrated in vacuo, and the product was purified by column 
chromatography (gradient: DCM:acetone 12:1 to 4:1) to be obtained as a red solid.  
Mp.: 109-111 °C 
1H NMR (600 MHz, CDCl3) = 8.57 (d, J= 8.5 Hz, 1H), 8.08 (d, J= 7.7 Hz, 1H), 7.54-
7.48 (m, 2H), 7.42-7.30 (m, 4H), 7.27-7.23 (m, 1H), 7.11 (ddd, J= 8.1, 6.8, 2.4 Hz, 
1H), 6.96 (d, J= 7.7 Hz, 1H), 6.79-6.72 (m, 2H), 4.31 (dd, J= 5.9, 4.6 Hz, 1H), 
3.68 (d, J= 16.0 Hz, 1H), 3.40 (ddd, J= 18.4, 13.9, 5.3 Hz, 2H), 2.96 (d, J= 16.0 Hz, 
1H), 2.64-2.50 (m, 2H), 2.30 (td, J= 12.0, 4.5 Hz, 1H), 2.18-2.05 (m, 3H), 1.84-
1.76 (m, 1H), 1.58-1.49 (m, 2H), 1.49-1.41 (m, 1H), 1.33-1.21 (m, 2H), 0.99 (dt, 
J= 22.6, 7.4 Hz, 6H). 
13C NMR (151 MHz, CDCl3) = 177.5, 176.2, 171.2, 142.8, 140.1, 140.0, 134.0, 
133.5, 132.8, 132.5, 129.8, 129.2, 129.1, 129.05, 128.9, 127.54, 127.45, 126.9, 
123.7, 121.0, 102.7, 71.7, 63.5, 58.6, 55.7, 44.1, 29.3, 24.82, 20.8, 20.5, 14.1, 13.9. 
IR (CHCl3): = 2945, 2870, 2323, 2089, 1641, 1444, 1326, 1256, 1161, 1062, 1012, 
869, 750.  
HRMS (ESI) m/z calculated for C32H37N3O3INi [M+H]
+: 696.1228, found: 696.1228. 
 
Nickel complex 218 
 
Obtained as a side-product in the formation of Ni(II)-complex 217 under HSBM 
conditions. The product was obtained as a red solid. 
Mp.: 236-238 °C 
1H NMR (400 MHz, CDCl3) = 8.37 (dd, J= 8.5 Hz, 1.0 Hz, 1H), 8.00 (dd, J= 7.9, 
1.2 Hz, 2H), 7.53 (dd, J= 7.8 Hz, 1.5 Hz, 2H), 7.48 (t, J= 7.5 Hz, 1H), 7.41 (td, J= 7.6, 
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1.3 Hz, 2H), 7.27-7.20 (m, 3H), 7.03 (td, J= 7.7, 1.6 Hz, 2H), 6.86 (d, J= 7.1 Hz, 2H), 
6.64-6.59 (m, 1H), 6.56 (dd, J= 8.5, 1.6 Hz, 1H), 3.30 (d, J= 16.2 Hz, 2H), 
3.13 (s, 2H), 2.84 (d, J= 16.1 Hz, 2H), 2.43-2.35 (m, 2H), 2.17-1.98 (m, 4H), 1.78-
1.64 (m, 2H), 1.50-1.31 (m, 4H), 0.99 (t, J= 7.3 Hz, 6H). 
13C NMR (151 MHz, CDCl3) = 177.3, 175.1, 171.9, 142.6, 140.3, 140.2, 135.9, 
134.2, 132.3, 131.0, 130.0, 128.6, 128.4, 128.1, 126.8, 123.8, 120.8, 103.0, 81.6, 
63.4, 56.8, 51.2, 26.9, 20.8, 14.1.  
IR (CHCl3): = 3544, 3462, 3060, 2956, 2867, 2326, 2100, 1670, 1632, 1534, 1464, 
1436, 1366, 1330, 1254, 1162, 1044, 1011, 865, 789, 749, 710.  
HRMS (ESI) m/z calculated for C39H41N3O3I2NiNa [M+Na]
+: 934.0483, found: 
934.0472. 
5.4.14 Derivatization of Ni(II)-complex 206 by one-pot alkylation/click reaction 
Nickel complex 223[183] 
 
Ni(II)-complex 206 (56.7 mg, 0.1 mmol), propargyl bromide (210q, 17.8 mg, 12.9 L, 
0.15 mmol, 1.5 equiv), NaOMe (108.0 mg, 2.0 mmol, 20 equiv) and MgSO4 (12.0 mg, 
0.1 mmol, 1 equiv.) were transferred to a clean, dry ZrO2 ball milling vessel loaded 
with 3 milling balls (⌀= 10.0 mm, ZrO2). The vessel was placed in a RETSCH Mixer 
Mill MM400 and milling was started at 20 Hz. After 30 min of milling the vessel was 
removed, opened, and full conversion was confirmed by TLC analysis. Benzyl azide 
(33.3 mg, 33.0 L, 0.25 mmol, 2.5 equiv), Cu(OAc)2 (3.6 mg, 0.02 mmol, 20 mol%), 
sodium ascorbate (4.0 mg, 0.02 mmol, 20 mol%) and silica gel (120 mg) were added.  
The vessel was placed back in the Mixer Mill and milling was conducted for 75 min 
(two milling cycles of 30 min followed by 10 min pause, then one milling cycle of 
15 min) at 20 Hz until full conversion was confirmed by TLC analysis. The product 
was obtained by washing the vessel and the balls with 5 mL of acetic acid (5% in 
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H2O) and 3 times with 3-5 mL of DCM. The phases were separated and the aqueous 
phase washed 3 times with 5 mL of DCM. The organic phase was dried with Na2SO4, 
concentrated in vacuo, and the product was purified by column chromatography 
(gradient: DCM:acetone 2:1 to 1:1). The product was obtained as a red solid in 88% 
yield and has S-configuration at the newly formed stereogenic center. 
Mp.: 107-110 °C 
Optical rotation:       = +2287 (c= 0.135, CHCl3). 
1H NMR (400 MHz, acteone) = 8.38 (dd, J= 8.2, 1.1 Hz, 2H), 8.31 (d, J= 9.4 Hz, 
1H), 7.85 (s, 1H), 7.73-7.69 (m, 1H), 7.63 (ddd, J= 8.2, 7.5, 1.6 Hz, 1H), 7.46 (td, 
J= 7.6 , 1.2 Hz, 1H), 7.37-7.26 (m, 7H), 7.14 (dd, J= 7.7, 1.4 Hz, 1H), 7.11-
7.03 (m, 2H), 6.44 (d, J= 2.6 Hz, 1H), 5.68 (d, J= 1.8 Hz, 2H), 4.08 (d, J= 12.3 Hz, 
1H), 3.69 (dd, J= 6.5, 4.1 Hz, 1H), 3.49-3.45 (m, 1H), 3.41 (d, J= 12.3 Hz, 1H), 
3.30 (ddd, J= 10.3, 6.5, 2.3 Hz, 1H), 3.09 (ddd, J= 21.2, 14.8, 5.3 Hz, 2H), 2.96-
2.86 (m, 1H), 2.48-2.39 (m, 2H), 2.17-2.06 (m, 1H), 2.00-1.91 (m, 1H). 
13C NMR (101 MHz, acetone) = 180.55, 176.13, 166.49, 142.84, 142.00, 136.13, 
135.43, 132.48, 132.03, 131.40, 131.25, 130.55, 130.22, 130.14, 130.08, 128.76, 
128.63, 128.35, 128.13, 128.06, 127.79, 125.87, 124.98, 123.68, 123.67, 70.50, 
70.39, 63.58, 58.12, 53.32, 30.66, 30.46, 23.02. 
IR (CHCl3): = 3515, 3063, 2943, 2658, 2322, 2091, 1962, 1644, 1455, 1337, 1242, 
1160, 1053, 904, 823, 712. 
HRMS (ESI) m/z calculated for C37H33N6O3Br2Cl2Ni [M+H]
+: 737.1339, found: 
737.1340. 
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5.4.15 Epimerization of Ni(II)-complex 207 
 
In a 10 mL microwave tube with a stirring bar nickel complex 207 (1.4 g, 2.5 mmol) 
was dissolved in 1,2-dichloroethane (4.94 mL) and heated in a laboratory microwave 
to 140 °C (conditions: 300 W, 140 °C, monitored reaction conditions: 150 W, 140 °C, 
6 bar) for 45 min. After cooling to room temperature, the reaction mixture was 
analyzed by 1H NMR spectroscopy. Diastereomers 206 and 207 were obtained in a 
ratio of 55:45. The solvent was evaporated, and the product was purified by column 
chromatography (DCM:acetone 7:1 to 2:1) to afford the two diastereomers 206 and 
207 in 45% and 35% yield, respectively. 
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6. Abbreviations 
ACDC   asymmetric counteranion directed catalysis 
AcOH   acetic acid 
Ac   acetyl 
BINAM  1,1'-binaphthalene-2,2'-diamine 
BINOL  1,1‟-bi-2-naphthol 
Bn   benzyl 
Boc   tert-butoxycarbonyl 
br   broad 
BTC   bis(trichloromethyl) carbonate, triphosgene 
Bu   butyl 
calc.   calculated 
CI   chemical ionization 
conc.   concentrated 
Cy   cyclohexyl 
DAAD   Deutscher Akademischer Austausch Dienst 
DABCO  1,4-diazabicyclo[2.2.2]octan 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM   dichloromethane 
DMEDA  N,N′-dimethylethylenediamine 
DMF   dimethylformamide 
DMSO  dimethyl sulfoxide 
L-dopa  L-3,4-dihydroxyphenylalanine 
dr   diastereomeric ratio 
ECD   electronic circular dichroism 
EI   electronic ionization 
eq.   equation 
equiv.   equivalents 
er   enantiomeric ratio 
ESI   electronspray ionization 
HOMO  highest occupied molecular orbital 
HPLC   high-performance liquid chromatography 
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HRMS  high resolution mass spectroscopy 
HSBM  high speed ball milling 
i-Pr   iso-propyl 
iso-PrOH  iso-propyl alcohol 
IR   infrared 
LUMO  lowest unoccupied molecular orbital 
m   multiplet 
min   minutes 
MM   mixer mill 
Mp   melting point 
MTBE   methyl-tert-butylether 
NMR   nuclear magnetic resonance 
o/n   over night 
PM   planetary mill 
ppm   parts per million 
PTC   phase-transfer catalysis 
q   quartet 
quant.   quantitative 
rt   room temperature 
s   singulet 
sat.   saturated 
SOMO  singly occupied molecular orbital 
t   triplet 
tret   retention time 
TADDOL  ,, „, ´-tetraaryl-2,2-dimethyl-1,3-dioxolan-4,5-dimethanol 
t-Bu   tert-butyl 
i-Bu   iso-butyl 
TFAA   trifluoroacetic anhydride 
THF   tetrahydrofuran 
TMS   trimethylsilyl 
VBM   vibrational ball mill 
VCD    vibrational circular dichroism 
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